U.S. patent number 8,802,661 [Application Number 13/151,722] was granted by the patent office on 2014-08-12 for c-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors.
This patent grant is currently assigned to Bristol-Myers Squibb Company. The grantee listed for this patent is Jie Chen, Yan Chen, Zheng Liu, Nicholas A. Meanwell, Alicia Regueiro-Ren, Ny Sin, Sing-Yuen Sit, Jacob Swidorski. Invention is credited to Jie Chen, Yan Chen, Zheng Liu, Nicholas A. Meanwell, Alicia Regueiro-Ren, Ny Sin, Sing-Yuen Sit, Jacob Swidorski.
United States Patent |
8,802,661 |
Regueiro-Ren , et
al. |
August 12, 2014 |
C-28 amides of modified C-3 betulinic acid derivatives as HIV
maturation inhibitors
Abstract
Compounds having drug and bio-affecting properties, their
pharmaceutical compositions and methods of use are set forth. In
particular, modified C-3 and C-28 betulinic acid derivatives that
possess unique antiviral activity are provided as HIV maturation
inhibitors. These compounds are useful for the treatment of HIV and
AIDS.
Inventors: |
Regueiro-Ren; Alicia
(Middletown, CT), Liu; Zheng (Beacon Falls, CT),
Swidorski; Jacob (Southington, CT), Meanwell; Nicholas
A. (East Hampton, CT), Sit; Sing-Yuen (Meriden, CT),
Chen; Jie (Madison, CT), Chen; Yan (Guilford, CT),
Sin; Ny (East Hampton, CT) |
Applicant: |
Name |
City |
State |
Country |
Type |
Regueiro-Ren; Alicia
Liu; Zheng
Swidorski; Jacob
Meanwell; Nicholas A.
Sit; Sing-Yuen
Chen; Jie
Chen; Yan
Sin; Ny |
Middletown
Beacon Falls
Southington
East Hampton
Meriden
Madison
Guilford
East Hampton |
CT
CT
CT
CT
CT
CT
CT
CT |
US
US
US
US
US
US
US
US |
|
|
Assignee: |
Bristol-Myers Squibb Company
(Princeton, NJ)
|
Family
ID: |
44627254 |
Appl.
No.: |
13/151,722 |
Filed: |
June 2, 2011 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20120142653 A1 |
Jun 7, 2012 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
61351332 |
Jun 4, 2010 |
|
|
|
|
Current U.S.
Class: |
514/169; 552/510;
540/47; 514/176; 514/172 |
Current CPC
Class: |
A61P
31/00 (20180101); A61P 31/18 (20180101); A61P
37/00 (20180101); C07J 63/008 (20130101); A61P
31/12 (20180101) |
Current International
Class: |
A61K
31/56 (20060101); A61K 31/58 (20060101); C07J
53/00 (20060101) |
Field of
Search: |
;514/169,172,176,183
;540/47 ;544/58.2,106,358,383 ;546/184,242,245
;548/146,152,267.6,300.1,400 ;549/76 ;552/510 ;564/161 |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
WO 98/51293 |
|
Nov 1998 |
|
WO |
|
WO 98/51294 |
|
Nov 1998 |
|
WO |
|
WO 2004/089357 |
|
Oct 2004 |
|
WO |
|
WO 2006/001964 |
|
Jan 2006 |
|
WO |
|
WO 2008/097341 |
|
Aug 2008 |
|
WO |
|
WO 2008/127364 |
|
Oct 2008 |
|
WO |
|
WO 2009/100532 |
|
Aug 2009 |
|
WO |
|
WO 2009/114083 |
|
Sep 2009 |
|
WO |
|
Other References
US. Appl. No. 61/537,099, filed Sep. 21, 2011, Liu et al. cited by
applicant .
U.S. Appl. No. 61/599,040, filed Feb. 15, 2012, Swidorski et al.
cited by applicant .
U.S. Appl. No. 13/151,706, filed Jun. 2, 2011, Regueiro-Ren et al.
cited by applicant .
U.S. Appl. No. 13/359,680, filed Jan. 27, 2012, Regueiro-Ren et al.
cited by applicant .
U.S. Appl. No. 13/359,727, filed Jan. 27, 2012, Regueiro-Ren et al.
cited by applicant .
Blair, W.S. et al., "HIV-1 entry--an expanding portal for drug
discovery", Drug Discovery Today, vol. 5, No. 5, pp. 183-194
(2000). cited by applicant .
Hotoda, H., "Small-molecule inhibitors of HIV-1 entry via chemokine
receptors", Drugs of the Future, vol. 24, No. 12, pp. 1355-1362
(1999). cited by applicant .
Kashiwada, Y. et al., "Betulinic Acid and Dihydrobetulinic Acid
Derivatives as Potent Anti-HIV Agents", Journal of Medicinal
Chemistry, vol. 39, No. 5, pp. 1016-1017 (1996). cited by applicant
.
Meanwell, N.A. et al., "Inhibitors of the entry of HIV into host
cells", Current Opinion in Drug Discovery & Development, vol.
6, No. 4, pp. 451-461 (2003). cited by applicant .
Pokrovskii, A.G. et al., "Synthesis of derivatives of plant
triterpenes and study of their antiviral and immunostimulating
activity", Khimiya y Interesakh Ustoichivogo Razvitiya, vol. 9, No.
3, pp. 485-491 (2001) (English abstract). cited by applicant .
Sodroski, J.G., "HIV-1 Entry Inhibitors in the Side Pocket:
Minireview", Cell, vol. 99, pp. 243-246 (1999). cited by applicant
.
Yu, D. et al., "Anti-AIDS Agents 69. Moronic Acid and Other
Triterpene Derivatives as Novel Potent Anti-HIV Agents", Journal of
Medicinal Chemistry, vol. 49, No. 18, pp. 5462-5469 (2006). cited
by applicant.
|
Primary Examiner: Badio; Barbara P
Attorney, Agent or Firm: Levis; John F.
Parent Case Text
CROSS-REFERENCE TO RELATED APPLICATION
This non-provisional application claims the benefit of U.S.
Provisional Application Ser. No. 61/351,332 filed Jun. 4, 2010.
Claims
What is claimed is:
1. A compound which is selected from the group of: a compound of
formula I ##STR00417## a compound of formula II ##STR00418## a
compound of formula III ##STR00419## wherein R.sub.1 is isopropenyl
or isopropyl; J and E are --H or --CH.sub.3; E is absent when the
double bond is present; X is a phenyl or heteroaryl ring
substituted with A, wherein A is at least one member selected from
the group of --H, -halo, -alkyl, -alkoxy, --COOR.sub.2 and
-hydroxyl wherein R.sub.2 is --H--C.sub.1-6 alkyl, or substituted
--C.sub.1-6 alkyl; Y is selected from the group of --COOR.sub.2,
--C(O)NR.sub.2SO.sub.2R.sub.3,
--C(O)NR.sub.2SO.sub.2NR.sub.2R.sub.2, --SO.sub.2NR.sub.2R.sub.2,
--NR.sub.2SO.sub.2R.sub.2, --C.sub.1-6 cycloalkyl-COOR.sub.2,
--C.sub.1-6 alkenyl-COOR.sub.2, --C.sub.1-6 alkynyl-COOR.sub.2,
--C.sub.1-6 alkyl-COOR.sub.2, --NHC(O)(CH.sub.2).sub.n--COOR.sub.2,
--SO.sub.2NR.sub.2C(O)R.sub.2, -tetrazole, B(OH).sub.2 and --CONHOH
wherein n=1-6 and wherein R.sub.3 is C.sub.1-6 alkyl; and Z is
--CONR.sub.4R.sub.5; R.sub.4 is selected from the group of H,
C.sub.1-6 alkyl, and C.sub.1-6 alkyl-OH; R.sub.5 is selected from
the group of H, C.sub.1-6 alkyl, substituted-alkyl, C.sub.1-6
alkyl-R.sub.6, C.sub.2-6 alkyl-R.sub.7, SO.sub.2R.sub.8,
SO.sub.2NR.sub.9R.sub.10; R.sub.6 is selected from phenyl,
substituted phenyl, heteroaryl, substituted heteroaryl,
SO.sub.2R.sub.11, SO.sub.2NR.sub.12R.sub.13, C.sub.1-6 cycloalkyl,
substituted C.sub.1-6 cycloalkyl, SO.sub.3H, COOR.sub.14,
C(O)NR.sub.15R.sub.16; R.sub.7 is selected from OR.sub.17,
N.sup.+(O.sup.-)R.sub.18R.sub.19, NR.sub.20(COR.sub.21) and
NR.sub.22R.sub.23; or R.sub.4 and R.sub.5 are taken together to
form a cycle selected from the group of: ##STR00420## R.sub.22 and
R.sub.23 are selected from the group of H, C.sub.1-6 alkyl,
substituted-alkyl, C.sub.1-6 alkyl-R.sub.32, C.sub.2-6
alkyl-R.sub.33, SO.sub.2R.sub.8, SO.sub.2NR.sub.9R.sub.10; R.sub.32
is selected from phenyl, substituted phenyl, heteroaryl,
substituted heteroaryl, SO.sub.2R.sub.11,
SO.sub.2NR.sub.12R.sub.13, C.sub.1-6 cycloalkyl, substituted
C.sub.1-6 cycloalkyl, SO.sub.3H, COOR.sub.14,
C(O)NR.sub.15R.sub.16, R.sub.33 is selected from OR.sub.17,
N.sup.+(O.sup.-)R.sub.18R.sub.19, NR.sub.20(COR.sub.21) and
NR.sub.9R.sub.10; or R.sub.22 and R.sub.23 are taken together to
form a cycle selected from the group of: ##STR00421## R.sub.8,
R.sub.9, R.sub.10, R.sub.11, R.sub.12, R.sub.13, R.sub.14,
R.sub.15, R.sub.16, R.sub.17, R.sub.18, R.sub.19, R.sub.20,
R.sub.21, R.sub.27, R.sub.29, R.sub.30 and R.sub.31 are each
independently selected from the group of H, C.sub.1-6 alkyl,
substituted-alkyl, C.sub.1-6 cycloalkyl and substituted C.sub.1-6
cycloalkyl; R.sub.24, R.sub.26 and R.sub.28 are selected from the
group of H, alkyl, substituted alkyl, COOR.sub.29,
COONR.sub.30R.sub.31; and R.sub.25 is selected from the group of
alkyl, substituted alkyl, COOR.sub.29, COONR.sub.30R.sub.31; and
pharmaceutically acceptable salts thereof.
2. The compound as claimed in claim 1, wherein said compound is a
compound of Formula I.
3. The compound as claimed in claim 1, wherein said compound is a
compound of Formula II.
4. The compound as claimed in claim 2, wherein X is a phenyl ring,
and Y is in the para position.
5. The compound as claimed in claim 2, wherein X is a substituted
phenyl ring.
6. The compound as claimed in claim 5, wherein said phenyl ring is
substituted with A, and A is at least one member selected from the
group of --H, --OH and --F.
7. The compound as claimed in claim 6, wherein Y is --COOH.
8. The compound as claimed in claim 4, wherein X is a phenyl ring
and Y is --COOH in the para position according to Formula Ia:
##STR00422##
9. The compound as claimed in claim 8, wherein A is at least one
member selected from the group of --H, --OH and --F.
10. The compound as claimed in claim 9, wherein A is --H or
--F.
11. A compound which is selected from the group consisting of:
##STR00423## ##STR00424## ##STR00425## ##STR00426## ##STR00427##
##STR00428## ##STR00429## ##STR00430## ##STR00431## ##STR00432##
##STR00433## ##STR00434## ##STR00435## ##STR00436## ##STR00437##
##STR00438## ##STR00439## ##STR00440## ##STR00441## ##STR00442##
##STR00443## ##STR00444## ##STR00445## ##STR00446## ##STR00447##
##STR00448## ##STR00449## ##STR00450## ##STR00451## ##STR00452##
##STR00453## ##STR00454## and pharmaceutically acceptable salts
thereof.
12. A compound as claimed in claim 11, which is selected from the
group consisting of: ##STR00455## ##STR00456## ##STR00457##
13. A compound which is selected from the group consisting of:
##STR00458## and pharmaceutically acceptable salts thereof.
14. The compound as claimed in claim 2, wherein X is a 5-membered
heteroaryl ring and said compound is of the following formula:
##STR00459## wherein each of U, V and W is selected from the group
consisting of C, N, O and S, with the proviso that at least one of
U, V and W is other than C.
15. The compound as claimed in claim 14, wherein X is selected from
the group of thiophene, pyrazole, isoxazole, and oxadiazole
groups.
16. The compound as claimed in claim 15, wherein X is
thiophene.
17. The compound as claimed in claim 3, wherein X is a phenyl group
and Y is --COOH in the para position according to Formula IIa
below: ##STR00460## wherein A is at least one member selected from
the group of --H, -halo, --OH, --C.sub.1-3 alkyl and --C.sub.1-3
alkoxy, and wherein -halo is selected from the group of -fluoro and
-chloro.
18. The compound as claimed in claim 1, wherein said compound is a
compound of formula III.
19. A compound which is selected from the group consisting of:
##STR00461## and pharmaceutically acceptable salts thereof.
20. A pharmaceutical composition which comprises an antiviral
effective amount of one or more of the compounds as claimed in
claim 1, together with one or more pharmaceutically acceptable
carriers, excipients or diluents.
21. An intermediate compound which is selected from the group of:
##STR00462## wherein A is selected from the group of --H, -halo,
-alkyl, -alkoxy, --COOR.sub.2 and -hydroxyl, wherein R.sub.2 is
--H, --C.sub.1-6 alkyl, or substituted C.sub.1-6 alkyl, wherein
R.sub.4 is selected from the group of H, C.sub.1-6 alkyl, and
C.sub.1-6 alkyl-OH; wherein R.sub.5 is selected from the group of
H, C.sub.1-6 alkyl, substituted-alkyl, C.sub.1-6 alkyl-R.sub.6,
C.sub.2-6 alkyl-R.sub.7, SO.sub.2R.sub.8, SO.sub.2NR.sub.9R.sub.10;
wherein R.sub.6 is selected from phenyl, substituted phenyl,
heteroaryl, substituted heteroaryl, SO.sub.2R.sub.11,
SO.sub.2NR.sub.12R.sub.13, C.sub.1-6 cycloalkyl, substituted
C.sub.1-6 cycloalkyl, SO.sub.3H, COOR.sub.14,
C(O)NR.sub.15R.sub.16; wherein R.sub.7 is selected from OR.sub.17,
N.sup.+(O.sup.-)R.sub.18R.sub.19, NR.sub.20(COR.sub.21) and
NR.sub.22R.sub.23; wherein R.sub.8, R.sub.9, R.sub.10, R.sub.11,
R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17,
R.sub.18, R.sub.19, R.sub.20, R.sub.21 are each independently
selected from the group of H, C.sub.1-6 alkyl, substituted-alkyl,
C.sub.1-6 cycloalkyl and substituted C.sub.1-6 cycloalkyl; wherein
R.sub.22 and R.sub.23 are selected from the group of H, C.sub.1-6
alkyl, substituted-alkyl, C.sub.1-6 alkyl-R.sub.32, C.sub.2-6
alkyl-R.sub.33, SO.sub.2R.sub.8, SO.sub.2NR.sub.9R.sub.10; wherein
R.sub.32 is selected from phenyl, substituted phenyl, heteroaryl,
substituted heteroaryl, SO.sub.2R.sub.11,
SO.sub.2NR.sub.12R.sub.13, C.sub.1-6 cycloalkyl, substituted
C.sub.1-6 cycloalkyl, SO.sub.3H, COOR.sub.14,
C(O)NR.sub.15R.sub.16, and wherein R.sub.33 is selected from
OR.sub.17, N.sup.+(O.sup.-)R.sub.18R.sub.19, NR.sub.20(COR.sub.21)
and NR.sub.9R.sub.10.
22. An intermediate compound with the structure: ##STR00463##
Description
FIELD OF THE INVENTION
The present invention relates to novel compounds useful against
HIV, and more particularly, to compounds derived from betulinic
acid and other structurally related compounds which are useful as
HIV maturation inhibitors, and to pharmaceutical compositions
containing same, as well as to methods for their preparation and
use.
BACKGROUND OF THE INVENTION
HIV-1 (human immunodeficiency virus-1) infection remains a major
medical problem, with an estimated 45 million people infected
worldwide at the end of 2007. The number of cases of HIV and AIDS
(acquired immunodeficiency syndrome) has risen rapidly. In 2005,
approximately 5.0 million new infections were reported, and 3.1
million people died from AIDS. Currently available drugs for the
treatment of HIV include nucleoside reverse transcriptase (RT)
inhibitors or approved single pill combinations: zidovudine (or AZT
or RETROVIR.RTM.), didanosine (or VIDEX.RTM.), stavudine (or
ZERIT.RTM.), lamivudine (or 3TC or EPIVIR.RTM.), zalcitabine (or
DDC or HIVID.RTM.), abacavir succinate (or ZIAGEN.RTM.), Tenofovir
disoproxil fumarate salt (or VIREAD.RTM.), emtricitabine (or
FTC-EMTRIVA.RTM.), COMBIVIR.RTM. (contains -3TC plus AZT),
TRIZIVIR.RTM. (contains abacavir, lamivudine, and zidovudine),
EPZICOM.RTM. (contains abacavir and lamivudine), TRUVADA.RTM.
(contains VIREAD.RTM. and EMTRIVA.RTM.); non-nucleoside reverse
transcriptase inhibitors: nevirapine (or VIRAMUNE.RTM.),
delavirdine (or RESCRIPTOR.RTM.) and efavirenz (or SUSTIVA.RTM.),
ATRIPLA.RTM. (TRUVADA.RTM.+SUSTIVA.RTM.), and etravirine, and
peptidomimetic protease inhibitors or approved formulations:
saquinavir, indinavir, ritonavir, nelfinavir, amprenavir,
lopinavir, KALETRA.RTM. (lopinavir and Ritonavir), darunavir,
atazanavir (REYATAZ.RTM.) and tipranavir (APTIVUS.RTM.), and
integrase inhibitors such as raltegravir (ISENTRESS.RTM.), and
entry inhibitors such as enfuvirtide (T-20) (FUZEON.RTM.) and
maraviroc (SELZENRY.RTM.).
Each of these drugs can only transiently restrain viral replication
if used alone. However, when used in combination, these drugs have
a profound effect on viremia and disease progression. In fact,
significant reductions in death rates among AIDS patients have been
recently documented as a consequence of the widespread application
of combination therapy. However, despite these impressive results,
30 to 50% of patients may ultimately fail combination drug
therapies. Insufficient drug potency, non-compliance, restricted
tissue penetration and drug-specific limitations within certain
cell types (e.g. most nucleoside analogs cannot be phosphorylated
in resting cells) may account for the incomplete suppression of
sensitive viruses. Furthermore, the high replication rate and rapid
turnover of HIV-1 combined with the frequent incorporation of
mutations, leads to the appearance of drug-resistant variants and
treatment failures when sub-optimal drug concentrations are
present. Therefore, novel anti-HIV agents exhibiting distinct
resistance patterns, and favorable pharmacokinetic as well as
safety profiles are needed to provide more treatment options.
Improved HIV fusion inhibitors and HIV entry coreceptor antagonists
are two examples of new classes of anti-HIV agents further being
studied by a number of investigators.
HIV attachment inhibitors are a further subclass of antiviral
compounds that bind to the HIV surface glycoprotein gp120, and
interfere with the interaction between the surface protein gp120
and the host cell receptor CD4. Thus, they prevent HIV from
attaching to the human CD4 T-cell, and block HIV replication in the
first stage of the HIV life cycle. The properties of HIV attachment
inhibitors have been improved in an effort to obtain compounds with
maximized utility and efficacy as antiviral agents. In particular,
U.S. Pat. No. 7,354,924 and US 2005/0209246 are illustrative of HIV
attachment inhibitors.
Another emerging class of HIV treatment compounds are called HIV
maturation inhibitors. Maturation is the last of as many as 10 or
more steps in HIV replication or the HIV life cycle, in which HIV
becomes infectious as a consequence of several HIV
protease-mediated cleavage events in the gag protein that
ultimately results in release of the caspid (CA) protein.
Maturation inhibitors prevent the HIV capsid from properly
assembling and maturing, from forming a protective outer coat, or
from emerging from human cells. Instead, non-infectious viruses are
produced, preventing subsequent cycles of HIV infection.
Certain derivatives of betulinic acid have now been shown to
exhibit potent anti-HIV activity as HIV maturation inhibitors. For
example, U.S. Pat. No. 7,365,221 discloses monoacylated betulin and
dihydrobetuline derivatives, and their use as anti-HIV agents. As
discussed in the '221 reference, esterification of betulinic acid
(1) with certain substituted acyl groups, such as
3',3'-dimethylglutaryl and 3',3'-dimethylsuccinyl groups produced
derivatives having enhanced activity (Kashiwada, Y., et al., J.
Med. Chem. 39:1016-1017 (1996)). Acylated betulinic acid and
dihydrobetulinic acid derivatives that are potent anti-HIV agents
are also described in U.S. Pat. No. 5,679,828. Esterification of
the 3 carbon of betulin with succinic acid also produced a compound
capable of inhibiting HIV-1 activity (Pokrovskii, A. G., et al.,
Gos. Nauchnyi Tsentr Virusol. Biotekhnol. "Vector" 9:485-491
(2001)).
Other references to the use of treating HIV infection with
compounds derived from betulinic acid include US 2005/0239748 and
US 2008/0207573.
One HIV maturation compound that has been in development has been
identified as Bevirimat or PA-457, with the chemical formula of
C.sub.36H.sub.56O.sub.6 and the IUPAC name of
3.beta.-(3-carboxy-3-methyl-butanoyloxy) lup-20(29)-en-28-oic
acid.
Reference is also made herein to the provisional application by
Bristol-Myers Squibb entitled "MODIFIED C-3 BETULINIC ACID
DERIVATIVES AS HIV MATURATION INHIBITORS," filed on Jun. 4, 2010
and assigned U.S. Ser. No. 61/351,338.
What is now needed in the art are new compounds which are useful as
HIV maturation inhibitors, as well as new pharmaceutical
compositions containing these compounds.
SUMMARY OF THE INVENTION
The present invention provides compounds of Formulas I, II, and III
below, including pharmaceutically acceptable salts thereof, their
pharmaceutical formulations, and their use in patients suffering
from or susceptible to a virus such as HIV. The compounds of
Formulas I-III are effective antiviral agents, particularly as
inhibitors of HIV. They are useful for the treatment of HIV and
AIDS.
One embodiment of the present invention is directed to a compound,
including pharmaceutically acceptable salts thereof, which is
selected from the group of:
a compound of formula I
##STR00001## a compound of formula II
##STR00002## a compound of formula III
##STR00003## wherein R.sub.1 is isopropenyl or isopropyl; J and E
are --H or --CH.sub.3; E is absent when the double bond is present;
X is a phenyl or heteroaryl ring substituted with A, wherein A is
at least one member selected from the group of --H, -halo, -alkyl,
-alkoxy, --COOR.sub.2 and -hydroxyl wherein R.sub.2 is
--H--C.sub.1-6 alkyl or substituted --C.sub.1-6 alkyl; Y is
selected from the group of --COOR.sub.2,
--C(O)NR.sub.2SO.sub.2R.sub.3,
--C(O)NR.sub.2SO.sub.2NR.sub.2R.sub.2, --SO.sub.2NR.sub.2R.sub.2,
--NR.sub.2SO.sub.2R.sub.2, --C.sub.1-6 cycloalkyl-COOR.sub.2,
--C.sub.1-6 alkenyl-COOR.sub.2, --C.sub.1-6 alkynyl-COOR.sub.2,
--C.sub.1-6 alkyl-COOR.sub.2, --NHC(O)(CH.sub.2).sub.n--COOR.sub.2,
--SO.sub.2NR.sub.2C(O)R.sub.2, -tetrazole, B(OH).sub.2 and
--CONHOH, wherein n=1-6 and wherein R.sub.3 is C.sub.1-6 alkyl; and
Z is --CONR.sub.4R.sub.5; R.sub.4 is selected from the group of H,
C.sub.1-6 alkyl, and C.sub.1-6 alkyl-OH; R.sub.5 is selected from
the group of H, C.sub.1-6 alkyl, substituted-alkyl, C.sub.1-6
alkyl-R.sub.6, C.sub.2-6 alkyl-R.sub.7, SO.sub.2R.sub.8,
SO.sub.2NR.sub.9R.sub.10; R.sub.6 is selected from phenyl,
substituted phenyl, heteroaryl, substituted heteroaryl,
SO.sub.2R.sub.11, SO.sub.2NR.sub.12R.sub.13, C.sub.1-6 cycloalkyl,
substituted C.sub.1-6 cycloalkyl, SO.sub.3H, COOR.sub.14,
C(O)NR.sub.15R.sub.16; R.sub.7 is selected from OR.sub.17,
N.sup.+(O.sup.-)R.sub.18R.sub.19, NR.sub.20(COR.sub.21) and
NR.sub.22R.sub.23; or R.sub.4 and R.sub.5 are taken together to
form a cycle selected from the group of:
##STR00004## R.sub.22 and R.sub.23 are selected from the group of
H, C.sub.1-6 alkyl, substituted-alkyl, C.sub.1-6 alkyl-R.sub.32,
C.sub.2-6 alkyl-R.sub.33, SO.sub.2R.sub.8,
SO.sub.2NR.sub.9R.sub.10; R.sub.32 is selected from phenyl,
substituted phenyl, heteroaryl, substituted heteroaryl,
SO.sub.2R.sub.11, SO.sub.2NR.sub.12R.sub.13, C.sub.1-6 cycloalkyl,
substituted C.sub.1-6 cycloalkyl, SO.sub.3H, COOR.sub.14,
C(O)NR.sub.15R.sub.16, R.sub.33 is selected from the group of
OR.sub.17, N.sup.+(O.sup.-)R.sub.18R.sub.19, NR.sub.20(COR.sub.21)
and NR.sub.9R.sub.10, or R.sub.22 and R.sub.23 are taken together
to form a cycle selected from the group of:
##STR00005## R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12,
R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, R.sub.18,
R.sub.19, R.sub.20, R.sub.21, R.sub.27, R.sub.29, R.sub.30 and
R.sub.31 are each independently selected from the group of H,
C.sub.1-6 alkyl, substituted-alkyl, C.sub.1-6 cycloalkyl and
substituted C.sub.1-6 cycloalkyl; R.sub.24, R.sub.26 and R.sub.28
are selected from the group of H, alkyl, substituted alkyl,
COOR.sub.29, COONR.sub.30R.sub.31; and R.sub.25 is selected from
the group of alkyl, substituted alkyl, COOR.sub.29,
COONR.sub.30R.sub.31.
In a further embodiment, there is provided a method for treating
mammals infected with a virus, especially wherein said virus is
HIV, comprising administering to said mammal an antiviral effective
amount of a compound which is selected from the group of compounds
of Formulas I, II, III above, and one or more pharmaceutically
acceptable carriers, excipients or diluents. Optionally, the
compound of Formulas I, II, and/or III can be administered in
combination with an antiviral effective amount of another--AIDS
treatment agent selected from the group consisting of: (a) an AIDS
antiviral agent; (b) an anti-infective agent; (c) an
immunomodulator; and (d) other HIV entry inhibitors.
Another embodiment of the present invention is a pharmaceutical
composition comprising an antiviral effective amount of a compound
which is selected from the group of compounds of Formulas I, II,
and III, and one or more pharmaceutically acceptable carriers,
excipients, and diluents; and optionally in combination with an
antiviral effective amount of another AIDS treatment agent selected
from the group consisting of: (a) an AIDS antiviral agent; (b) an
anti-infective agent; (c) an immunomodulator; and (d) other HIV
entry inhibitors.
In another embodiment of the invention there is provided one or
more methods for making the compounds of Formulas I, II, and
III.
The present invention is directed to these, as well as other
important ends, hereinafter described.
DETAILED DESCRIPTION OF THE EMBODIMENTS
Since the compounds of the present invention may possess asymmetric
centers and therefore occur as mixtures of diastereomers and
enantiomers, the present disclosure includes the individual
diastereoisomeric and enantiomeric forms of the compounds of
Formulas I, II and III in addition to the mixtures thereof.
The terms "C-3" and "C-28" refer to certain positions of a
triterpene core as numbered in accordance with IUPAC rules
(positions depicted below with respect to an illustrative
triterpene: betulin):
##STR00006## The same numbering is maintained when referring to the
compound series in schemes and general descriptions of methods.
##STR00007##
DEFINITIONS
Unless otherwise specifically set forth elsewhere in the
application, one or more of the following terms may be used herein,
and shall have the following meanings:
"H" refers to hydrogen, including its isotopes, such as
deuterium.
The term "C.sub.1-6 alkyl" as used herein and in the claims (unless
specified otherwise) mean straight or branched chain alkyl groups
such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl,
amyl, hexyl and the like.
"C.sub.1-C.sub.4 fluoroalkyl" refers to F-substituted
C.sub.1-C.sub.4 alkyl wherein at least one H atom is substituted
with F atom, and each H atom can be independently substituted by F
atom;
"Halogen" refers to chlorine, bromine, iodine or fluorine.
An "aryl" or "Ar" group refers to an all carbon monocyclic or
fused-ring polycyclic (i.e., rings which share adjacent pairs of
carbon atoms) groups having a completely conjugated pi-electron
system. Examples, without limitation, of aryl groups are phenyl,
napthalenyl and anthracenyl. The aryl group may be substituted or
unsubstituted. When substituted the substituted group(s) is
preferably one or more selected from alkyl, cycloalkyl, aryl,
heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy,
heteroaryloxy, heteroalicycloxy, thiohydroxy, thioaryloxy,
thioheteroaryloxy, thioheteroalicycloxy, cyano, halogen, nitro,
carbonyl, O-carbamyl, N-carbamyl, C-amido, N-amido, C-carboxy,
O-carboxy, sulfinyl, sulfonyl, sulfonamido, trihalomethyl, ureido,
amino and --NR.sup.xR.sup.y, wherein R.sup.x and R.sup.y are
independently selected from the group consisting of hydrogen,
alkyl, cycloalkyl, aryl, carbonyl, C-carboxy, sulfonyl,
trihalomethyl, and, combined, a five- or six-member heteroalicyclic
ring.
As used herein, a "heteroaryl" group refers to a monocyclic or
fused ring (i.e., rings which share an adjacent pair of atoms)
group having in the ring(s) one or more atoms selected from the
group consisting of nitrogen, oxygen and sulfur and, in addition,
having a completely conjugated pi-electron system. Unless otherwise
indicated, the heteroaryl group may be attached at either a carbon
or nitrogen atom within the heteroaryl group. It should be noted
that the term heteroaryl is intended to encompass an N-oxide of the
parent heteroaryl if such an N-oxide is chemically feasible as is
known in the art. Examples, without limitation, of heteroaryl
groups are furyl, thienyl, benzothienyl, thiazolyl, imidazolyl,
oxazolyl, oxadiazolyl, thiadiazolyl, benzothiazolyl, triazolyl,
tetrazolyl, isoxazolyl, isothiazolyl, pyrrolyl, pyranyl,
tetrahydropyranyl, pyrazolyl, pyridyl, pyrimidinyl, quinolinyl,
isoquinolinyl, purinyl, carbazolyl, benzoxazolyl, benzimidazolyl,
indolyl, isoindolyl, pyrazinyl. diazinyl, pyrazine, triazinyl,
tetrazinyl, and tetrazolyl. When substituted the substituted
group(s) is preferably one or more selected from alkyl, cycloalkyl,
aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy,
heteroaryloxy, heteroalicycloxy, thioalkoxy, thiohydroxy,
thioaryloxy, thioheteroaryloxy, thioheteroalicycloxy, cyano,
halogen, nitro, carbonyl, O-carbamyl, N-carbamyl, C-amido, N-amido,
C-carboxy, O-carboxy, sulfinyl, sulfonyl, sulfonamido,
trihalomethyl, ureido, amino, and --NR.sup.xR.sup.y, wherein
R.sup.x and R.sup.y are as defined above.
As used herein, a "heteroalicyclic" group refers to a monocyclic or
fused ring group having in the ring(s) one or more atoms selected
from the group consisting of nitrogen, oxygen and sulfur. Rings are
selected from those which provide stable arrangements of bonds and
are not intended to encompass systems which would not exist. The
rings may also have one or more double bonds. However, the rings do
not have a completely conjugated pi-electron system. Examples,
without limitation, of heteroalicyclic groups are azetidinyl,
piperidyl, piperazinyl, imidazolinyl, thiazolidinyl,
3-pyrrolidin-1-yl, morpholinyl, thiomorpholinyl and
tetrahydropyranyl. When substituted the substituted group(s) is
preferably one or more selected from alkyl, cycloalkyl, aryl,
heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy,
heteroaryloxy, heteroalicycloxy, thiohydroxy, thioalkoxy,
thioaryloxy, thioheteroaryloxy, thioheteroalicycloxy, cyano,
halogen, nitro, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl,
O-thiocarbamyl, N-thiocarbamyl, C-amido, C-thioamido, N-amido,
C-carboxy, O-carboxy, sulfinyl, sulfonyl, sulfonamido,
trihalomethanesulfonamido, trihalomethanesulfonyl, silyl, guanyl,
guanidino, ureido, phosphonyl, amino and --NR.sup.xR.sup.y, wherein
R.sup.x and R.sup.y are as defined above.
An "alkyl" group refers to a saturated aliphatic hydrocarbon
including straight chain and branched chain groups. Preferably, the
alkyl group has 1 to 20 carbon atoms (whenever a numerical range;
e.g., "1-20", is stated herein, it means that the group, in this
case the alkyl group may contain 1 carbon atom, 2 carbon atoms, 3
carbon atoms, etc. up to and including 20 carbon atoms). More
preferably, it is a medium size alkyl having 1 to 10 carbon atoms.
Most preferably, it is a lower alkyl having 1 to 4 carbon atoms.
The alkyl group may be substituted or unsubstituted. When
substituted, the substituent group(s) is preferably one or more
individually selected from trihaloalkyl, cycloalkyl, aryl,
heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy,
heteroaryloxy, heteroalicycloxy, thiohydroxy, thioalkoxy,
thioaryloxy, thioheteroaryloxy, thioheteroalicycloxy, cyano, halo,
nitro, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl,
O-thiocarbamyl, N-thiocarbamyl, C-amido, C-thioamido, N-amido,
C-carboxy, O-carboxy, sulfinyl, sulfonyl, sulfonamido,
trihalomethanesulfonamido, trihalomethanesulfonyl, and combined, a
five- or six-member heteroalicyclic ring.
A "cycloalkyl" group refers to an all-carbon monocyclic or fused
ring (i.e., rings which share and adjacent pair of carbon atoms)
group wherein one or more rings does not have a completely
conjugated pi-electron system. Examples, without limitation, of
cycloalkyl groups are cyclopropane, cyclobutane, cyclopentane,
cyclopentene, cyclohexane, cyclohexene, cycloheptane, cycloheptene
and adamantane. A cycloalkyl group may be substituted or
unsubstituted. When substituted, the substituent group(s) is
preferably one or more individually selected from alkyl, aryl,
heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy,
heteroaryloxy, heteroalicycloxy, thiohydroxy, thioalkoxy,
thioaryloxy, thioheteroaryloxy, thioheteroalicycloxy, cyano, halo,
nitro, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl,
O-thiocarbamyl, N-thiocarbamyl, C-amido, C-thioamido, N-amido,
C-carboxy, O-carboxy, sulfinyl, sulfonyl, sulfonamido,
trihalomethanesulfonamido, trihalomethanesulfonyl, silyl, amidino,
guanidino, ureido, phosphonyl, amino and --NR.sup.xR.sup.y with
R.sup.x and R.sup.Y as defined above.
An "alkenyl" group refers to an alkyl group, as defined herein,
having at least two carbon atoms and at least one carbon-carbon
double bond.
An "alkynyl" group refers to an alkyl group, as defined herein,
having at least two carbon atoms and at least one carbon-carbon
triple bond.
A "hydroxy" group refers to an --OH group.
An "alkoxy" group refers to both an --O-alkyl and an --O-cycloalkyl
group as defined herein.
An "aryloxy" group refers to both an --O-aryl and an --O-heteroaryl
group, as defined herein.
A "heteroaryloxy" group refers to a heteroaryl-O-- group with
heteroaryl as defined herein.
A "heteroalicycloxy" group refers to a heteroalicyclic-O-- group
with heteroalicyclic as defined herein.
A "thiohydroxy" group refers to an --SH group.
A "thioalkoxy" group refers to both an S-alkyl and an
--S-cycloalkyl group, as defined herein.
A "thioaryloxy" group refers to both an --S-aryl and an
--S-heteroaryl group, as defined herein.
A "thioheteroaryloxy" group refers to a heteroaryl-S-- group with
heteroaryl as defined herein.
A "thioheteroalicycloxy" group refers to a heteroalicyclic-S--
group with heteroalicyclic as defined herein.
A "carbonyl" group refers to a --C(.dbd.O)--R'' group, where R'' is
selected from the group consisting of hydrogen, alkyl, alkenyl,
alkynyl, cycloalkyl, aryl, heteroaryl (bonded through a ring
carbon) and heteroalicyclic (bonded through a ring carbon), as each
is defined herein.
An "aldehyde" group refers to a carbonyl group where R'' is
hydrogen.
A "thiocarbonyl" group refers to a --C(.dbd.S)--R'' group, with R''
as defined herein.
A "Keto" group refers to a --CC(.dbd.O)C-- group wherein the carbon
on either or both sides of the C.dbd.O may be alkyl, cycloalkyl,
aryl or a carbon of a heteroaryl or heteroalicyclic group.
A "trihalomethanecarbonyl" group refers to a Z.sub.3CC(.dbd.O)--
group with said Z being a halogen.
A "C-carboxy" group refers to a --C(.dbd.O)O--R'' groups, with R''
as defined herein.
An "O-carboxy" group refers to a R''C(--O)O-group, with R'' as
defined herein.
A "carboxylic acid" group refers to a C-carboxy group in which R''
is hydrogen.
A "trihalomethyl" group refers to a --CZ.sub.3, group wherein Z is
a halogen group as defined herein.
A "trihalomethanesulfonyl" group refers to an
Z.sub.3CS(.dbd.O).sub.2-- groups with Z as defined above.
A "trihalomethanesulfonamido" group refers to a
Z.sub.3CS(.dbd.O).sub.2NR.sup.x-- group with Z as defined above and
R.sup.x being H or (C.sub.1-6)alkyl.
A "sulfinyl" group refers to a --S(.dbd.O)--R'' group, with R''
being (C.sub.1-6)alkyl.
A "sulfonyl" group refers to a --S(.dbd.O).sub.2R'' group with R''
being (C.sub.1-6)alkyl.
A "S-sulfonamido" group refers to a
--S(.dbd.O).sub.2NR.sup.xR.sup.Y, with R.sup.X and R.sup.Y
independently being H or (C.sub.1-6)alkyl.
A "N-Sulfonamido" group refers to a R''S(.dbd.O).sub.2NR.sub.x--
group, with R.sub.x being H or (C.sub.1-6)alkyl.
A "O-carbamyl" group refers to a --OC(.dbd.O)NR.sup.xR.sup.y group,
with R.sup.X and R.sup.Y independently being H or
(C.sub.1-6)alkyl.
A "N-carbamyl" group refers to a R.sup.xOC(.dbd.O)NR.sup.y group,
with R.sup.x and R.sup.y independently being H or
(C.sub.1-6)alkyl.
A "O-thiocarbamyl" group refers to a --OC(.dbd.S)NR.sup.xR.sup.y
group, with R.sup.x and R.sup.Y independently being H or
(C.sub.1-6)alkyl.
A "N-thiocarbamyl" group refers to a R.sup.xOC(.dbd.S)NR.sup.y--
group, with R.sup.x and R.sup.y independently being H or
(C.sub.1-6)alkyl.
An "amino" group refers to an --NH.sub.2 group.
A "C-amido" group refers to a --C(.dbd.O)NR.sup.xR.sup.y group,
with R.sup.x and R.sup.y independently being H or
(C.sub.1-6)alkyl.
A "C-thioamido" group refers to a --C(.dbd.S)NR.sup.xR.sup.y group,
with R.sup.x and R.sup.y independently being H or
(C.sub.1-6)alkyl.
A "N-amido" group refers to a R.sup.xC(.dbd.O)NR.sup.y-- group,
with R.sup.x and R.sup.y independently being H or
(C.sub.1-6)alkyl.
An "ureido" group refers to a --NR.sup.xC(.dbd.O)NR.sup.yR.sup.y2
group, with R.sup.x, R.sup.y, and R.sup.y2 independently being H or
(C.sub.1-6)alkyl.
A "guanidino" group refers to a --R.sup.xNC(.dbd.N)NR.sup.yR.sup.y2
group, with R.sup.x, R.sup.y, and R.sup.y2 independently being H or
(C.sub.1-6)alkyl.
A "amidino" group refers to a R.sup.xR.sup.yNC(.dbd.N)-- group,
with R.sup.x and R.sup.y independently being H or
(C.sub.1-6)alkyl.
A "cyano" group refers to a --CN group.
A "silyl" group refers to a --Si(R'').sub.3, with R'' being
(C.sub.1-6)alkyl or phenyl.
A "phosphonyl" group refers to a P(.dbd.O)(OR.sup.x).sub.2 with
R.sup.x being (C.sub.1-6)alkyl.
A "hydrazino" group refers to a --NR.sup.xNR.sup.yR.sup.y2 group,
with R.sup.x, R.sup.y, and R.sup.y2 independently being H or
(C.sub.1-6)alkyl.
A "4, 5, or 6 membered ring cyclic N-lactam" group refers to
##STR00008##
Any two adjacent R groups may combine to form an additional aryl,
cycloalkyl, heteroaryl or heterocyclic ring fused to the ring
initially bearing those R groups.
It is known in the art that nitrogen atoms in heteroaryl systems
can be "participating in a heteroaryl ring double bond", and this
refers to the form of double bonds in the two tautomeric structures
which comprise five-member ring heteroaryl groups. This dictates
whether nitrogens can be substituted as well understood by chemists
in the art. The disclosure and claims of the present disclosure are
based on the known general principles of chemical bonding. It is
understood that the claims do not encompass structures known to be
unstable or not able to exist based on the literature.
Pharmaceutically acceptable salts and prodrugs of compounds
disclosed herein are within the scope of the invention. The term
"pharmaceutically acceptable salt" as used herein and in the claims
is intended to include nontoxic base addition salts. Suitable salts
include those derived from organic and inorganic acids such as,
without limitation, hydrochloric acid, hydrobromic acid, phosphoric
acid, sulfuric acid, methanesulfonic acid, acetic acid, tartaric
acid, lactic acid, sulfinic acid, citric acid, maleic acid, fumaric
acid, sorbic acid, aconitic acid, salicylic acid, phthalic acid,
and the like. The term "pharmaceutically acceptable salt" as used
herein is also intended to include salts of acidic groups, such as
a carboxylate, with such counterions as ammonium, alkali metal
salts, particularly sodium or potassium, alkaline earth metal
salts, particularly calcium or magnesium, and salts with suitable
organic bases such as lower alkylamines (methylamine, ethylamine,
cyclohexylamine, and the like) or with substituted lower
alkylamines (e.g. hydroxyl-substituted alkylamines such as
diethanolamine, triethanolamine or
tris(hydroxymethyl)-aminomethane), or with bases such as piperidine
or morpholine.
As stated above, the compounds of the invention also include
"prodrugs". The term "prodrug" as used herein encompasses both the
term "prodrug esters" and the term "prodrug ethers". The term
"prodrug esters" as employed herein includes esters and carbonates
formed by reacting one or more hydroxyls of compounds of Formula I
with either alkyl, alkoxy, or aryl substituted acylating agents or
phosphorylating agent employing procedures known to those skilled
in the art to generate acetates, pivalates, methylcarbonates,
benzoates, amino acid esters, phosphates, half acid esters such as
malonates, succinates or glutarates, and the like. In certain
embodiments, amino acid esters may be especially preferred.
Examples of such prodrug esters include
##STR00009##
The term "prodrug ethers" include both phosphate acetals and
O-glucosides. Representative examples of such prodrug ethers
include
##STR00010##
As set forth above, the invention is directed to a compound,
including pharmaceutically acceptable salts thereof, which is
selected from the group of:
a compound of formula I
##STR00011## a compound of formula II
##STR00012## a compound of formula III
##STR00013## wherein R.sub.1 is isopropenyl or isopropyl; J and E
are --H or --CH.sub.3; E is absent when the double bond is present;
X is a phenyl or heteroaryl ring substituted with A, wherein A is
at least one member selected from the group of --H, -halo, -alkyl,
-alkoxy, --COOR.sub.2 and -hydroxyl wherein R.sub.2 is
--H--C.sub.1-6 alkyl, or substituted --C.sub.1-6 alkyl; Y is
selected from the group of --COOR.sub.2,
--C(O)NR.sub.2SO.sub.2R.sub.3,
--C(O)NR.sub.2SO.sub.2NR.sub.2R.sub.2, --SO.sub.2NR.sub.2R.sub.2,
--NR.sub.2SO.sub.2R.sub.2, --C.sub.1-6 cycloalkyl-COOR.sub.2,
--C.sub.1-6 alkenyl-COOR.sub.2, --C.sub.1-6 alkynyl-COOR.sub.2,
--C.sub.1-6 alkyl-COOR.sub.2, --NHC(O)(CH.sub.2).sub.n--COOR.sub.2,
--SO.sub.2NR.sub.2C(O)R.sub.2, -tetrazole, B(OH).sub.2 and --CONHOH
wherein n=1-6 and wherein R.sub.3 is C.sub.1-6 alkyl; and Z is
--CONR.sub.4R.sub.5; R.sub.4 is selected from the group of H,
C.sub.1-6 alkyl, and C.sub.1-6 alkyl-OH; R.sub.5 is selected from
the group of H, C.sub.1-6 alkyl, substituted-alkyl, C.sub.1-6
alkyl-R.sub.6, C.sub.2-6 alkyl-R.sub.7, SO.sub.2R.sub.8,
SO.sub.2NR.sub.9R.sub.10; R.sub.6 is selected from phenyl,
substituted phenyl, heteroaryl, substituted heteroaryl,
SO.sub.2R.sub.11, SO.sub.2NR.sub.12R.sub.13, C.sub.1-6 cycloalkyl,
substituted C.sub.1-6 cycloalkyl, SO.sub.3H, COOR.sub.14,
C(O)NR.sub.15R.sub.16; R.sub.7 is selected from OR.sub.12,
N.sup.+(O.sup.-)R.sub.18R.sub.19, NR.sub.20(COR.sub.21) and
NR.sub.22R.sub.23; or R.sub.4 and R.sub.5 are taken together to
form a cycle selected from the group of:
##STR00014## R.sub.22 and R.sub.23 are selected from the group of
H, C.sub.1-6 alkyl, substituted-alkyl, C.sub.1-6 alkyl-R.sub.32,
C.sub.2-6 alkyl-R.sub.33, SO.sub.2R.sub.8,
SO.sub.2NR.sub.9R.sub.10; R.sub.32 is selected from phenyl,
substituted phenyl, heteroaryl, substituted heteroaryl,
SO.sub.2R.sub.11, SO.sub.2NR.sub.12R.sub.13, C.sub.1-6 cycloalkyl,
substituted C.sub.1-6 cycloalkyl, SO.sub.3H, COOR.sub.14,
C(O)NR.sub.15R.sub.16; R.sub.33 is selected from OR.sub.12,
N.sup.+(O.sup.-)R.sub.18R.sub.19, NR.sub.20(COR.sub.21) and
NR.sub.9R.sub.10; or R.sub.22 and R.sub.23 are taken together to
form a cycle selected from the group of:
##STR00015## R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12,
R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, R.sub.18,
R.sub.19, R.sub.20, R.sub.21, R.sub.27, R.sub.29, R.sub.30 and
R.sub.31 are each independently selected from the group of H,
C.sub.1-6 alkyl, substituted-alkyl, C.sub.1-6 cycloalkyl and
substituted C.sub.1-6 cycloalkyl; R.sub.24, R.sub.26 and R.sub.28
are selected from the group of H, alkyl, substituted alkyl,
--COOR.sub.29, --COONR.sub.30R.sub.31; and R.sub.25 is selected
from the group of alkyl, substituted alkyl, --COOR.sub.29,
--COONR.sub.30R.sub.31.
More preferred compounds include those which are encompassed by
Formula I. Of these, those wherein X is a phenyl ring are even more
preferred. Even more preferred are compounds of Formula I wherein X
is a phenyl ring and Y is in the para position.
Also preferred are compounds of Formula I wherein A is at least one
member selected from the group of --H, --OH, -halo, --C.sub.1-3
alkyl, and --C.sub.1-3 alkoxy, wherein -halo is selected from the
group of --Cl, --F and --Br, with --F being more preferred.
Also preferred are compounds of Formula I wherein Y is --COOH.
In another preferred embodiment there is provided a compound of
Formula Ia below wherein X is a phenyl ring and Y is --COOH in the
para position:
##STR00016## In this embodiment, it is also preferred that A is at
least one member selected from the group of --H, -halo, --OH,
--C.sub.1-3 alkyl and --C.sub.1-3 alkoxy. It is particularly
preferred that A is at least one member selected from the group of
--H, -fluoro, -chloro, --OH, -methyl and -methoxy. Other compounds
encompassed by Formula I which are preferred as part of the
invention
##STR00017## ##STR00018## ##STR00019## ##STR00020## ##STR00021##
##STR00022## ##STR00023## ##STR00024## ##STR00025## ##STR00026##
##STR00027## ##STR00028## ##STR00029## ##STR00030## ##STR00031##
##STR00032## ##STR00033## ##STR00034## ##STR00035## ##STR00036##
##STR00037## ##STR00038## ##STR00039## ##STR00040## ##STR00041##
##STR00042## ##STR00043## ##STR00044## ##STR00045## ##STR00046##
##STR00047## ##STR00048##
Of the foregoing, the following compounds are particularly
preferred:
##STR00049## ##STR00050## ##STR00051##
Also preferred as part of the invention are the compounds of
Formula I wherein X is 5 or 6-membered heteroaryl ring. In
particular, the compounds of Formula I wherein X is a 5-membered
heteroaryl ring having the following structure are particularly
preferred:
##STR00052## wherein each of U, V and W is selected from the group
consisting of C, N, O and S, with the proviso that at least one of
U, V and W is other than C. Of these, the compounds wherein X is
selected from the group of thiophene, pyrazole, isoxaxole, and
oxadiazole groups are particularly preferred, with thiophene being
even more preferred.
Also preferred are the compounds of Formula I wherein X is a
6-membered heteroaryl ring selected from the group of pyridyl and
pyrimidine rings.
Other preferred compounds of the invention include those which are
encompassed by Formula II as set forth above. Of these, the
compounds wherein X is a phenyl group and Y is --COOH in the para
position (and wherein A is as previously set forth) according to
Formula IIa below are particularly preferred:
##STR00053##
Preferred examples of the compounds of Formula IIa include the
following:
##STR00054##
In addition, preferred examples of the compounds of Formula III
include the following:
##STR00055##
The compounds of the present invention, according to all the
various embodiments described above, may be administered orally,
parenterally (including subcutaneous injections, intravenous,
intramuscular, intrasternal injection or infusion techniques), by
inhalation spray, or rectally, and by other means, in dosage unit
formulations containing non-toxic pharmaceutically acceptable
carriers, excipients and diluents available to the skilled artisan.
One or more adjuvants may also be included.
Thus, in accordance with the present invention, there is further
provided a method of treatment, and a pharmaceutical composition,
for treating viral infections such as HIV infection and AIDS. The
treatment involves administering to a patient in need of such
treatment a pharmaceutical composition which contains an antiviral
effective amount of one or more of the compounds of Formulas I, II,
and/or III, together with one or more pharmaceutically acceptable
carriers, excipients or diluents. As used herein, the term
"antiviral effective amount" means the total amount of each active
component of the composition and method that is sufficient to show
a meaningful patient benefit, i.e., inhibiting, ameliorating, or
healing of acute conditions characterized by inhibition of the HIV
infection. When applied to an individual active ingredient,
administered alone, the term refers to that ingredient alone. When
applied to a combination, the term refers to combined amounts of
the active ingredients that result in the therapeutic effect,
whether administered in combination, serially or simultaneously.
The terms "treat, treating, treatment" as used herein and in the
claims means preventing, ameliorating or healing diseases
associated with HIV infection.
The pharmaceutical compositions of the invention may be in the form
of orally administrable suspensions or tablets; as well as nasal
sprays, sterile injectable preparations, for example, as sterile
injectable aqueous or oleaginous suspensions or suppositories.
Pharmaceutically acceptable carriers, excipients or diluents may be
utilized in the pharmaceutical compositions, and are those utilized
in the art of pharmaceutical preparations.
When administered orally as a suspension, these compositions are
prepared according to techniques typically known in the art of
pharmaceutical formulation and may contain microcrystalline
cellulose for imparting bulk, alginic acid or sodium alginate as a
suspending agent, methylcellulose as a viscosity enhancer, and
sweeteners/flavoring agents known in the art. As immediate release
tablets, these compositions may contain microcrystalline cellulose,
dicalcium phosphate, starch, magnesium stearate and lactose and/or
other excipients, binders, extenders, disintegrants, diluents, and
lubricants known in the art.
The injectable solutions or suspensions may be formulated according
to known art, using suitable non-toxic, parenterally acceptable
diluents or solvents, such as mannitol, 1,3-butanediol, water,
Ringer's solution or isotonic sodium chloride solution, or suitable
dispersing or wetting and suspending agents, such as sterile,
bland, fixed oils, including synthetic mono- or diglycerides, and
fatty acids, including oleic acid.
The compounds herein set forth can be administered orally to humans
in a dosage range of about 1 to 100 mg/kg body weight in divided
doses, usually over an extended period, such as days, weeks,
months, or even years. One preferred dosage range is about 1 to 10
mg/kg body weight orally in divided doses. Another preferred dosage
range is about 1 to 20 mg/kg body weight in divided doses. It will
be understood, however, that the specific dose level and frequency
of dosage for any particular patient may be varied and will depend
upon a variety of factors including the activity of the specific
compound employed, the metabolic stability and length of action of
that compound, the age, body weight, general health, sex, diet,
mode and time of administration, rate of excretion, drug
combination, the severity of the particular condition, and the host
undergoing therapy.
Also contemplated herein are combinations of the compounds of
Formulas I, II, and/or III herein set forth, together with one or
more other agents useful in the treatment of AIDS. For example, the
compounds of this disclosure may be effectively administered,
whether at periods of pre-exposure and/or post-exposure, in
combination with effective amounts of the AIDS antivirals,
immunomodulators, antiinfectives, or vaccines, such as those in the
following non-limiting table:
TABLE-US-00001 Drug Name Manufacturer Indication ANTIVIRALS 097
Hoechst/Bayer HIV infection, AIDS, ARC (non-nucleoside reverse
transcriptase (RT) inhibitor) Amprenavir Glaxo Wellcome HIV
infection, AIDS, 141 W94 ARC (protease inhibitor) GW 141 Abacavir
(1592U89) Glaxo Wellcome HIV infection, AIDS, GW 1592 ARC (RT
inhibitor) Acemannan Carrington Labs ARC (Irving, TX) Acyclovir
Burroughs Wellcome HIV infection, AIDS, ARC AD-439 Tanox Biosystems
HIV infection, AIDS, ARC AD-519 Tanox Biosystems HIV infection,
AIDS, ARC Adefovir dipivoxil Gilead Sciences HIV infection ARC,
AL-721 Ethigen PGL (Los Angeles, CA) HIV positive, AIDS Alpha
Interferon Glaxo Wellcome Kaposi's sarcoma, HIV in combination
w/Retrovir Ansamycin Adria Laboratories ARC LM 427 (Dublin, OH)
Erbamont (Stamford, CT) Antibody which Advanced Biotherapy AIDS,
ARC Neutralizes pH Concepts Labile alpha aberrant (Rockville, MD)
Interferon AR177 Aronex Pharm HIV infection, AIDS, ARC
Beta-fluoro-ddA Nat'l Cancer Institute AIDS-associated diseases
BMS-234475 Bristol-Myers Squibb/ HIV infection, AIDS, (CGP-61755)
Novartis ARC (protease inhibitor) CI-1012 Warner-Lambert HIV-1
infection Cidofovir Gilead Science CMV retinitis, herpes,
papillomavirus Curdlan sulfate AJI Pharma USA HIV infection
Cytomegalovirus MedImmune CMV retinitis Immune globin Cytovene
Syntex Sight threatening Ganciclovir CMV peripheral CMV retinitis
Darunavir Tibotec- J & J HIV infection, AIDS, ARC (protease
inhibitor) Delaviridine Pharmacia-Upjohn HIV infection, AIDS, ARC
(RT inhibitor) Dextran Sulfate Ueno Fine Chem. AIDS, ARC, HIV Ind.
Ltd. (Osaka, positive Japan) asymptomatic ddC Hoffman-La Roche HIV
infection, AIDS, Dideoxycytidine ARC ddI Bristol-Myers Squibb HIV
infection, AIDS, Dideoxyinosine ARC; combination with AZT/d4T
DMP-450 AVID HIV infection, AIDS, (Camden, NJ) ARC (protease
inhibitor) Efavirenz Bristol Myers Squibb HIV infection, AIDS, (DMP
266, SUSTIVA .RTM.) ARC (non-nucleoside RT (-)6-Chloro-4-(S)-
inhibitor) cyclopropylethynyl- 4(S)-trifluoro- methyl-1,4-dihydro-
2H-3,1-benzoxazin- 2-one, STOCRINE EL10 Elan Corp, PLC HIV
infection (Gainesville, GA) Etravirine Tibotec/J & J HIV
infection, AIDS, ARC (non-nucleoside reverse transcriptase
inhibitor) Famciclovir Smith Kline herpes zoster, herpes simplex GS
840 Gilead HIV infection, AIDS, ARC (reverse transcriptase
inhibitor) HBY097 Hoechst Marion HIV infection, AIDS, Roussel ARC
(non-nucleoside reverse transcriptase inhibitor) Hypericin VIMRx
Pharm. HIV infection, AIDS, ARC Recombinant Human Triton
Biosciences AIDS, Kaposi's Interferon Beta (Almeda, CA) sarcoma,
ARC Interferon alfa-n3 Interferon Sciences ARC, AIDS Indinavir
Merck HIV infection, AIDS, ARC, asymptomatic HIV positive, also in
combination with AZT/ddI/ddC ISIS 2922 ISIS Pharmaceuticals CMV
retinitis KNI-272 Nat'l Cancer Institute HIV-assoc. diseases
Lamivudine, 3TC Glaxo Wellcome HIV infection, AIDS, ARC (reverse
transcriptase inhibitor); also with AZT Lobucavir Bristol-Myers
Squibb CMV infection Nelfinavir Agouron HIV infection, AIDS,
Pharmaceuticals ARC (protease inhibitor) Nevirapine Boeheringer
Ingleheim HIV infection, AIDS, ARC (RT inhibitor) Novapren
Novaferon Labs, Inc. HIV inhibitor (Akron, OH) Peptide T Peninsula
Labs AIDS Octapeptide (Belmont, CA) Sequence Trisodium Astra Pharm.
CMV retinitis, HIV Phosphonoformate Products, Inc. infection, other
CMV infections PNU-140690 Pharmacia Upjohn HIV infection, AIDS, ARC
(protease inhibitor) Probucol Vyrex HIV infection, AIDS RBC-CD4
Sheffield Med. HIV infection, AIDS, Tech (Houston, TX) ARC
Ritonavir Abbott HIV infection, AIDS, ARC (protease inhibitor)
Saquinavir Hoffmann-LaRoche HIV infection, AIDS, ARC (protease
inhibitor) Stavudine; d4T Bristol-Myers Squibb HIV infection, AIDS,
Didehydrodeoxy- ARC Thymidine Tipranavir Boehringer Ingelheim HIV
infection, AIDS, ARC (protease inhibitor) Valaciclovir Glaxo
Wellcome Genital HSV & CMV infections Virazole Viratek/ICN
asymptomatic HIV Ribavirin (Costa Mesa, CA) positive, LAS, ARC
VX-478 Vertex HIV infection, AIDS, ARC Zalcitabine Hoffmann-LaRoche
HIV infection, AIDS, ARC, with AZT Zidovudine; AZT Glaxo Wellcome
HIV infection, AIDS, ARC, Kaposi's sarcoma, in combination with
other therapies Tenofovir disoproxil, Gilead HIV infection, AIDS,
fumarate salt (VIREAD .RTM.) (reverse transcriptase inhibitor)
EMTRIVA .RTM. Gilead HIV infection, AIDS, (Emtricitabine) (reverse
transcriptase (FTC) inhibitor) Combivir .RTM. GSK HIV infection,
AIDS, (reverse transcriptase inhibitor) Abacavir succinate GSK HIV
infection, AIDS, (or ZIAGEN .RTM.) (reverse transcriptase
inhibitor) REYATAZ .RTM. Bristol-Myers Squibb HIV infection AIDs,
(or atazanavir) protease inhibitor FUZEON .RTM. Roche/Trimeris HIV
infection AIDs, (Enfuvirtide or T-20) viral Fusion inhibitor LEXIVA
.RTM. GSK/Vertex HIV infection AIDs, (or Fosamprenavir calcium)
viral protease inhibitor SELZENTRY .RTM. Pfizer HIV infection AIDs,
Maraviroc; (UK 427857) (CCR5 antagonist, in development) TRIZIVIR
.RTM. GSK HIV infection AIDs, (three drug combination) Sch-417690
(vicriviroc) Schering-Plough HIV infection AIDs, (CCR5 antagonist,
in development) TAK-652 Takeda HIV infection AIDs, (CCR5
antagonist, in development) GSK 873140 GSK/ONO HIV infection AIDs,
(ONO-4128) (CCR5 antagonist, in development) Integrase Inhibitor
Merck HIV infection AIDs MK-0518 Raltegravir TRUVADA .RTM. Gilead
Combination of Tenofovir disoproxil fumarate salt (VIREAD .RTM.)
and EMTRIVA .RTM. (Emtricitabine) Integrase Inhibitor Gilead/Japan
Tobacco HIV Infection AIDs GS917/JTK-303 in development
Elvitegravir Triple drug combination Gilead/Bristol-Myers Squibb
Combination of Tenofovir ATRIPLA .RTM. disoproxil fumarate salt
(VIREAD .RTM.), EMTRIVA .RTM. (Emtricitabine), and SUSTIVA .RTM.
(Efavirenz) 4'-ethynyl-d4T Bristol-Myers Squibb HIV infection AIDs
in development CMX-157 Chimerix HIV infection AIDs Lipid conjugate
of nucleotide tenofovir GSK1349572 GSK HIV infection AIDs Integrase
inhibitor IMMUNOMODULATORS AS-101 Wyeth-Ayerst AIDS Bropirimine
Pharmacia Upjohn Advanced AIDS Acemannan Carrington Labs, Inc.
AIDS, ARC (Irving, TX) CL246,738 Wyeth AIDS, Kaposi's Lederle Labs
sarcoma FP-21399 Fuki ImmunoPharm Blocks HIV fusion with CD4+ cells
Gamma Interferon Genentech ARC, in combination w/TNF (tumor
necrosis factor) Granulocyte Genetics Institute AIDS Macrophage
Colony Sandoz Stimulating Factor Granulocyte Hoechst-Roussel AIDS
Macrophage Colony Immunex Stimulating Factor Granulocyte
Schering-Plough AIDS, combination Macrophage Colony w/AZT
Stimulating Factor HIV Core Particle Rorer Seropositive HIV
Immunostimulant IL-2 Cetus AIDS, in combination Interleukin-2 w/AZT
IL-2 Hoffman-LaRoche AIDS, ARC, HIV, in Interleukin-2 Immunex
combination w/AZT IL-2 Chiron AIDS, increase in Interleukin-2 CD4
cell counts (aldeslukin) Immune Globulin Cutter Biological
Pediatric AIDS, in Intravenous (Berkeley, CA) combination w/AZT
(human) IMREG-1 Imreg AIDS, Kaposi's (New Orleans, LA) sarcoma,
ARC, PGL IMREG-2 Imreg AIDS, Kaposi's (New Orleans, LA) sarcoma,
ARC, PGL Imuthiol Diethyl Merieux Institute AIDS, ARC Dithio
Carbamate Alpha-2 Schering Plough Kaposi's sarcoma Interferon
w/AZT, AIDS Methionine- TNI Pharmaceutical AIDS, ARC Enkephalin
(Chicago, IL) MTP-PE Ciba-Geigy Corp. Kaposi's sarcoma
Muramyl-Tripeptide Granulocyte Amgen AIDS, in combination Colony
Stimulating w/AZT Factor Remune Immune Response Immunotherapeutic
Corp. rCD4 Genentech AIDS, ARC Recombinant
Soluble Human CD4 rCD4-IgG AIDS, ARC hybrids Recombinant Biogen
AIDS, ARC Soluble Human CD4 Interferon Hoffman-La Roche Kaposi's
sarcoma Alfa 2a AIDS, ARC, in combination w/AZT SK&F106528
Smith Kline HIV infection Soluble T4 Thymopentin Immunobiology HIV
infection Research Institute (Annandale, NJ) Tumor Necrosis
Genentech ARC, in combination Factor; TNF w/gamma Interferon
ANTI-INFECTIVES Clindamycin with Pharmacia Upjohn PCP Primaquine
Fluconazole Pfizer Cryptococcal meningitis, candidiasis Pastille
Squibb Corp. Prevention of Nystatin Pastille oral candidiasis
Ornidyl Merrell Dow PCP Eflornithine Pentamidine LyphoMed PCP
treatment Isethionate (IM & IV) (Rosemont, IL) Trimethoprim
Antibacterial Trimethoprim/sulfa Antibacterial Piritrexim Burroughs
Wellcome PCP treatment Pentamidine Fisons Corporation PCP
prophylaxis Isethionate for Inhalation Spiramycin Rhone-Poulenc
Cryptosporidial diarrhea Intraconazole- Janssen-Pharm.
Histoplasmosis; R51211 cryptococcal meningitis Trimetrexate
Warner-Lambert PCP Daunorubicin NeXstar, Sequus Kaposi's sarcoma
Recombinant Human Ortho Pharm. Corp. Severe anemia Erythropoietin
assoc. with AZT therapy Recombinant Human Serono AIDS-related
Growth Hormone wasting, cachexia Megestrol Acetate Bristol-Myers
Squibb Treatment of anorexia assoc. W/AIDS Testosterone Alza, Smith
Kline AIDS-related wasting Total Enteral Norwich Eaton Diarrhea and
Nutrition Pharmaceuticals malabsorption related to AIDS
Additionally, the compounds of the disclosure herein set forth may
be used in combination with HIV entry inhibitors. Examples of such
HIV entry inhibitors are discussed in DRUGS OF THE FUTURE 1999,
24(12), pp. 1355-1362; CELL, Vol. 9, pp. 243-246, Oct. 29, 1999;
and DRUG DISCOVERY TODAY, Vol. 5, No. 5, May 2000, pp. 183-194 and
Inhibitors of the entry of HIV into host cells. Meanwell, Nicholas
A.; Kadow, John F. Current Opinion in Drug Discovery &
Development (2003), 6(4), 451-461. Specifically the compounds can
be utilized in combination with attachment inhibitors, fusion
inhibitors, and chemokine receptor antagonists aimed at either the
CCR5 or CXCR4 coreceptor. HIV attachment inhibitors are also set
forth in U.S. Pat. No. 7,354,924 and US 2005/0209246.
It will be understood that the scope of combinations of the
compounds of this application with AIDS antivirals,
immunomodulators, anti-infectives, HIV entry inhibitors or vaccines
is not limited to the list in the above Table but includes, in
principle, any combination with any pharmaceutical composition
useful for the treatment of AIDS.
Preferred combinations are simultaneous or alternating treatments
with a compound of the present disclosure and an inhibitor of HIV
protease and/or a non-nucleoside inhibitor of HIV reverse
transcriptase. An optional fourth component in the combination is a
nucleoside inhibitor of HIV reverse transcriptase, such as AZT,
3TC, ddC or ddI. A preferred inhibitor of HIV protease is
REYATAZ.RTM. (active ingredient Atazanavir). Typically a dose of
300 to 600 mg is administered once a day. This may be
co-administered with a low dose of Ritonavir (50 to 500 mgs).
Another preferred inhibitor of HIV protease is KALETRA.RTM..
Another useful inhibitor of HIV protease is indinavir, which is the
sulfate salt of
N-(2(R)-hydroxy-1-(S)-indanyl)-2(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(4-(3-
-pyridyl-methyl)-2(S)--N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide
ethanolate, and is synthesized according to U.S. Pat. No.
5,413,999. Indinavir is generally administered at a dosage of 800
mg three times a day. Other preferred protease inhibitors are
nelfinavir and ritonavir. Another preferred inhibitor of HIV
protease is saquinavir which is administered in a dosage of 600 or
1200 mg tid. Preferred non-nucleoside inhibitors of HIV reverse
transcriptase include efavirenz. These combinations may have
unexpected effects on limiting the spread and degree of infection
of HIV. Preferred combinations include those with the following (1)
indinavir with efavirenz, and, optionally, AZT and/or 3TC and/or
ddI and/or ddC; (2) indinavir, and any of AZT and/or ddI and/or ddC
and/or 3TC, in particular, indinavir and AZT and 3TC; (3) stavudine
and 3TC and/or zidovudine; (4) tenofovir disoproxil fumarate salt
and emtricitabine.
In such combinations the compound of the present invention and
other active agents may be administered separately or in
conjunction. In addition, the administration of one element may be
prior to, concurrent to, or subsequent to the administration of
other agent(s).
General Chemistry (Methods of Synthesis)
The present invention comprises compounds of Formulas I, II, and
III, their pharmaceutical formulations, and their use in patients
suffering from or susceptible to HIV infection. The compounds of
Formulas I, II, and III also include pharmaceutically acceptable
salts thereof. General procedures to construct compounds of
Formulas I, II, and III and intermediates useful for their
synthesis are described in the following Schemes (after the
Abbreviations).
ABBREVIATIONS
One or more of the following abbreviations, most of which are
conventional abbreviations well known to those skilled in the art,
may be used throughout the description of the disclosure and the
examples:
h=hour(s)
min=minute(s)
rt=room temperature
mol=mole(s)
mmol=millimole(s)
g=gram(s)
mg=milligram(s)
mL=milliliter(s)
TFA=trifluoroacetic Acid
DCE=1,2-Dichloroethane
THF=tetrahydrofuran
DIEA=N,N-diisopropylethylamine
DMAP=4-dimethylaminopyridine
DMF=N,N-dimethylformamide
EDC=1-(3-dimethylaminopropyl)-3-ethyldiimide hydrochloride
KHMDS=potassium hexamethyldisilazide
TMS=trimethylsilyl
DCM=dichloromethane
MeOH=methanol
EtOAc=ethyl acetate
DME=dimethoxyethane
TLC=thin layer chromatography
DMSO=dimethylsulfoxide
PCC=pyridinium chlorochromate
ATM=atmosphere(s)
HOAc=acidic acid
SOCl.sub.2=thionylchloride
TBAF=tetrabutylammonium fluoride
TBDPSCl=tertbutyldiphenylchlorosilane
TBTU=o-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium
tetrafluoroborate
Hex=hexane(s)
Equiv.=equivalents
Rb=round bottom
Prep HPLC=preparative High performance liquid chromatography
Preparation of Compounds of Formulas I, II and III General
Chemistry Schemes:
Compounds of Formulas I, II and III can be prepared from
commercially available (Aldrich, others) betulinic acid and betulin
by chemistry described in the following schemes.
General reaction schemes are set forth as follows:
Schemes A through E can be used for the preparation of compounds of
Formula I:
##STR00056## The synthesis starts with introduction of a suitable
carboxylic acid protective group. Oxidation of the C-3 alcohol
using standard oxidation reagents affords the C-3 ketone which is
converted into the triflate by methods available to those skilled
in the art. The ketone can be subjected to standard Suzuki couping
with boronic acids; Stille coupling using tin reagents can also be
used. Selective deprotection of the carboxylic acid in the C-28
position allowed the preparation of the corresponding acid chloride
which can be reacted with amines to afford the desired amide.
Sometimes the amines can carry a protective group that can be
deprotected sequentially or simultaneously with the deprotection of
the carboxylic acid. Alternatively, the C-28 amides can be prepared
from the C-28 acid intermediate as shown in scheme B:
##STR00057##
##STR00058## Oxidation of betulin with oxidants such as Jones'
reagent can afford betulonic acid which can be further converted
into the corresponding acid chloride. Treatment with amine affords
the corresponding C-28 amide. Conversion of the C-3 ketone into the
triflate followed by Suzuki coupling and deprotection as described
above affords the desired compound.
##STR00059##
##STR00060## ##STR00061## Compounds of formula II can be prepared
as shown in schemes F-G:
##STR00062##
##STR00063## Alternatively, compounds of formula II can be prepared
from betulinic acid by hydrogenation of the double bond, followed
by protection of the carboxylic acid with a suitable protecting
group. Then oxidation of the hydroxyl group to ketone and triflate
formation followed by palladium promoted cross coupling such as
Suzuki or Stille coupling provide the benzoic ester intermediate.
Selective deprotection of the ester in the C-28 position affords
the corresponding carboxylic acid which is converted to the acid
chloride and reacted with the desired amine to provide the C-28
amide. Deprotection of the benzoic ester provides the final
compound. Some of the amides can be further modified as exemplified
in the following schemes:
##STR00064## The amine in the amide side chain can be derivatized
with an alkylating reagent containing a carboxylic ester or by
Michal addition to and .alpha.,.beta.-unsaturated carboxylic ester
followed by deprotection of the two carboxylic esters.
##STR00065## Amides containing amines can be alkylated with an
alkyl halide as shown above. Deprotection of the carboxylic esters
affords the final compounds.
##STR00066## Amides containing amines can be also derivatized using
a Michael acceptor as shown above. Deprotection of the carboxylic
esters affords the final compounds.
##STR00067## A compound with an amine group can be acylated with
and acid chloride or by treatment with a carboxylic acid and the
appropriate coupling reagent in the presence of a base to provide
an amide. Unmasking of the carboxylic acid afford the final
compounds.
##STR00068## The preparation of amides with a pending carboxylic
amide can be done as shown above. The C-28 acid chloride can be
treated with an amine containing a carboxylic ester. Selective
deprotection of this carboxylic ester followed by standard amide
coupling and deprotection of the benzoic acid afford the final
compounds.
##STR00069## A compound with a hydroxyl group can be acylated with
an acid chloride or by treatment with a carboxylic acid and
coupling reagent in the presence of a base to provide an ester.
Unmasking of the terminal carboxylic acids afford the final
compounds. Amides containing an amine can be converted into the
corresponding N-oxide under standard oxidation conditions. The same
synthetic methods can be applied to prepare compounds of Formula
III using ursolic acid, oleanoic acid or moronic acid (oxidation is
not necessary in this case, since the C-3 ketone is already
present) as starting material instead of betulinic acid or betulin
as shown, for example, in the following scheme:
##STR00070##
EXAMPLES
The following examples illustrate typical syntheses of the
compounds of Formulas I, II and III as described generally above.
These examples are illustrative only and are not intended to limit
the disclosure in any way. The reagents and starting materials are
readily available to one of ordinary skill in the art.
Chemistry
Typical Procedures and Characterization of Selected Examples:
Unless otherwise stated, solvents and reagents were used directly
as obtained from commercial sources, and reactions were performed
under a nitrogen atmosphere. Flash chromatography was conducted on
Silica gel 60 (0.040-0.063 particle size; EM Science supply).
.sup.1H NMR spectra were recorded on Bruker DRX-500f at 500 MHz (or
Bruker AV 400 MHz, Bruker DPX-300B or Varian Gemini 300 at 300 MHz
as stated). The chemical shifts were reported in ppm on the .delta.
scale relative to .delta.TMS=0. The following internal references
were used for the residual protons in the following solvents:
CDCl.sub.3 (.sym..sub.H 7.26), CD.sub.3OD (.delta..sub.H 3.30),
Acetic-d4 (Acetic Acid d.sub.4) (.delta..sub.H 11.6, 2.07), DMSOmix
or DMSO-D6_CDCl.sub.3 ((.sub.H 2.50 and 8.25) (ratio 75%:25%), and
DMSO-D6 (.delta..sub.H 2.50). Standard acronyms were employed to
describe the multiplicity patterns: s (singlet), br. s (broad
singlet), d (doublet), t (triplet), q (quartet), m (multiplet), b
(broad), app (apparent). The coupling constant (J) is in Hertz. All
Liquid Chromatography (LC) data were recorded on a Shimadzu LC-10AS
liquid chromatograph using a SPD-10AV UV-Vis detector with Mass
Spectrometry (MS) data determined using a Micromass Platform for LC
in electrospray mode.
LC/MS Methods
Method 1
Start % B=0, Final % B=100 over 2 minute gradient
Flow Rate=4 mL/Min
Solvent A=95% Water/5% Methanol/10 mM Ammonium Acetate
Solvent B=5% Water/95% Methanol/10 mM Ammonium Acetate
Column=PHENOMENEX-LUNA 3.0.times.50 mm
Method 2
Start % B=0, Final % B=100 over 2 minute gradient
Flow Rate=1 mL/Min
Solvent A=90% Water/10% Acetonitrile/0.1% TFA
Solvent B=10% Water/90% Acetonitrile/0.1% TFA
Column=PHENOMENEX-LUNA 2.0.times.30 mm C18, 3u
Method 3
Start % B=0, Final % B=100 over 2 minute gradient
Flow Rate=4 mL/Min
Solvent A=95% Water/5% methanol/10 mM Ammonium Acetate
Solvent B=5% Water/95% methanol/10 mM Ammonium Acetate
Column=Xbridge 4.6.times.50 mm 5u C18
Method 4
Start % B=0, Final % B=100 over 2 minute gradient
Flow Rate=0.8 mL/Min
Solvent A=95% Water/5% methanol/10 mM Ammonium Acetate
Solvent B=5% Water/95% methanol/10 mM Ammonium Acetate
Column=Xbridge 2.1.times.50 mm 3.5 um C18
Method 5
Start % B=15, Final % B=100 over 2 minute gradient, hold at 100%
for 3 minutes
Flow Rate=1 mL/Min
Solvent A=95% Water/5% acetonitrile/10 mM Ammonium Acetate
Solvent B=5% Water/95% acetonitrile/10 mM Ammonium Acetate
Column=PHENOMENEX-LUNA 2.0.times.30 mm C18, 3u
Preparation of Compounds:
##STR00071##
Preparation of (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-benzyl
9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclo-
penta[a]chrysene-3a-carboxylate. Intermediate 1
##STR00072##
To a suspension of betulinic acid (12 g, 26.3 mmol) and potassium
carbonate (7.26 g, 52.6 mmol) in DMF (150 mL) was added benzyl
bromide (3.28 mL, 27.6 mmol). The mixture was heated to 60.degree.
C. for 3.5 h, and was cooled to rt. Solids started to precipitate
upon cooling. The mixture was diluted with 200 mL of water and the
solids that formed were collected by filtration to give
(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-benzyl
9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclo-
penta[a]chrysene-3a-carboxylate (13.92 g, 25.5 mmol, 97% yield) as
a white solid. .sup.1H NMR (500 MHz, CHLOROFORM-d) .delta. ppm
7.39-7.28 (m, 5H), 5.16-5.06 (m, 2H), 4.71 (d, J=1.83 Hz, 1H), 4.59
(s, 1H), 3.17 (ddd, J=11.44, 5.65, 5.49 Hz, 1H), 3.01 (td, J=10.99,
4.88 Hz, 1H), 2.27 (ddd, J=12.36, 3.20, 3.05 Hz, 1H), 2.21-2.13 (m,
1H), 1.93-1.81 (m, 2H), 1.67 (s, 3H), 0.95 (s, 3H), 0.93 (s, 3H),
1.71-0.82 (m, 20H), 0.79 (s, 3H), 0.75 (s, 3H), 0.74 (s, 3H).
Preparation of (1R,3aS,5aR,5bR,7aR,11aR,11bR,13aR,13bR)-benzyl
5a,5b,8,8,11a-pentamethyl-9-oxo-1-(prop-1-en-2-yl)icosahydro-1H-cyclopent-
a[a]chrysene-3a-carboxylate. Intermediate 2
##STR00073##
To a solution of (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-benzyl
9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclo-
penta[a]chrysene-3a-carboxylate (7.1 g, 12.98 mmol) in
dichloromethane (100 mL) was added PCC (4.20 g, 19.48 mmol). After
stirring for five minutes, the mixture turned a deep crimson color.
The mixture was further stirred for 5.5 h. The mixture was filtered
through a pad of celite and silica gel which was washed with
dichloromethane and then a 1:1 mixture of ethyl acetate:hexanes.
The filtrate was concentrated under reduced pressure to give
(1R,3aS,5aR,5bR,7aR,11aR,11bR,13aR,13bR)-benzyl
5a,5b,8,8,11a-pentamethyl-9-oxo-1-(prop-1-en-2-yl)icosahydro-1H-cyclopent-
a[a]chrysene-3a-carboxylate (6.92 g, 12.7 mmol, 98% yield) as a
white foam. .sup.1H NMR (500 MHz, CHLOROFORM-d) .delta. ppm
7.38-7.28 (m, 5H), 5.17-5.06 (m, 2H), 4.72 (d, J=1.83 Hz, 1H), 4.59
(s, 1H), 3.01 (td, J=10.99, 4.88 Hz, 1H), 2.51-2.43 (m, 1H),
2.42-2.34 (m, 1H), 2.28 (dt, J=12.59, 3.17 Hz, 1H), 2.21 (td,
J=12.28, 3.51 Hz, 1H), 1.94-1.82 (m, 3H), 1.67 (s, 3H), 1.05 (s,
3H), 1.01 (s, 3H), 1.73-0.95 (m, 17H), 0.94 (s, 3H), 0.89 (s, 3H),
0.78 (s, 3H).
Preparation of (1R,3aS,5aR,5bR,7aR,11aR,11bR,13aR,13bR)-benzyl
5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-9-(trifluoromethylsulfonylox-
y)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyc-
lopenta[a]chrysene-3a-carboxylate. Intermediate 3
##STR00074##
To a solution of (1R,3aS,5aR,5bR,7aR,11aR,13aR,13bR)-benzyl
5a,5b,8,8,11a-pentamethyl-9-oxo-1-(prop-1-en-2-yl)icosahydro-1H-cyclopent-
a[a]chrysene-3a-carboxylate (6.9 g, 12.67 mmol) and
1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide
(9.05 g, 25.3 mmol) in THF (200 mL) at -78.degree. C. was added
KHMDS (50.7 mL, 25.3 mmol) slowly. The reaction mixture was stirred
for 1 hour at -78.degree. C. TLC indicated starting material was
consumed and desired product was formed. The reaction mixture was
quenched with brine, extracted with diethyl ether. The extracts
were dried over Na.sub.2SO.sub.4, filtered and concentrated under
reduced pressure. The residue was dissolved in toluene and purified
by biotage 2-10% toluene/hexanes and 5-10% ethyl acetate/hexanes to
provide the title compound as a white solid (5.0 g, 58%). .sup.1H
NMR (500 MHz, CHLOROFORM-d) .delta. ppm 0.77 (s, 3H), 0.88 (s, 3H),
0.91-1.77 (m, 17H), 0.94 (s, 3H), 1.00 (s, 3H), 1.10 (s, 3H), 1.67
(s, 3H), 1.81-1.96 (m, 2H), 2.14 (dd, J=17.09, 6.71 Hz, 1H), 2.22
(td, J=12.21, 3.36 Hz, 1H), 2.25-2.31 (m, 1H), 3.02 (td, J=10.99,
4.58 Hz, 1H), 4.59 (s, 1H), 4.72 (d, J=1.53 Hz, 1H), 5.05-5.12 (m,
1H), 5.13-5.18 (m, 1H), 5.54 (dd, J=6.71, 1.53 Hz, 1H), 7.29-7.41
(m, 5H).
Procedure for the Suzuki Coupling.
Preparation of (1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-benzyl
9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl-
)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cycl-
openta[a]chrysene-3a-carboxylate. Intermediate 4
##STR00075##
To a rb flask containing a solution of
(1R,3aS,5aR,5bR,7aR,11aR,11bR,13bR)-benzyl
5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-9-(trifluoromethylsulfonylox-
y)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyc-
lopenta[a]chrysene-3a-carboxylate (6.21 g, 9.18 mmol) in dioxane
(25 mL) was added 2-propanol (25 mL) and water (15 mL) followed by
sodium carbonate monohydrate (3.42 g, 27.5 mmol),
4-methoxycarbonylphenylboronic acid (2.478 g, 13.77 mmol), and
tetrakis(triphenylphosphine)palladium(0) (0.318 g, 0.275 mmol). The
flask was attached to a reflux condenser, was flushed with N.sub.2,
and was heated to reflux overnight. After heating the mixture for
14.5 h, it was cooled to rt and was diluted with water (75 mL). The
mixture was extracted with ethyl acetate (3.times.75 mL) and washed
with brine. The combined organic layers were dried with MgSO.sub.4,
filtered, and concentrated under reduced pressure. The residue was
adsorbed to silica gel and was purified by Biotage flash
chromatography using a 0-20% ethyl acetate in hexanes gradient. The
fractions containing the expected product was combined and
concentrated under reduced pressure to give the expected product,
(1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR 13bR)-benzyl
9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl-
)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cycl-
openta[a]chrysene-3a-carboxylate (4.16 g, 6.28 mmol, 68.4% yield),
as a white foam. .sup.1H NMR (500 MHz, CHLOROFORM-d) .delta. ppm
7.92 (d, J=8.24 Hz, 2H), 7.40-7.29 (m, 5H), 7.19 (d, J=8.24 Hz,
2H), 5.28 (dd, J=6.10, 1.83 Hz, 1H), 5.19-5.07 (m, 2H), 4.73 (d,
J=1.83 Hz, 1H), 4.60 (s, 1H), 3.90 (s, 3H), 3.04 (td, J=10.91, 4.73
Hz, 1H), 2.20-2.32 (m, 2H), 2.09 (dd, J=17.24, 6.26 Hz, 1H),
1.95-1.82 (m, 2H), 1.69 (s, 3H), 0.97 (s, 3H), 0.95 (s, 3H), 0.92
(s, 3H), 0.91 (s, 3H), 1.75-0.87 (m, 17H), 0.82 (s, 3H).
(1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-tert-butyldimethylsilyl
9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl-
)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cycl-
openta[a]chrysene-3a-carboxylate. Intermediate 5
##STR00076##
To a solution of (1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-benzyl
9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl-
)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cycl-
openta[a]chrysene-3a-carboxylate (3.82 g, 5.76 mmol) in
dichloroethane (100 mL) was added triethylamine (1.285 mL, 9.22
mmol), tert-butyldimethylsilane (1.912 mL, 11.52 mmol), and
palladium(II) acetate (0.647 g, 2.88 mmol). The mixture was flushed
with N.sub.2 and was heated to 60.degree. C. After 2 h, the
reaction was cooled to rt, was filtered through a pad of celite and
silica gel to remove the solids which were washed with 25% EtOAc in
hexanes. The filtrate was concentrated under reduced pressure and
was treated with 20 mL of acetic acid, 10 mL of THF and 3 mL of
water. After stirring for 1 h the solids that formed were collected
by filtration and were washed with water to give
(1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-tert-butyldimethylsilyl
9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl-
)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cycl-
openta[a]chrysene-3a-carboxylate (3.62 g, 5.27 mmol, 91% yield) as
a white solid. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 7.94
(d, J=8.28 Hz, 2H), 7.21 (d, J=8.28 Hz, 2H), 5.30 (dd, J=6.15, 1.63
Hz, 1H), 4.75 (d, J=1.76 Hz, 1H), 4.62 (s, 1H), 3.92 (s, 4H), 3.08
(td, J=10.92, 4.27 Hz, 1H), 2.35-2.22 (m, 2H), 2.17-2.06 (m, 1H),
2.02-1.84 (m, 2H), 1.71 (s, 3H), 1.01 (s, 6H), 0.99 (br. s., 3H),
0.98 (s, 9H), 0.94 (s, 6H), 1.78-0.90 (m, 16H), 0.32-0.28 (m,
6H).
Preparation of
(1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-(methoxycarbonyl)phenyl)-5a-
,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11-
a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxylic
acid. Intermediate 6
##STR00077##
To solution of
(1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-tert-butyldimethylsilyl
9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl-
)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cycl-
openta[a]chrysene-3a-carboxylate (3.12 g, 4.54 mmol) in Dioxane (25
mL) was added TBAF (75% wt in water) (2.375 g, 6.81 mmol). The
mixture was stirred at rt for 4 h then was diluted with 1N HCl (25
mL) and water (5 mL) and extracted with dichloromethane
(3.times.100 mL). The combined organic layers were dried with
Na.sub.2SO.sub.4, filtered, and partially concentrated under
reduced pressure to about 10 mL volume. To the partially
concentrated mixture was added 1N HCl (50 mL). The solids that
formed were collected by filtration and were washed with water. The
expected product,
(1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-(methoxycarbonyl)phenyl)-5a-
,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11-
a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxylic
acid (2.58 g, 4.50 mmol, 99% yield), was isolated as a white solid.
LCMS: m/e 571.47 (M-H).sup.-, 3.60 min (method 1). .sup.1H NMR (500
MHz, CHLOROFORM-d) .delta. ppm 9.80 (br. s., 1H), 7.92 (d, J=8.24
Hz, 2H), 7.18 (d, J=8.24 Hz, 2H), 5.32-5.26 (m, 1H), 4.75 (s, 1H),
4.62 (br. s., 1H), 3.90 (s, 3H), 3.07-2.99 (m, 1H), 2.33-2.21 (m,
2H), 2.10 (dd, J=17.09, 6.10 Hz, 1H), 2.06-1.94 (m, 2H), 1.70 (s,
3H), 1.01 (br. s., 3H), 1.00 (br. s., 3H), 0.98 (s, 3H), 0.91 (s,
6H), 1.79-0.89 (m, 17H).
General Procedure for C-28 Amide Formation
##STR00078##
Step 1
Preparation of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(chlorocarbonyl)-5a,5b,8,8-
,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,1-
2,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoate.
Intermediate 7
##STR00079##
To a flask containing
(1R,3aS,5aR,5bR,7aR,11aS,11bR,13bR)-9-(4-(methoxycarbonyl)phenyl)-5a,5b,8-
,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b-
,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxylic
acid (0.1-4.2 mmol scale) was added oxalyl chloride (2M in
dichloromethane) (10-50 equiv.). The solution was stirred at rt for
2-5 h and was stripped of solvent. The residue was dissolved in
dichloromethane and concentrated two additional times, then was
used with no additional purification in the next step. .sup.1H NMR
(500 MHz, CHLOROFORM-d) .delta. ppm 7.92 (d, J=8.55 Hz, 2H), 7.19
(d, J=8.24 Hz, 2H), 5.26-5.30 (m, 1H), 4.73 (d, J=1.53 Hz, 1H),
4.62-4.64 (m, 1H), 3.90 (s, 3H), 2.81 (td, J=11.14, 4.58 Hz, 1H),
2.47 (ddd, J=13.58, 3.20, 3.05 Hz, 1H), 2.19-2.28 (m, 2H), 2.10
(dd, J=17.09, 6.41 Hz, 1H), 1.85-1.99 (m, 1H), 1.68 (s, 3H), 1.00
(s, 6H), 0.98 (s, 3H), 0.92 (s, 3H), 0.92 (s, 3H), 0.84-1.83 (m,
17H). .sup.13C NMR (126 MHz, CHLOROFORM-d) .delta. ppm 177.49,
167.35, 149.46, 148.81, 146.39, 130.17 (s, 2C), 128.61 (s, 2C),
128.03, 124.12, 110.40, 68.00, 52.99, 52.11, 49.78, 49.67, 46.11,
42.54, 41.86, 40.70, 38.00, 37.60, 36.39, 36.31, 33.64, 32.3,
29.98, 29.72, 29.54, 25.60, 21.37, 21.13, 19.86, 19.48, 16.59,
15.71, 14.89.
Step 2
To a solution of the acid chloride in dichloroethane or
dichloromethane (0.02-0.15 M) was added Hunig's Base (3-5 equiv.),
the amine (1.1-2.6 equiv.), and DMAP (0.03-0.1 equiv.). The mixture
was stirred at rt for 2-72 h. The reaction mixture was diluted with
1N HCl or water and was extracted with dichloromethane. The organic
layer was dried with Na.sub.2SO.sub.4, the drying agent was removed
by filtration, and the filtrate was concentrated under reduced
pressure. The residue was purified by Biotage flash chromatography
or was directly used in the next step with no additional
purification.
Note: The same reaction conditions can be used without DMAP to
successfully form the corresponding amides.
General Procedures for Hydrolysis of the Benzoic Ester Using NaOH
or LiOH.H.sub.2O
The C-28 amide formed above was dissolved in 1,4-dioxane and either
aq. 1N or 10 N NaOH was added to the mixture and it was heated to
50-85.degree. C. After heating for 2-24 h, the mixture was cooled
to rt. The crude mixture was either purified by prep HPLC or was
made acidic by dropwise addition of 1N HCL and the final product
was crystallized from dioxane/water or dioxane/methanol/water.
Alternative, the deprotection can be carried out as follows: The
C-28 amide formed above was dissolved in 1,4-dioxane. To the
solution was added water (4:1 dioxane:water or 5:1 dioxane:water)
followed by LiOH.H.sub.2O (5-12 equiv.). The mixture was heated to
50-85.degree. C. After heating for 2-24 h, the mixture was cooled
to rt. The crude mixture was either purified by prep HPLC or was
made acidic by dropwise addition of 1N HCL and the final product
was crystallized from dioxane/water or dioxane/methanol/water.
Preparation of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(chlorocarbonyl)-5a,5b,8,8-
,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,1-
2,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)-2-fluorobenzoate.
Intermediate 7a
##STR00080##
The title compound was prepared from
(1R,3aS,5aR,5bR,7aR,11aR,11bR,13aR,13bR)-benzyl
5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-9-(trifluoromethylsulfonylox-
y)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyc-
lopenta[a]chrysene-3a-carboxylate (Intermediate 3) following the
above described procedures for the Suzuki coupling (as described
for intermediate 4, but using
3-fluoro-4-(methoxycarbonyl)phenylboronic acid as the reactant);
deprotection of the C-28 acid (as described for intermediate 5 and
6) and conversion into acid chloride (as described for intermediate
7). The crude material was taken to the next step without further
purification. LCMS: m/e 605.39 (M-Cl+OMe+H).sup.+, 4.12 min (method
1).
Example 1
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-1-(-
prop-1-en-2-yl)-3a-(2-(pyridin-2-yl)ethylcarbamoyl)-2,3,3a,4,5,5a,5b,6,7,7-
a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)be-
nzoic acid
##STR00081##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
2-(2-Aminoethyl)pyridine as the reactant amine. The product was
isolated as a white solid (13 mg, 14%). LCMS: m/e 661.7
(M-H).sup.-, 2.16 min (method 1). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 8.59-8.50 (m, 1H), 8.02-7.95 (m, 2H),
7.69-7.64 (m, 1H), 7.24-7.17 (m, 3H), 6.77-6.71 (m, 1H), 5.28 (d,
J=6.10 Hz, 1H), 4.73 (br. s., 1H), 4.58 (br. s., 1H), 3.73-3.66 (m,
2H), 3.12-3.03 (m, 3H), 2.42 (t, J=12.21 Hz, 1H), 2.08 (dd,
J=16.94, 5.65 Hz, 1H), 1.97 (d, J=13.73 Hz, 1H), 1.89-1.78 (m, 1H),
1.67 (s, 3H), 1.73-0.95 (m, 19H), 0.95 (s, 3H), 0.93 (s, 3H), 0.92
(br. s., 6H), 0.89 (s, 3H).
Example 2
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-1-(-
prop-1-en-2-yl)-3a-(pyridin-2-ylmethylcarbamoyl)-2,3,3a,4,5,5a,5b,6,7,7a,8-
,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzo-
ic acid
##STR00082##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
2-(Aminomethyl)pyridine as the reactant amine. The product was
isolated as an off-white solid (38 mg, 41%). LCMS: m/e 647.6
(M-H).sup.-, 2.13 min (method 1). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 8.54 (d, J=4.88 Hz, 1H), 7.99 (d, J=7.93
Hz, 2H), 7.69 (td, J=7.63, 1.53 Hz, 1H), 7.38 (d, J=7.93 Hz, 1H),
7.24-7.20 (m, 3H), 7.09-7.03 (m, 1H), 5.29 (d, J=5.49 Hz, 1H), 4.74
(s, 1H), 4.62-4.54 (m, 2H), 4.54-4.47 (m, 1H), 3.16 (td, J=10.99,
4.58 Hz, 1H), 2.49-2.42 (m, 1H), 2.13-2.05 (m, 2H), 2.00-1.80 (m,
3H), 1.69 (s, 3H), 0.98 (s, 3H), 1.75-0.95 (m, 16H), 0.94 (s, 3H),
0.92 (s, 3H), 0.92 (s, 3H), 0.82 (s, 3H).
Example 3
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-1-(-
prop-1-en-2-yl)-3a-(2-(pyridin-3-yl)ethylcarbamoyl)-2,3,3a,4,5,5a,5b,6,7,7-
a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)be-
nzoic acid
##STR00083##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
3-(2-aminoethyl)pyridine as the reactant amine. The product was
isolated as an off-white solid (70 mg, 74%). LCMS: m/e 661.7
(M-H).sup.-, 2.12 min (method 1). .sup.1H NMR (500 MHz, MeOD)
.delta. ppm 8.45 (br. s., 1H), 8.41 (d, J=4.27 Hz, 1H), 7.93 (d,
J=8.24 Hz, 2H), 7.80 (d, J=7.93 Hz, 1H), 7.41 (dd, J=7.48, 5.04 Hz,
1H), 7.23 (d, J=8.24 Hz, 2H), 5.33-5.29 (m, 1H), 4.72 (d, J=2.14
Hz, 1H), 4.60 (br. s., 1H), 3.57-3.40 (m, 2H), 3.10-3.02 (m, 1H),
2.94-2.84 (m, 2H), 2.68-2.58 (m, 1H), 2.17 (dd, J=17.24, 6.56 Hz,
1H), 2.06 (d, J=13.43 Hz, 1H), 1.70 (s, 3H), 1.04 (s, 3H),
1.80-0.95 (m, 19H), 1.03 (s, 3H), 0.98 (s, 3H), 0.97 (s, 3H), 0.96
(s, 3H).
Example 4
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(4-methoxyphenethylcarbamo-
yl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8-
,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzo-
ic acid
##STR00084##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
2-(4-methoxyphenyl)ethylamine as the reactant amine. The product
was isolated as a white solid (36 mg, 49%). LCMS: m/e 690.7
(M-H).sup.-, 2.19 min (method 1). .sup.1H NMR (400 MHz,
CHLOROFORM-d) .delta. ppm 8.01 (d, J=8.28 Hz, 2H), 7.24 (d, J=8.28
Hz, 2H), 7.15 (d, J=8.78 Hz, 2H), 6.89-6.84 (m, 2H), 5.58 (t,
J=5.65 Hz, 1H), 5.34-5.29 (m, 1H), 4.75 (d, J=1.76 Hz, 1H), 4.61
(s, 1H), 3.81 (s, 3H), 3.63-3.42 (m, 2H), 3.07 (td, J=11.04, 3.51
Hz, 1H), 2.85-2.71 (m, 2H), 2.46 (td, J=12.17, 3.26 Hz, 1H),
2.17-2.08 (m, 1H), 2.01-1.82 (m, 2H), 1.70 (s, 3H), 1.75-0.98 (m,
18H), 0.99 (s, 6H), 0.98 (s, 3H), 0.95 (s, 3H), 0.95 (s, 3H).
Example 5
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-1-(-
prop-1-en-2-yl)-3a-(1-(pyridin-2-yl)cyclopropylcarbamoyl)-2,3,3a,4,5,5a,5b-
,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-
-yl)benzoic acid
##STR00085##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
1-(pyridin-2-yl)cyclopropanamine, 2 HCl as the reactant amine. The
product was isolated as a white film (10 mg, 12%). LCMS: m/e 673.7
(M-H).sup.-, 2.11 min (method 1). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 8.47 (d, J=4.88 Hz, 1H), 7.99 (d, J=7.93
Hz, 2H), 7.66-7.59 (m, 1H), 7.43 (d, J=7.93 Hz, 1H), 7.22 (d,
J=7.93 Hz, 2H), 7.11 (dd, J=7.32, 4.88 Hz, 1H), 6.83 (s, 1H), 5.28
(br. s., 1H), 4.71 (s, 1H), 4.58 (s, 1H), 3.16 (td, J=10.83, 3.97
Hz, 1H), 2.49 (t, J=12.05 Hz, 1H), 2.13-1.98 (m, 2H), 1.97-1.85 (m,
1H), 1.82 (dd, J=11.75, 7.78 Hz, 1H), 1.67 (s, 3H), 0.99 (s, 3H),
1.74-0.87 (m, 21H), 0.95 (s, 3H), 0.93 (s, 3H), 0.92 (s, 3H), 0.91
(s, 3H).
Example 6
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(cyclopropylsulfonylcarbam-
oyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,-
8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benz-
oic acid
##STR00086##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
cyclopropanesulfonamide as the reactant amine. The product was
isolated as a white solid (25 mg, 21%). LCMS: m/e 660.6
(M-H).sup.-, 2.04 min (method 1). .sup.1H NMR (400 MHz,
CHLOROFORM-d) .delta. ppm 7.99 (d, J=7.53 Hz, 2H), 7.22 (d, J=8.03
Hz, 2H), 7.01 (br. s., 1H), 5.31 (s, 1H), 4.76 (s, 1H), 4.64 (s,
1H), 3.18-3.00 (m, 2H), 2.51 (t, J=10.92 Hz, 1H), 2.18-2.06 (m,
2H), 2.04-1.82 (m, 3H), 1.70 (s, 3H), 1.03 (s, 3H), 1.02 (s, 3H),
0.99 (s, 3H), 0.94 (s, 6H), 1.80-0.87 (m, 20H).
Example 7
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(N,N-dimethylsulfamoylcarb-
amoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7-
a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)be-
nzoic acid
##STR00087##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
N,N-Dimethylsulfamide as the reactant amine. The product was
isolated as a white solid (12 mg, 10%). LCMS: m/e 663.5
(M-H).sup.-, 2.08 min (method 1). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 7.99 (d, J=8.24 Hz, 2H), 7.22 (d, J=8.24
Hz, 1H), 5.30 (d, J=4.27 Hz, 1H), 4.74 (s, 1H), 4.62 (s, 1H), 3.05
(td, J=10.99, 4.27 Hz, 1H), 2.98 (s, 6H), 2.48 (td, J=12.13, 3.20
Hz, 1H), 2.11 (dd, J=17.24, 6.26 Hz, 1H), 2.00-1.90 (m, 2H), 1.84
(dd, J=12.21, 7.63 Hz, 1H), 1.68 (s, 3H), 1.76-0.95 (m, 18H), 1.03
(s, 3H), 1.00 (s, 3H), 0.98 (s, 3H), 0.93 (s, 6H).
Example 8
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(methylsulfonylcarbamoyl)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,-
11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic
acid
##STR00088##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
methanesulfonamide as the reactant amine. The product was isolated
as a white solid (22 mg, 19%). LCMS: m/e 634.4 (M-H).sup.-, 2.01
min (method 1). .sup.1H NMR (500 MHz, CHLOROFORM-d) .delta. ppm
7.97 (d, J=8.24 Hz, 2H), 7.21 (d, J=8.55 Hz, 2H), 5.31-5.27 (m,
1H), 4.74 (s, 1H), 4.62 (s, 1H), 3.32 (s, 3H), 3.07 (td, J=10.99,
4.58 Hz, 1H), 2.45 (td, J=12.44, 3.20 Hz, 1H), 1.99-1.87 (m, 2H),
1.83 (dd, J=12.51, 7.63 Hz, 1H), 1.68 (s, 3H), 1.75-0.95 (m, 18H),
1.01 (s, 6H), 0.97 (s, 3H), 0.93 (s, 3H), 0.92 (s, 3H).
Example 9
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((R)-2-(hydroxymethyl)pyrr-
olidine-1-carbonyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,-
5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]ch-
rysen-9-yl)benzoic acid
##STR00089##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
D(-)Prolinol as the reactant amine. The product was isolated as a
white solid (22 mg, 27%). LCMS: m/e 640.6 (M-H).sup.-, 2.18 min
(method 1). .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 7.99
(d, J=8.53 Hz, 2H),7.24 (d, J=8.53 Hz, 2H), 5.34-5.30 (m, 1H), 4.75
(d, J=2.01 Hz, 1H), 4.61 (s, 1H), 4.40-4.33 (m, 1H), 3.89-3.81 (m,
1H), 3.69-3.63 (m, 1H), 3.60-3.54 (m, 1H), 3.35 (ddd, J=10.73,
8.34, 6.27 Hz, 1H), 3.06-2.93 (m, 2H), 1.71 (s, 3H), 2.14-0.95 (m,
25H), 1.03 (s, 3H), 1.01 (s, 6H), 0.95 (s, 3H), 0.94 (s, 3H).
Example 10
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(4-methylpiperazine-1-carbonyl)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a-
,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)ben-
zoic acid
##STR00090##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
1-methyl piperazine as the reactant amine. The product was isolated
as a white film (8 mg, 10%). LCMS: m/e 639.7 (M-H).sup.-, 2.22 min
(method 1). .sup.1H NMR (500 MHz, CHLOROFORM-d) .delta. ppm 7.98
(d, J=8.24 Hz, 2H), 7.22 (d, J=8.24 Hz, 2H), 5.29 (d, J=4.58 Hz,
1H), 4.73 (s, 1H), 4.60 (s, 1H), 4.52 (br. s., 4H), 3.68-3.58 (m,
2H), 3.38 (br. s., 4H), 2.99-2.90 (m, 1H), 2.85 (s, 3H), 2.86-2.78
(m, 1H), 2.73-2.57 (m, 2H), 2.11 (dd, J=17.09, 6.41 Hz, 1H), 1.98
(d, J=13.43 Hz, 1H), 1.69 (s, 3H), 1.88-0.95 (m, 15H), 0.99 (s,
3H), 0.97 (s, 6H), 0.93 (s, 3H), 0.92 (br. s., 3H). Note:
piperazine peaks are broadened into baseline
Example 11
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(3-(diethylcarbamoyl)piper-
idine-1-carbonyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,-
5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chry-
sen-9-yl)benzoic acid
##STR00091##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
N,N-diethylnipecotamide as the reactant amine. The product was
isolated as a white solid (42 mg, 46%). LCMS: m/e 723.7
(M-H).sup.-, 2.21 min (method 1). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 8.01-7.95 (m, 2H), 7.24-7.24 (m, 2H),
5.30 (d, J=4.27 Hz, 1H), 4.58 (s, 1H), 4.76-4.71 (m, 1H), 1.72-1.66
(m, 3H), 3.59-0.95 (m, 42H), 1.02-0.99 (m, 3H), 0.99-0.95 (m, 6H),
0.95-0.90 (m, 6H.
Example 12
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(2-morpholinoethylcarbamoyl)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,-
11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoi-
c acid
##STR00092##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
N-(2-aminoethyl)morpholine as the reactant amine. The product was
isolated as a white solid (13.7 mg, 16%). LCMS: m/e 669.7
(M-H).sup.-, 2.14 min (method 1). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 12.70 (br. s., 1H), 7.97 (d, J=8.24 Hz,
2H), 7.24-7.18 (m, 3H), 5.29 (d, J=4.88 Hz, 1H), 4.73 (s, 1H), 4.59
(s, 1H), 3.99 (br. s., 4H), 3.80-3.72 (m, 1H), 3.70-3.61 (m, 1H),
3.56 (t, J=11.44 Hz, 2H), 3.23 (t, J=5.19 Hz, 2H), 3.08 (td,
J=10.76, 4.12 Hz, 1H), 2.96-2.87 (m, 2H), 2.48-2.39 (m, 1H), 2.09
(dd, J=17.24, 6.26 Hz, 1H), 2.01 (d, J=13.73 Hz, 1H), 0.98 (s, 3H),
1.68 (s, 3H), 1.89-0.95 (m, 19H), 0.95 (s, 6H), 0.92 (s, 6H).
Example 13
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(4-(2-hydroxyethyl)piperaz-
ine-1-carbonyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a-
,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chryse-
n-9-yl)benzoic acid, TFA
##STR00093##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
1-(2-hydroxyethyl)piperazine as the reactant amine. The product was
isolated as a white film (2.6 mg, 2.6%). LCMS: m/e 669.6
(M-H).sup.-, 2.13 min (method 1). .sup.1H NMR (400 MHz, MeOD)
.delta. ppm 7.93 (d, J=8.28 Hz, 2H), 7.23 (d, J=8.28 Hz, 2H), 5.31
(d, J=6.27 Hz, 1H), 4.72 (s, 1H), 4.62 (s, 1H), 3.92-3.87 (m, 1H),
3.52-3.10 (m, 10H), 3.01-2.83 (m, 2H), 2.23-2.11 (m, 1H), 2.07-1.97
(m, 1H), 1.72 (s, 3H), 1.06 (s, 3H), 1.04 (s, 3H), 1.91-0.95 (m,
20H), 1.03 (s, 3H), 0.97 (s, 3H), 0.95 (s, 3H).
Example 14
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(4-methoxyphenylcarbamoyl)-
-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11-
,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic
acid
##STR00094##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
p-anisidine as the reactant amine. The product was isolated as a
tan solid (40 mg, 47%). LCMS: m/e 662.6 (M-H).sup.-, 2.15 min
(method 1). .sup.1H NMR (500 MHz, CHLOROFORM-d) .delta. ppm 7.98
(d, J=8.55 Hz, 2H), 7.40-7.34 (m, 2H), 7.22 (d, J=8.24 Hz, 2H),
7.15 (s, 1H), 6.90-6.84 (m, 2H), 5.31-5.28 (m, 1H), 4.76 (d, J=1.83
Hz, 1H), 4.61 (s, 1H), 3.79 (s, 3H), 3.21 (td, J=11.06, 4.43 Hz,
1H), 2.67-2.58 (m, 1H), 2.16-1.97 (m, 3H), 1.89 (dd, 1H), 1.76 (d,
J=10.99 Hz, 1H), 1.71 (s, 3H), 1.03 (s, 3H), 1.01 (s, 3H),
1.72-0.95 (m, 16H), 0.97 (s, 3H), 0.92 (s, 6H).
Example 15
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(4-methoxybenzylcarbamoyl)-
-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11-
,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic
acid
##STR00095##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
4-aminomethyl-anisole as the reactant amine. The product was
isolated as an off-white solid (31 mg, 36%). LCMS: m/e 676.6
(M-H).sup.-, 2.16 min (method 1). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 7.99 (d, J=8.24 Hz, 2H), 7.24-7.19 (m,
4H), 6.86 (d, J=8.55 Hz, 2H), 5.80 (t, J=5.65 Hz, 1H), 5.30 (d,
J=4.58 Hz, 1H), 4.75 (s, 1H), 4.60 (s, 1H), 4.44 (dd, J=14.34, 5.80
Hz, 1H), 4.30 (dd, J=14.34, 5.49 Hz, 1H), 3.80 (s, 3H), 3.20 (td,
J=10.99, 4.27 Hz, 1H), 2.59-2.51 (m, 1H), 2.11 (dd, J=17.24, 6.26
Hz, 1H), 2.04-1.94 (m, 1H), 1.90 (d, J=13.12 Hz, 1H), 1.78-1.72 (m,
2H), 1.69 (s, 3H), 0.99 (s, 3H), 1.71-0.95 (m, 16H), 0.98 (s, 6H),
0.94 (s, 3H), 0.92 (s, 3H).
Example 16
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(dimethylamino)ethylcar-
bamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,-
7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)b-
enzoic acid
##STR00096##
The title compound was prepared following the method described
above for the general procedure for C-28 amide formation and
hydrolysis using N,N-dimethylethylenediamine as the reactant amine.
The product was isolated as a white solid (200 mg, 66%). LCMS: m/e
627.6 (M-H).sup.-, 2.20 min (method 1). .sup.1H NMR (400 MHz,
CHLOROFORM-d) .delta. ppm 12.52 (br. s., 1H), 8.00 (d, J=8.03 Hz,
2H), 7.40 (t, J=4.64 Hz, 1H), 7.23 (d, J=8.28 Hz, 2H), 5.31 (d,
J=4.52 Hz, 1H), 4.75 (d, J=1.51 Hz, 1H), 4.61 (s, 1H), 3.79-3.61
(m, 2H), 3.30-3.20 (m, 2H), 3.12 (td, J=10.79, 4.02 Hz, 1H), 2.88
(s, 6H), 2.51-2.42 (m, 1H), 2.16-2.03 (m, 2H), 1.00 (s, 3H), 1.70
(s, 3H), 0.99 (s, 3H), 1.95-0.95 (m, 19H), 0.98 (s, 3H), 0.94 (s,
6H).
Example 17
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-hydroxyethylcarbamoyl)--
5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,-
11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic
acid
##STR00097##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
ethanolamine as the reactant amine. The product was isolated as a
white solid (12 mg, 16%). LCMS: m/e 600.6 (M-H).sup.-, 2.06 min
(method 1). .sup.1H NMR (500 MHz, CHLOROFORM-d) .delta. ppm 7.99
(d, J=8.24 Hz, 2H), 7.22 (d, J=8.24 Hz, 2H), 6.07 (t, J=5.65 Hz,
1H), 5.33-5.25 (m, 1H), 4.75 (s, 1H), 4.60 (s, 1H), 3.74 (t, J=4.88
Hz, 2H), 3.55-3.46 (m, 1H), 3.43-3.35 (m, 1H), 3.12 (td, J=10.99,
3.97 Hz, 1H), 2.52-2.45 (m, 1H), 2.10 (dd, J=17.24, 6.26 Hz, 1H),
2.03-1.92 (m, 2H), 1.69 (s, 3H), 1.00 (s, 6H), 1.82-0.95 (m, 18H),
0.97 (s, 3H), 0.92 (s, 6H).
Example 18
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(benzyl(methyl)carbamoyl)--
5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,-
11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic
acid
##STR00098##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
N-methylbenzylamine as the reactant amine. The product was isolated
as a white film (15 mg, 18%). LCMS: m/e 660.6 (M-H).sup.-, 2.28 min
(method 1). .sup.1H NMR (500 MHz, CHLOROFORM-d) .delta. ppm 7.99
(d, J=8.55 Hz, 2H). 7.33 (t, J=7.32 Hz, 2H), 7.29-7.20 (m, 5H),
5.32-5.28 (m, 1H), 4.76 (d, J=2.14 Hz, 1H), 4.72 (d, J=14.34 Hz,
1H), 4.60 (s, 1H), 4.47 (br. s., 1H), 3.09 (td, J=11.06, 3.51 Hz,
1H), 3.05-2.88 (m, 3H), 2.32-2.18 (m, 1H), 2.16-2.03 (m, 2H), 1.71
(s, 3H), 1.04 (s, 3H), 0.99 (s, 6H), 1.82-0.95 (m, 19H), 0.94 (s,
3H), 0.93 (s, 3H).
Example 19
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(piperidine-1-carbonyl)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11-
a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic
acid
##STR00099##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
piperidine as the reactant amine. The product was isolated as a
white solid (23 mg, 29%). .sup.1H NMR (400 MHz, CHLOROFORM-d)
.delta. ppm 7.99 (d, J=8.03 Hz, 2H), 7.24 (d, J=8.03 Hz, 2H), 5.32
(d, J=3.01 Hz, 1H), 4.75 (s, 1H), 4.60 (s, 1H), 3.66-3.46 (m, 4H),
3.09-2.93 (m, 2H), 1.71 (s, 3H), 2.20-0.95 (m, 27H), 1.03 (s, 3H),
1.01 (s, 3H), 0.99 (s, 3H), 0.95 (s, 3H), 0.94 (s, 3H).
Example 20
Preparation of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-1-(-
prop-1-en-2-yl)-3a-(2-(pyridin-2-yl)ethylcarbamoyl)-2,3,3a,4,5,5a,5b,6,7,7-
a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)be-
nzoate
##STR00100##
The title compound was prepared following the general procedures
described above for the C-28 amide formation using
2-(2-aminoethyl)pyridine as the reactant amine. The product was
isolated as a white solid (44 mg, 25%). LCMS: m/e 677.63
(M+H).sup.+, 2.71 min (method 1). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 8.52 (d, J=3.97 Hz, 1H), 7.91 (d, J=8.24
Hz, 2H), 7.62 (td, J=7.63, 1.83 Hz, 1H), 7.21-7.12 (m, 5H), 6.73
(t, J=5.34 Hz, 1H), 5.26 (dd, J=6.26, 1.68 Hz, 1H), 4.73 (d, J=1.83
Hz, 1H), 4.58 (s, 1H), 3.89 (s, 3H), 3.67 (q, J=6.00 Hz, 2H), 3.10
(td, J=11.14, 3.97 Hz, 1H), 3.03-2.97 (m, 2H), 2.41 (td, J=12.21,
3.36 Hz, 1H), 2.07 (dd, J=17.40, 6.41 Hz, 1H), 2.00-1.94 (m, 1H),
1.94-1.84 (m, 1H), 1.67 (s, 3H), 0.95 (s, 3H), 1.74-0.92 (m, 17H),
0.92 (s, 3H), 0.89 (s, 6H), 0.88 (s, 3H).
Example 21
Preparation of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(4-hydroxypiperidine-1-car-
bonyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7-
a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)be-
nzoate
##STR00101##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
4-hydroxypiperidine as the reactant amine. LCMS: m/e 656.6
(M+H).sup.+, 3.10 min (method 2). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 7.92 (d, J=8.55 Hz, 2H), 7.19 (d, J=8.55
Hz, 2H), 5.28 (dd, J=6.26, 1.68 Hz, 1H), 4.73 (d, J=2.14 Hz, 1H),
4.58 (s, 1H), 3.90 (s, 3H), 4.19-3.88 (m, 2H), 3.22-3.01 (m, 2H),
3.01 (td, J=10.99, 3.36 Hz, 1H), 2.97-2.90 (m, 1H), 2.15-2.06 (m,
2H), 1.69 (s, 3H), 2.01-0.95 (m, 25H), 0.99 (s, 3H), 0.99 (s, 3H),
0.97 (s, 3H), 0.92 (s, 3H), 0.91 (s, 3H).
Example 22
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(4-hydroxypiperidine-1-car-
bonyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7-
a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)be-
nzoic acid
##STR00102##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
4-hydroxypiperidine as the reactant amine. The product was isolated
as a white solid (7.7 mg, 9.4%). LCMS: m/e 642.6 (M+H).sup.+, 2.46
min (method 2). .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm
8.00 (d, J=8.28 Hz, 2H), 7.24 (d, J=8.28 Hz, 2H), 5.32 (d, J=4.77
Hz, 1H), 4.75 (d, J=1.51 Hz, 1H), 4.60 (s, 1H), 4.21-3.89 (m, 3H),
3.25-2.90 (m, 4H), 1.71 (s, 3H), 2.17-0.95 (m, 26H), 1.02 (s, 3H),
1.01 (s, 3H), 1.00 (s, 3H), 0.95 (s, 3H), 0.95 (s, 3H).
Example 23
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-hydroxyethyl)(methyl)c-
arbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,-
7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl-
)benzoic acid
##STR00103##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
2-methylaminoethanol as the reactant amine. The product was
isolated as a white film (6.1 mg, 7.8%). LCMS: m/e 616.6
(M+H).sup.+, 2.50 min (method 2). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 7.98 (d, J=7.63 Hz, 2H), 7.21 (d, J=7.93
Hz, 2H), 5.31-5.27 (m, 1H), 4.73 (s, 1H), 4.59 (s, 1H), 3.81 (t,
J=4.73 Hz, 2H), 3.58-3.53 (m, 2H), 3.15 (s, 3H), 3.01-2.93 (m, 1H),
2.88 (t, J=10.83 Hz, 1H), 2.29 (d, J=13.43 Hz, 1H), 2.16-2.03 (m,
3H), 1.94-1.81 (m, 1H), 1.69 (s, 3H), 1.78-0.95 (m, 16H), 1.00 (s,
6H), 0.97 (s, 3H), 0.92 (s, 6H).
Example 24
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(methyl(2-(pyridin-2-yl)ethyl)carbamoyl)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,-
5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-
-9-yl)benzoic acid
##STR00104##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
2-(2-methylaminoethyl)pyridine as the reactant amine. The product
was isolated as a white solid (22 mg, 25%). LCMS: m/e 675.7
(M-H).sup.-, 2.23 min (method 1). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 8.49 (d, J=4.58 Hz, 1H), 7.83 (d, J=8.24
Hz, 2H), 7.71 (td, J=7.63, 1.53 Hz, 1H), 7.27 (d, J=7.93 Hz, 1H),
7.22 (dd, J=7.02, 5.19 Hz, 1H), 7.15 (d, J=7.93 Hz, 2H), 5.23 (d,
J=4.88 Hz, 1H), 4.67 (s, 1H), 4.55 (s, 1H), 3.69-3.60 (m, 1H),
3.02-2.84 (m, 7H), 2.19 (d, J=12.82 Hz, 1H), 2.07 (dd, J=17.55,
6.56 Hz, 1H), 2.01-1.93 (m, 1H), 1.65 (s, 3H), 1.72-0.95 (m, 19H),
0.95 (s, 6H), 0.92 (s, 3H), 0.88 (s, 6H).
Example 25
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-carboxyethylcarbamoyl)--
5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,-
11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic
acid
##STR00105##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
beta-alanine, ethyl ester hydrochloride as the reactant amine. The
product was isolated as a white solid (102 mg, 73%). LCMS: m/e
628.6 (M-H).sup.-, 1.96 min (method 1). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 7.97 (d, J=8.24 Hz, 2H), 7.20 (d, J=8.24
Hz, 2H), 6.27 (t, J=6.10 Hz, 1H), 5.24 (d, J=4.58 Hz, 1H), 4.75 (d,
J=1.53 Hz, 1H), 4.60 (s, 1H), 3.63-3.47 (m, 2H), 3.08 (td, 1H),
2.71-2.59 (m, 2H), 2.39 (td, J=12.21, 3.36 Hz, 1H), 2.06-1.90 (m,
3H), 1.69 (s, 3H), 0.98 (s, 3H), 1.79-0.95 (m, 18H), 0.95 (s, 3H),
0.88 (br. s., 9H).
Example 26
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(methylcarbamoyl)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,-
12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic
acid
##STR00106##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
methylamine (2M in THF, 10 equiv. used) as the reactant amine. The
product was isolated as a white solid (92 mg, 77%). LCMS: m/e 570.6
(M-H).sup.-, 2.22 min (method 3). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 12.88 (br. s., 1H), 7.86 (d, J=8.24 Hz,
2H), 7.49 (q, J=4.27 Hz, 1H), 7.21 (d, J=8.24 Hz, 2H), 5.24 (d,
J=4.58 Hz, 1H), 4.67 (d, J=2.14 Hz, 1H), 4.55 (s, 1H), 3.04 (td,
J=10.76, 4.43 Hz, 1H), 2.66-2.59 (m, 1H), 2.56 (d, J=4.58 Hz, 3H),
2.13-2.04 (m, 2H), 1.64 (s, 3H), 0.95 (s, 3H), 0.94 (s, 3H),
1.80-0.93 (m, 19H), 0.91 (s, 3H), 0.88 (s, 6H).
Example 27
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(3-(dimethylamino)propylca-
rbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7-
,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)-
benzoic acid
##STR00107##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
3-(Dimethylamino)propylamine as the reactant amine. The product was
isolated as a white solid (65 mg, 51%). LCMS: m/e 641.7
(M-H).sup.-, 2.22 min (method 3). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 7.86 (d, J=8.24 Hz, 2H), 7.80 (t, J=5.80
Hz, 1H), 7.21 (d, J=7.93 Hz, 2H), 5.24 (d, J=4.88 Hz, 1H), 4.67 (d,
J=1.83 Hz, 1H), 4.56 (s, 1H), 3.14-3.07 (m, 2H), 3.03 (td, J=10.76,
4.43 Hz, 1H), 2.95 (t, J=7.48 Hz, 2H), 2.72 (s, 6H), 2.66-2.57 (m,
1H), 2.13 (d, J=13.12 Hz, 1H), 2.07 (dd, J=17.55, 6.56 Hz, 1H),
1.65 (s, 3H), 1.83-0.95 (m, 21H), 0.96 (s, 3H), 0.94 (s, 3H), 0.92
(s, 3H), 0.88 (s, 6H).
Example 28
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-1-(-
prop-1-en-2-yl)-3a-(pyridin-4-ylmethylcarbamoyl)-2,3,3a,4,5,5a,5b,6,7,7a,8-
,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzo-
ic acid
##STR00108##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
4-picolylamine as the reactant amine. The product was isolated as a
white solid (14 mg, 11%). LCMS: m/e 647.7 (M-H).sup.-, 2.21 min
(method 3). .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 8.49
(d, J=5.80 Hz, 2H),8.30 (t, J=5.95 Hz, 1H), 7.84 (d, J=8.24 Hz,
2H), 7.23 (d, J=5.80 Hz, 2H), 7.17 (d, J=7.93 Hz, 2H), 5.23 (d,
J=4.58 Hz, 1H), 4.66 (d, J=1.83 Hz, 1H), 4.55 (s, 1H), 4.31-4.25
(m, 1H), 4.23-4.18 (m, 1H), 3.01 (td, J=10.99, 4.58 Hz, 1H),
2.60-2.53 (m, 1H), 2.22 (d, J=13.73 Hz, 1H), 2.06 (dd, J=17.24,
6.26 Hz, 1H), 1.87 (dd, J=12.05, 7.78 Hz, 1H), 1.65 (s, 3H),
1.77-0.95 (m, 18H), 0.96 (s, 3H), 0.93 (s, 3H), 0.88 (s, 6H), 0.83
(s, 3H).
Example 29
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-1-(-
prop-1-en-2-yl)-3a-(pyridin-3-ylmethylcarbamoyl)-2,3,3a,4,5,5a,5b,6,7,7a,8-
,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzo-
ic acid
##STR00109##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
3-(aminomethyl)pyridine as the reactant amine. The product was
isolated as an off-white solid (25 mg, 18%). LCMS: m/e 647.6
(M-H).sup.-, 2.21 min (method 3). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 8.48 (d, J=1.83 Hz, 1H), 8.43 (dd,
J=4.58, 1.53 Hz, 1H), 8.26 (t, J=5.95 Hz, 1H), 7.84 (d, J=8.24 Hz,
2H), 7.64 (d, J=7.93 Hz, 1H), 7.34 (dd, J=7.78, 4.73 Hz, 1H), 7.18
(d, J=8.24 Hz, 2H), 5.23 (d, J=4.58 Hz, 1H), 4.67 (d, J=1.83 Hz,
1H), 4.55 (s, 1H), 4.31 (dd, J=15.11, 5.95 Hz, 1H), 4.18 (dd,
J=14.95, 5.80 Hz, 1H), 3.03 (td, J=10.91, 4.12 Hz, 1H), 2.60-2.53
(m, 1H), 2.18 (d, J=13.43 Hz, 1H), 2.06 (dd, J=17.24, 6.56 Hz, 1H),
1.81 (dd, J=11.90, 7.63 Hz, 1H), 1.64 (s, 3H), 1.74-0.95 (m, 18H),
0.95 (s, 3H), 0.93 (s, 3H), 0.88 (s, 6H), 0.79 (s, 3H).
Example 30
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-acetamidoethylcarbamoyl-
)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,1-
1,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic
acid
##STR00110##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
N-acetylethylene diamine as the reactant amine. The product was
isolated as a white solid (43 mg, 34%). LCMS: m/e 641.7
(M-H).sup.-, 2.19 min (method 3). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 7.84 (d, J=8.24 Hz, 2H), 7.60 (br. s.,
1H), 7.19 (d, J=8.24 Hz, 2H), 5.23 (d, J=5.19 Hz, 1H), 4.66 (s,
1H), 4.54 (s, 1H), 3.16-2.97 (m, 5H), 2.65-2.55 (m, 1H), 2.13-2.03
(m, 2H), 1.79 (s, 3H), 1.64 (s, 3H), 1.82-0.95 (m, 19H), 0.95 (s,
3H), 0.94 (s, 3H), 0.91 (s, 3H), 0.88 (s, 6H).
Example 31
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-(dimethylamino)ethyl)(-
methyl)carbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,-
5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chry-
sen-9-yl)benzoic acid
##STR00111##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
N,N,N'-trimethylethylenediamine as the reactant amine. The product
was isolated as a white solid (58 mg, 48%). LCMS: m/e 641.7
(M-H).sup.-, 2.31 min (method 3). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 7.86 (d, J=8.24 Hz, 2H), 7.22 (d, J=8.55
Hz, 2H), 5.24 (d, J=4.58 Hz, 1H), 4.67 (d, J=1.83 Hz, 1H), 4.56 (s,
1H), 3.68-3.45 (m, 2H), 2.94-2.81 (m, 2H), 3.08 (br. s., 5H), 2.73
(br. s., 6H), 2.23 (br. s., 1H), 2.13-1.98 (m, 2H), 1.66 (s, 3H),
1.73-0.95 (m, 18H), 0.97 (s, 3H), 0.95 (s, 3H), 0.93 (s, 3H), 0.88
(s, 6H).
Example 32
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(3-morpholinopropylcarbamoyl)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8-
,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzo-
ic acid
##STR00112##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
N-(3-aminopropyl)morpholine as the reactant amine. The product was
isolated as a white solid (94 mg, 93%). LCMS: m/e 683.8
(M-H).sup.-, 2.25 min (method 3). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 12.86 (br. s., 1H). 7.86 (d, J=8.24 Hz,
2H), 7.79 (br. s., 1H), 7.22 (d, J=8.24 Hz, 2H), 5.24 (d, J=4.58
Hz, 1H), 4.67 (d, J=1.83 Hz, 1H), 4.55 (s, 1H), 4.05-3.92 (m, 2H),
3.78-3.67 (m, 2H), 3.62 (br. s., 1H), 3.17-2.95 (m, 6H), 2.68-2.58
(m, 1H), 2.31 (br. s., 1H), 2.19-2.02 (m, 2H), 1.65 (s, 3H), 0.96
(s, 3H), 0.95 (s, 3H), 1.86-0.95 (m, 22H), 0.92 (s, 3H), 0.89 (s,
6H).
Example 33
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(2-(piperidin-1-yl)ethylcarbamoyl)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7-
,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)-
benzoic acid
##STR00113##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
N-(2-aminoethyl)piperidine as the reactant amine. The product was
isolated as a white solid (100 mg, 75%). LCMS: m/e 667.7
(M-H).sup.-, 2.29 min (method 3). .sup.1H NMR (500 MHz, Pyr)
.delta. ppm 8.47 (d, J=8.24 Hz, 2H), 7.81 (br. s., 1H), 7.41 (d,
J=8.24 Hz, 2H), 5.40 (d, J=4.58 Hz, 1H), 4.98 (d, J=2.44 Hz, 1H),
4.81 (br. s., 1H), 3.73-3.56 (m, 3H), 3.13-3.05 (m, 1H), 2.58 (t,
J=6.26 Hz, 2H), 2.48-2.35 (m, 4H), 2.25 (t, J=8.39 Hz, 1H),
2.17-2.06 (m, 2H), 2.03-1.95 (m, 1H), 1.82 (s, 3H), 1.20 (s, 3H),
1.85-0.95 (m, 23H), 1.10 (s, 3H), 1.02 (s, 3H), 1.00 (s, 3H), 0.99
(s, 3H).
Example 34
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-amino-2-oxoethylcarbamo-
yl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8-
,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzo-
ic acid
##STR00114##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
glycinamide hydrochloride as the reactant amine. The product was
isolated as a white solid (29 mg, 33%). LCMS: m/e 613.6
(M-H).sup.-, 2.16 min (method 3). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 7.97 (d, J=8.24 Hz, 2H), 7.21 (d, J=8.24
Hz, 2H), 6.31 (t, J=5.34 Hz, 1H), 6.11 (br. s., 1H), 5.64 (br. s.,
1H), 5.31-5.27 (m, 1H), 4.75 (d, J=1.83 Hz, 1H), 4.61 (s, 1H), 4.00
(dd, J=16.17, 5.19 Hz, 1H), 3.89 (dd, J=16.17, 5.19 Hz, 1H), 3.11
(td, J=11.06, 4.73 Hz, 1H), 2.46 (td, J=12.13, 3.51 Hz, 1H), 2.10
(dd, J=17.24, 6.56 Hz, 1H), 2.04-1.87 (m, 2H), 1.81 (dd, J=12.05,
7.78 Hz, 1H), 1.69 (s, 3H), 1.00 (s, 3H), 1.76-0.95 (m, 17H), 0.97
(s, 3H), 0.95 (s, 3H), 0.92 (s, 3H), 0.91 (s, 3H).
Example 35
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(dimethylamino)-2-(pyri-
din-3-yl)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,-
3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta-
[a]chrysen-9-yl)benzoic acid
##STR00115##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
(2-Amino-1-(3-pyridyl)ethyl)dimethylamine as the reactant amine.
The product was isolated as a white solid (80 mg, 78%). LCMS: m/e
704.7 (M-H).sup.-, 2.23 min (method 3).
Example 36
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(2-(4-methylpiperazin-1-yl)ethylcarbamoyl)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5-
a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrys-
en-9-yl)benzoic acid
##STR00116##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
2-(4-methyl-piperazin-1-yl)-ethylamine as the reactant amine. The
product was isolated as a white solid (56 mg, 56%). LCMS: m/e 682.7
(M-H).sup.-, 2.25 min (method 3). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 7.88 (br. s., 1H), 7.86 (d, J=8.24 Hz,
2H), 7.22 (d, J=7.93 Hz, 2H), 5.24 (d, J=4.88 Hz, 1H), 4.68 (d,
J=1.53 Hz, 1H), 4.56 (s, 1H), 4.02-2.32 (m, 17H), 2.15 (d, J=12.51
Hz, 1H), 2.08 (dd, J=17.09, 6.10 Hz, 1H), 1.65 (s, 3H), 0.96 (s,
3H), 0.95 (s, 3H), 1.88-0.94 (m, 19H), 0.92 (s, 3H), 0.89 (s,
6H).
Example 37
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(4-(tert-butoxycarbonyl-
)piperazin-1-yl)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-y-
l)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyc-
lopenta[a]chrysen-9-yl)benzoic acid
##STR00117##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
4-N-(2-aminoethyl)-1-N-Boc-piperazine as the reactant amine. The
product was isolated as a white solid (69 mg, 56%). LCMS: m/e 768.8
(M-H).sup.-, 2.32 min (method 3). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 12.86 (br. s., 1H), 7.96 (br. s., 1H),
7.86 (d, J=8.24 Hz, 2H), 7.22 (d, J=8.24 Hz, 2H), 5.24 (d, J=4.58
Hz, 1H), 4.67 (s, 1H), 4.56 (s, 1H), 4.00 (br. s., 2H), 3.53-3.40
(m, 4H), 3.32-2.96 (m, 6H), 2.67-2.53 (m, 1H), 2.18-2.03 (m, 2H),
1.65 (s, 3H), 1.42 (s, 9H), 0.96 (s, 3H), 1.84-0.95 (m, 20H), 0.95
(s, 3H), 0.92 (s, 3H), 0.88 (s, 6H).
Example 38
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-amino-2-methylpropylcar-
bamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,-
7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)b-
enzoic acid
##STR00118##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
1,2-diamino-2-methylpropane as the reactant amine. The product was
isolated as a white solid (66 mg, 68%). LCMS: m/e 627.7
(M-H).sup.-, 2.19 min (method 3). .sup.1H NMR (500 MHz, Acetic
Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.24 Hz, 2H), 7.76 (t, J=6.41
Hz, 1H), 7.30 (d, J=8.24 Hz, 2H), 5.37 (d, J=4.58 Hz, 1H), 4.78 (d,
J=1.83 Hz, 1H), 4.65 (s, 1H), 3.66 (dd, J=14.95, 6.10 Hz, 1H), 3.58
(dd, J=14.65, 5.49 Hz, 1H), 3.15 (td, J=10.91, 4.12 Hz, 1H), 2.63
(td, J=12.36, 3.36 Hz, 1H), 2.29 (d, J=13.73 Hz, 1H), 1.74 (s, 3H),
1.44 (s, 3H), 1.42 (s, 3H), 1.09 (s, 3H), 2.23-0.95 (m, 20H), 1.07
(s, 3H), 1.05 (s, 3H), 1.01 (s, 3H), 0.99 (s, 3H).
Example 39
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((1-ethylpyrrolidin-2-yl)m-
ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a-
,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chryse-
n-9-yl)benzoic acid
##STR00119##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
1-ethyl-2-amino methylene pyrrolidine as the reactant amine. The
product was isolated as a white solid (35 mg, 34%). LCMS: m/e 667.7
(M-H).sup.-, 2.27 min (method 3). .sup.1H NMR (500 MHz, Acetic
Acid-d.sub.4) .delta. ppm 8.18 (br. s., 1H), 8.06 (d, J=8.24 Hz,
2H), 7.33 (d, J=8.24 Hz, 2H), 5.40 (d, J=4.58 Hz, 1H), 4.81 (s,
1H), 4.68 (s, 1H), 4.06-3.67 (m, 4H), 3.58-3.43 (m, 1H), 3.26-3.12
(m, 3H), 2.65-2.55 (m, 1H), 2.41 (d, J=13.12 Hz, 1H), 1.77 (s, 3H),
1.12 (s, 3H), 1.09 (s, 3H), 1.08 (s, 3H), 2.34-0.95 (m, 27H), 1.03
(s, 3H), 1.02 (s, 3H).
Example 40
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((1H-benzo[d]imidazol-2-yl-
)methylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,-
5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chry-
sen-9-yl)benzoic acid
##STR00120##
The title compound was prepared following the method described
above for the general procedure for C-28 amide formation and
hydrolysis using 2-aminomethylbenzimidazole, HCl as the reactant
amine. The product was isolated as a tan solid (32 mg, 46%). LCMS:
m/e 686.7 (M-H).sup.-, 2.27 min (method 3). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 12.83 (br. s., 1H), 8.49 (t, J=4.52 Hz,
1H), 7.87 (d, J=8.28 Hz, 2H), 7.72-7.65 (m, 2H), 7.42-7.35 (m, 2H),
7.22 (ddd, 2H), 5.24 (d, J=4.77 Hz, 1H), 4.65 (d, J=2.01 Hz, 1H),
4.55 (br. s., 2H), 4.53 (s, 1H), 3.00 (td, J=10.79, 4.27 Hz, 1H),
2.51-2.43 (m, 1H), 2.26 (d, J=12.80 Hz, 1H), 2.06 (dd, J=16.81,
6.27 Hz, 1H), 1.95 (dd, J=11.42, 7.91 Hz, 1H), 1.65 (s, 3H), 0.96
(s, 3H), 0.88 (s, 9H), 1.81-0.83 (m, 18H), 0.68 (s, 3H).
Example 41
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-1-(-
prop-1-en-2-yl)-3a-(thiazol-2-ylmethylcarbamoyl)-2,3,3a,4,5,5a,5b,6,7,7a,8-
,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzo-
ic acid
##STR00121##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
2-aminomethylthiazole hydrochloride as the reactant amine. The
product was isolated as a white solid (55 mg, 85%). LCMS: m/e 653.6
(M-H).sup.-, 2.23 min (method 3). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.53 (t, J=5.90 Hz, 1H), 7.87 (d, J=8.28
Hz, 2H), 7.71 (d, J=3.26 Hz, 1H), 7.62 (d, J=3.26 Hz, 1H), 7.23 (d,
J=8.28 Hz, 2H), 5.26 (d, J=4.52 Hz, 1H), 4.70 (d, J=2.26 Hz, 1H),
4.63-4.45 (m, 3H), 3.00-3.09 (m, 1H), 2.70-2.59 (m, 1H), 2.21 (d,
J=12.80 Hz, 1H), 2.09 (dd, J=17.44, 6.15 Hz, 1H), 1.67 (s, 3H),
0.98 (s, 3H), 1.94-0.95 (m, 20H), 0.96 (s, 3H), 0.92 (s, 3H), 0.90
(s, 6H).
Example 42
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-1-(-
prop-1-en-2-yl)-3a-(thiophen-2-ylmethylcarbamoyl)-2,3,3a,4,5,5a,5b,6,7,7a,-
8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benz-
oic acid
##STR00122##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
2-Thiophenemethylamine as the reactant amine. The product was
isolated as a white solid (44 mg, 66%). LCMS: m/e 652.7
(M-H).sup.-, 2.24 min (method 3). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 12.81 (br. s., 1H), 8.25 (t, J=5.90 Hz,
1H), 7.87 (d, J=8.28 Hz, 2H), 7.37 (dd, J=4.39, 1.88 Hz, 1H), 7.23
(d, J=8.28 Hz, 2H), 6.97-6.92 (m, 2H), 5.26 (d, J=4.52 Hz, 1H),
4.69 (d, J=2.26 Hz, 1H), 4.57 (s, 1H), 4.48 (dd, J=15.31, 5.77 Hz,
1H), 4.37 (dd, J=15.06, 6.02 Hz, 1H), 3.11-3.01 (m, 1H), 2.71-2.61
(m, 1H), 2.16 (d, J=12.80 Hz, 1H), 2.09 (dd, J=17.19, 6.15 Hz, 1H),
1.67 (s, 3H), 1.88-0.94 (m, 19H), 0.97 (s, 6H), 0.91 (s, 3H), 0.90
(s, 6H).
Example 43
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a#1H-imidazol-2-yl)methylcar-
bamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,-
7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)b-
enzoic acid
##STR00123##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
2-aminomethyl-1H-imidazole dihydrochloride as the reactant amine.
The product was isolated as a white solid (35 mg, 52%). LCMS: m/e
636.7 (M-H).sup.-, 2.23 min (method 3). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.33 (t, J=5.14 Hz, 1H), 7.87 (d, J=8.28
Hz, 2H), 7.37 (s, 2H), 7.23 (d, J=8.28 Hz, 2H), 5.25 (d, J=4.52 Hz,
1H), 4.67 (d, J=2.26 Hz, 1H), 4.57 (s, 1H), 4.41-4.30 (m, 2H), 3.01
(td, J=10.98, 5.14 Hz, 1H), 2.54-2.44 (m, 1H), 2.23-2.16 (m, 1H),
2.08 (dd, J=17.94, 6.65 Hz, 1H), 1.91-1.83 (m, 1H), 1.65 (s, 3H),
1.77-0.95 (m, 19H), 0.96 (s, 3H), 0.94 (s, 3H), 0.90 (s, 6H), 0.77
(s, 3H).
Example 44
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(1-(5-methyl-4H-1,2,4-triazol-3-yl)ethylcarbamoyl)-1-(prop-1-en-2-yl)-2,3,-
3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta-
[a]chrysen-9-yl)benzoic acid
##STR00124##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
1-(5-methyl-4H-1,2,4-triazol-3-yl)ethanamine, 2 HCl as the reactant
amine. The product was isolated as a white solid (24 mg, 35%).
LCMS: m/e 665.7 (M-H).sup.-, 2.20 min (method 3). .sup.1H NMR (500
MHz, DMSO-d.sub.6) .delta. ppm 13.29 (br. s., 1H), 12.85 (br. s.,
1H), 7.86 (d, J=8.24 Hz, 2H), 7.63 (br. s., 1H), 7.22 (d, J=8.24
Hz, 2H), 5.24 (d, J=4.58 Hz, 1H), 4.98 (br. s., 1H), 4.66 (d,
J=2.14 Hz, 1H), 4.54 (s, 1H), 3.00 (td, J=10.83, 4.58 Hz, 1H),
2.67-2.67 (m, 1H), 2.34-2.20 (m, 4H), 2.08 (dd, J=17.24, 6.26 Hz,
1H), 1.91 (dd, J=11.29, 7.93 Hz, 1H), 1.64 (s, 3H), 0.96 (s, 3H),
0.95 (s, 3H), 1.80-0.93 (m, 21H), 0.93 (s, 3H), 0.89 (s, 6H).
Example 45
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(benzo[d]thiazol-2-ylmethy-
lcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,-
6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9--
yl)benzoic acid
##STR00125##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
1,3-Benzothiazol-2-ylmethylamine hydrochloride as the reactant
amine. The product was isolated as a white solid (55 mg, 85%).
LCMS: m/e 703.7 (M-H).sup.-, 2.28 min (method 3). .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 12.83 (br. s., 1H), 8.64 (t, J=5.90
Hz, 1H), 8.09 (d, J=7.53 Hz, 1H), 7.95 (d, J=7.53 Hz, 1H), 7.87 (d,
J=8.28 Hz, 2H), 7.54-7.49 (m, 1H), 7.46-7.40 (m, 1H), 7.23 (d,
J=8.28 Hz, 2H), 5.26 (d, J=4.77 Hz, 1H), 4.69 (d, J=2.01 Hz, 1H),
4.66 (d, J=6.02 Hz, 2H), 4.57 (s, 1H), 3.04 (td, J=10.98, 4.14 Hz,
1H), 2.69-2.59 (m, 1H), 2.30-2.22 (m, 1H), 2.09 (dd, J=17.19, 6.40
Hz, 1H), 2.00-1.91 (m, 1H), 1.91-1.78 (m, 1H), 1.68 (s, 3H), 0.99
(s, 3H), 1.74-0.95 (m, 17H), 0.94 (s, 3H), 0.92 (s, 3H), 0.90 (s,
6H).
Example 46
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(2-(2-oxopyrrolidin-1-yl)ethylcarbamoyl)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,-
5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-
-9-yl)benzoic acid
##STR00126##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
1-(2-aminoethyl)pyrrolidin-2-one as the reactant amine. The product
was isolated as a white solid (52 mg, 45%). LCMS: m/e 667.5
(M-H).sup.-, 2.19 min (method 3). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 7.98 (d, J=8.24 Hz, 2H), 7.22 (d, J=8.24
Hz, 2H), 6.30-6.26 (m, 1H), 5.29 (d, J=4.58 Hz, 1H), 4.74 (d,
J=1.83 Hz, 1H), 4.59 (s, 1H), 3.54-3.41 (m, 6H), 3.14 (td, J=11.06,
4.12 Hz, 1H), 2.51-2.43 (m, 1H), 2.41 (t, J=8.09 Hz, 2H), 2.02-2.14
(m, 3H), 1.99-1.85 (m, 2H), 1.68 (s, 3H), 1.77-0.95 (m, 18H), 0.98
(s, 6H), 0.96 (s, 3H), 0.92 (s, 6H).
Example 47
Preparation of
2-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-5a,5b,8,8-
,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,1-
2,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)-5-meth-
ylthiazole-4-carboxylic acid
##STR00127##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
2-amino-4-methyl-thiazole-5-carboxylic acid ethyl ester as the
reactant amine. The product was isolated as a white solid (14 mg,
16%). LCMS: m/e 697.4 (M-H).sup.-, 2.41 min (method 4). .sup.1H NMR
(500 MHz, Acetic Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.24 Hz, 2H),
7.29 (d, J=8.24 Hz, 2H), 5.37 (d, J=4.88 Hz, 1H), 4.84 (s, 1H),
4.68 (s, 1H), 3.11-3.19 (m, 1H), 2.78-2.86 (m, 1H), 2.60 (s, 3H),
2.41 (d, J=13.73 Hz, 1H), 1.77 (s, 3H), 1.11 (s, 3H), 1.07 (s, 3H),
1.04 (s, 3H), 1.00 (s, 3H), 0.98 (s, 3H), 0.86-2.28 (m, 20H).
Example 48
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(5-methylthiazol-2-ylcarbamoyl)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a-
,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)ben-
zoic acid
##STR00128##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
2-amino-4-methyl-thiazole-5-carboxylic acid ethyl ester as the
reactant amine. Upon hydrolysis of the thiazole carboxylate,
decarboxylation occurred as a minor side product. The product was
isolated as a white solid (4.3 mg, 4.7%). LCMS: m/e 653.4
(M-H).sup.-, 2.68 min (method 4). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 7.99 (d, J=8.24 Hz, 2H), 7.21 (d, J=8.24
Hz, 2H), 6.52 (s, 1H), 5.30 (d, J=4.58 Hz, 1H), 4.78 (s, 1H), 4.62
(s, 1H), 3.10-3.18 (m, 1H), 2.58-2.69 (m, 1H), 2.45 (d, J=13.73 Hz,
1H), 2.39 (s, 3H), 1.71 (s, 3H), 1.02 (s, 3H), 0.97 (s, 3H), 0.95
(s, 3H), 0.92 (s, 3H), 0.90 (s, 3H), 0.80-2.17 (m, 20H).
##STR00129##
Preparation of
3-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-(methoxycarbonyl)phenyl)-
-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11-
,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxami-
do)propanoic acid. Intermediate 8
##STR00130##
The title compound was prepared following the method described
above for the general procedure for C-28 amide formation using
beta-alanine, ethyl ester hydrochloride as the reactant amine. The
resulting ethyl ester was hydrolyzed using 4 equiv. of 1N NaOH and
1,4-dioxane as the solvent at rt. After 1.5 h the mixture was
acidified with 1N HCl and was extracted with dichloromethane
(3.times.20 mL). The organic layers were combined, dried with
Na.sub.2SO.sub.4, filtered, and concentrated under reduced
pressure. The residue was purified by Biotage flash chromatography
(0-50% ethyl acetate in hexanes with 0.1% acetic acid added) to
give the title product as a white solid (330 mg, 61%). LCMS: m/e
642.4 (M-H).sup.-, 2.89 min (method 4). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 7.92 (d, J=8.24 Hz, 2H), 7.18 (d, J=8.24
Hz, 2H), 6.18 (t, J=5.80 Hz, 1H), 5.26-5.29 (m, 1H), 4.74 (d,
J=1.83 Hz, 1H), 4.60 (s, 1H), 3.90 (s, 3H), 3.53-3.61 (m, 1H),
3.44-3.52 (m, 1H), 3.11 (td, J=11.06, 4.12 Hz, 1H), 2.64 (t, J=5.49
Hz, 2H), 2.43-2.50 (m, 1H), 2.09 (dd, J=17.40, 6.10 Hz, 1H),
1.88-1.98 (m, 2H), 1.69 (s, 3H), 0.99 (s, 3H), 0.98 (s, 3H),
0.97-1.77 (m, 18H), 0.96 (s, 3H), 0.91 (s, 6H).
Example 49
Preparation of
1-(3-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-5a,5b,-
8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11-
b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)prop-
anoyl)piperidine-4-carboxylic acid
##STR00131##
To a solution of
3-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-(methoxycarbonyl)phenyl)-
-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11-
,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxami-
do)propanoic acid (0.06 g, 0.093 mmol) in DCE (2 mL) was added DIEA
(0.049 mL, 0.280 mmol),
O-benzotriazol-1-yl-N,N,N',N'-tetra-methyluronium tetrafluoroborate
(0.048 g, 0.149 mmol), and methyl isonipecotate (0.019 mL, 0.140
mmol). The mixture was stirred at rt for 15.75 h, then was diluted
with 7 mL of water and was extracted with dichloromethane
(3.times.7 mL). The combined organic layers were dried with
Na.sub.2SO.sub.4, the drying agent was removed by filtration and
the filtrate was concentrated under reduced pressure. The residue
was purified by Biotage flash chromatography using a 0-75% ethyl
acetate in hexanes gradient. The fractions containing the expected
product were combined and were concentrated under reduced pressure.
The expected product, methyl
1-(3-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-(methoxycarbonyl)phen-
yl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8-
,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carbox-
amido)propanoyl)piperidine-4-carboxylate (0.058 g, 0.075 mmol, 81%
yield), was isolated as a white foam. LCMS: m/e 767.5 (M-H).sup.-,
3.46 min (method 4).
To a solution of methyl
1-(3-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-(methoxycarbonyl)phen-
yl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8-
,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carbox-
amido)propanoyl)piperidine-4-carboxylate (0.058 g, 0.075 mmol) in
1,4-dioxane (2 mL) was added NaOH (1N) (0.377 mL, 0.377 mmol). The
mixture was heated to 85.degree. C. for 15 h then was cooled to rt.
The mixture was diluted with 5 mL of 1N HCl and was extracted with
dichloromethane (4.times.5 mL). The combined organic layers were
dried with Na.sub.2SO.sub.4, the drying agent was removed by
filtration and the filtrate was concentrated under reduced
pressure. The residue was purified by Biotage flash chromatography
using a 0-10% MeOH in dichloromethane gradient with 0.1% HOAc added
to the mixture. The compound was further purified by prep HPLC. The
fractions containing the expected product were combined and
concentrated under reduced pressure to give the title compound
(41.5 mg, 0.056 mmol, 74.3% yield) as a white solid. LCMS: m/e
739.4 (M-H).sup.-, 2.37 min (method 4). .sup.1H NMR (500 MHz,
Acetic Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d,
J=8.24 Hz, 2H), 5.37 (d, J=6.10 Hz, 1H), 4.79 (s, 1H), 4.64 (s,
1H), 4.43-4.53 (m, 1H), 3.95-4.02 (m, 1H), 3.46-3.70 (m, 2H),
3.18-3.27 (m, 1H), 3.13 (qd, J=11.04, 4.12 Hz, 1H), 2.65-2.97 (m,
4H), 2.47-2.57 (m, 1H), 1.74 (s, 3H), 1.07 (s, 3H), 1.06 (s, 3H),
1.05 (s, 3H), 1.03-2.24 (m, 25H), 1.00 (s, 3H), 0.99 (s, 3H).
Example 50
Preparation of
2-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-5a,5b,8,8-
,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,1-
2,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)thiazol-
e-5-carboxylic acid
##STR00132##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
methyl 2-aminothiazole-5-carboxylate as the reactant amine. The
product was isolated as a white solid (14 mg, 10.7%). LCMS: m/e
683.3 (M-H).sup.-, 2.36 min (method 4). .sup.1H NMR (500 MHz,
Acetic Acid-d.sub.4) .delta. ppm 8.18 (s, 1H), 8.03 (d, J=8.24 Hz,
2H), 7.30 (d, J=8.24 Hz, 2H), 5.37 (d, J=4.58 Hz, 1H), 4.84 (s,
1H), 4.69 (s, 1H), 3.16 (td, J=10.99, 4.58 Hz, 1H), 2.79-2.86 (m,
1H), 2.39-2.45 (m, 1H), 1.77 (s, 3H), 1.11 (s, 3H), 1.07 (s, 3H),
1.04 (s, 3H), 1.02-2.25 (m, 20H), 1.00 (s, 3H), 0.98 (s, 3H).
Example 51
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(1,3,4-thiadiazol-2-ylcarb-
amoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7-
a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)be-
nzoic acid
##STR00133##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
5-amino-1,3,4-thiadiazole-2-carboxylic acid ethyl ester as the
reactant amine. Upon hydrolysis of the thiadiazole carboxylate,
decarboxylation occurred as a minor side product. The product was
isolated as a white solid (9 mg, 9.9%). LCMS: m/e 640.3
(M-H).sup.-, 2.53 min (method 4). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 11.84 (br. s., 1H), 8.81 (s, 1H), 8.00
(d, J=8.24 Hz, 2H), 7.21 (d, J=7.93 Hz, 2H), 5.30 (d, J=4.58 Hz,
1H), 4.79 (s, 1H), 4.64 (s, 1H), 3.07-3.15 (m, 1H), 2.57-2.65 (m,
1H), 2.46 (d, J=13.73 Hz, 1H), 2.07-2.16 (m, 2H), 1.72 (s, 3H),
1.03 (s, 3H), 0.97 (s, 3H), 0.95-1.93 (m, 18H), 0.94 (s, 3H), 0.92
(s, 3H), 0.90 (s, 3H).
##STR00134##
Preparation of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(3-(tert-butoxycarbonyl(me-
thyl)amino)propylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2-
,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclope-
nta[a]chrysen-9-yl)benzoate. Intermediate 9
##STR00135##
To a flask containing
(1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-(methoxycarbonyl)phenyl)-5a-
,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11-
a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxylic
acid (0.1 g, 0.175 mmol) was added oxalyl chloride (2M in DCM) (3
mL, 6.00 mmol). The mixture bubbled vigorously for several minutes,
then bubbling ceased and the clear solution was stirred at rt for 3
h. The mixture was concentrated under reduced pressure. The residue
was dissolved in dichloromethane and concentrated two additional
times. The crude product was diluted with DCE (2 mL) and
Hunig'sBase (0.152 mL, 0.873 mmol) and
N-(3-aminopropyl)-N-methylcarbamic acid tert-butyl ester (0.061 g,
0.324 mmol) were added to the mixture. After stirring the mixture
for 19 h at rt, the mixture was diluted with 10 mL of water and was
extracted with dichloromethane (3.times.10 mL). The combined
organic layers were dried with Na.sub.2SO.sub.4. The drying agent
was removed by filtration and the filtrate was concentrated under
reduced pressure. The residue was purified by Biotage flash
chromatography using a 0-5% MeOH in DCM gradient. The fractions
containing the expected product were combined and concentrated
under reduced pressure to give methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(3-(tert-butoxycarbonyl(me-
thyl)amino)propylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2-
,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclope-
nta[a]chrysen-9-yl)benzoate (122 mg, 0.164 mmol, 94% yield) as a
white foam. LCMS: m/e 741.6 (M-H).sup.-, 3.41 min (method 3).
.sup.1H NMR (500 MHz, CHLOROFORM-d) .delta. ppm 7.90 (d, J=8.24 Hz,
2H), 7.17 (d, J=8.24 Hz, 2H), 6.89 (br. s., 1H), 5.26 (d, J=4.58
Hz, 1H), 4.74 (d, J=1.83 Hz, 1H), 4.57 (s, 1H), 3.88 (s, 3H),
3.40-3.04 (m, 5H), 2.81 (s, 3H), 2.51 (t, J=10.83 Hz, 1H),
2.19-2.04 (m, 2H), 1.99-1.87 (m, 1H), 1.68 (s, 3H), 1.45 (s, 9H),
0.98 (s, 3H), 1.52-0.95 (m, 20H), 0.97 (s, 3H), 0.94 (s, 3H), 0.90
(s, 6H).
Preparation of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(3-(methylamino)propylcarbamoyl)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7-
a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)be-
nzoate. Intermediate 10
##STR00136##
A vial containing methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(3-(tert-butoxycarbonyl(me-
thyl)amino)propylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2-
,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclope-
nta[a]chrysen-9-yl)benzoate (122 mg, 0.164 mmol) was diluted with
HCl (4M in dioxane) (3 mL, 12.00 mmol). The mixture was stirred at
rt. After 1.5 h of stirring at rt, LC/MS indicated the reaction was
complete. The mixture was concentrated under reduced pressure. The
crude product was carried forward to the next step with no
additional purification. LCMS: m/e 641.5 (M-H).sup.-, 2.73 min
(method 3).
Preparation of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(3-(N-methylacetamido)propylcarbamoyl)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b-
,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-
-yl)benzoate. Intermediate 11
##STR00137##
To a solution of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(3-(methylamino)propylcarbamoyl)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7-
a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)be-
nzoate, HCl (111 mg, 0.164 mmol) in dichloromethane (2 mL) was
added Hunig's Base (0.058 mL, 0.330 mmol) and acetic anhydride
(0.023 mL, 0.247 mmol). The mixture was stirred at rt for 3 h then
was diluted with 7 mL of water and was extracted with
dichloromethane (3.times.7 mL). The combined organic layers were
dried with Na.sub.2SO.sub.4. The drying agent was removed by
filtration and the filtrate was concentrated under reduced pressure
to give the crude product as a light-yellow foam. The crude product
was used in the next step with no additional purification. LCMS:
m/e 683.5 (M-H).sup.-, 2.87 min (method 3).
Example 52
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(3-(N-methylacetamido)propylcarbamoyl)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b-
,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-
-yl)benzoic acid
##STR00138##
The title compound was prepared following the method described
above for the general procedure for hydrolysis of the benzoic ester
using NaOH. The product was isolated as a white solid (62 mg, 56%).
LCMS: m/e 669.4 (M-H).sup.-, 2.24 min (method 3). .sup.1H NMR (500
MHz, CHLOROFORM-d) .delta. ppm 7.98 (d, J=8.24 Hz, 2H), 7.22 (d,
J=8.55 Hz, 2H), 6.93 (t, J=6.26 Hz, 1H), 5.29 (d, J=4.58 Hz, 1H),
4.74 (d, J=2.14 Hz, 1H), 4.58 (s, 1H), 3.64-3.56 (m, 1H), 3.36-3.25
(m, 2H), 3.20 (td, J=11.06, 4.43 Hz, 1H), 2.99 (s, 3H), 3.05-2.96
(m, 1H), 2.58-2.50 (m, 1H), 2.13 (s, 3H), 1.69 (s, 3H), 0.99 (s,
3H), 0.98 (s, 3H), 2.16-0.95 (m, 23H), 0.96 (s, 3H), 0.92 (s,
6H).
Preparation of N-(3-aminopropyl)acetamide, TFA
##STR00139##
To a solution of tert-butyl 3-aminopropylcarbamate (0.1 g, 0.574
mmol) in dichloromethane (5 mL) was added acetic anhydride (0.060
mL, 0.631 mmol). The mixture was stirred at rt for 1.5 h and was
concentrated under reduced pressure to give the acylated product as
a clear, colorless film. The film was dissolved in dichloromethane
(5 mL) and TFA (0.2 mL, 2.60 mmol) was added. The mixture was
stirred at rt for 2 h and an additional 0.5 mL of TFA was added.
The mixture was stirred for 3 h then was concentrated under reduced
pressure to give the title product (0.132 g, 100%). The crude
product was used in the next step with no additional purification.
.sup.1H NMR (500 MHz, MeOD) .delta. ppm 3.29 (t, J=6.71 Hz, 2H),
2.96 (t, J=7.17 Hz, 2H), 1.99 (s, 3H), 1.85 (quin, 2H).
Example 53
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(3-acetamidopropylcarbamoy-
l)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,-
11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoi-
c acid
##STR00140##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
N-(3-aminopropyl)acetamide, TFA as the reactant amine (4.08 equiv.
of amine used, 8.2 equiv. of Hunig's Base used). The product was
isolated as a white solid (77 mg, 90%). LCMS: m/e 655.6
(M-H).sup.-, 2.24 min (method 3). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 7.98 (d, J=7.93 Hz, 2H), 7.22 (d, J=7.93
Hz, 2H), 6.30 (t, J=6.26 Hz, 1H), 6.24 (t, J=6.41 Hz, 1H), 5.29 (d,
J=5.80 Hz, 1H), 4.75 (s, 1H), 4.60 (s, 1H), 3.44-3.33 (m, 2H),
3.25-3.10 (m, 3H), 2.58-2.50 (m, 1H), 2.11 (dd, J=17.40, 6.41 Hz,
1H), 2.04 (s, 3H), 1.69 (s, 3H), 1.00 (s, 3H), 0.98 (s, 3H),
2.06-0.95 (m, 22H), 0.97 (s, 3H), 0.92 (s, 6H).
##STR00141##
Preparation of
(1S,3aS,5aR,5bR,7aS,9S,11aS,11bR,13aR,13bR)-1-isopropyl-9-(4-(methoxycarb-
onyl)phenyl)-5a,5b,8,8,11a-pentamethylicosahydro-1H-cyclopenta[a]chrysene--
3a-carboxylic acid. Intermediate 12
##STR00142##
To a solution of (1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-benzyl
9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl-
)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cycl-
openta[a]chrysene-3a-carboxylate (0.2 g, 0.302 mmol) in ethanol (5
mL), 1,4-dioxane (7 mL), and acetic acid (0.5 mL, 8.73 mmol) was
added Pd/C (10% by wt.) (0.1 g, 0.094 mmol). The mixture was
flushed with N.sub.2 and was put on the Parr shaker under 30 psi
H.sub.2. After 2 h, the reaction was checked by .sup.1H NMR. The
benzyl group had been removed, but the alkene still remained. The
mixture was again flushed with N.sub.2. An additional 50 mg of 10%
Pd/C was added and the mixture was pressurized to 40 psi H.sub.2.
After stirring the mixture overnight, it reaction was removed from
the Parr shaker and the palladium catalyst was removed by
filtration. The filtrate was concentrated under reduced pressure to
give the expected product,
(1S,3aS,5aR,5bR,7aS,9S,11aS,11bR,13aR,13bR)-1-isopropyl-9-(4-(methoxycarb-
onyl)phenyl)-5a,5b,8,8,11a-pentamethylicosahydro-1H-cyclopenta[a]chrysene--
3a-carboxylic acid (0.174 g, 100% yield), as a white solid. .sup.1H
NMR (500 MHz, CHLOROFORM-d) .delta. ppm 7.91 (d, J=8.24 Hz, 2H),
7.22 (d, J=8.55 Hz, 2H), 3.89 (s, 3H), 2.39 (dd, J=13.12, 3.05 Hz,
1H), 2.19-2.29 (m, 3H), 2.01-2.13 (m, 1H), 0.99 (s, 3H), 0.96 (s,
3H), 0.95 (s, 3H), 0.86 (d, J=6.71 Hz, 3H), 0.79-1.92 (m, 22H),
0.76 (d, J=6.71 Hz, 3H), 0.75 (s, 3H), 0.68 (s, 3H).
Preparation of methyl
4-((1S,3aS,5aR,5bR,7aS,9S,11aS,11bR,13aR,13bR)-3a-(chlorocarbonyl)-1-isop-
ropyl-5a,5b,8,8,11a-pentamethylicosahydro-1H-cyclopenta[a]chrysen-9-yl)ben-
zoate. Intermediate 13
##STR00143##
To a flask containing
(1S,3aS,5aR,5bR,7aS,9S,11aS,11bR,13aR,13bR)-1-isopropyl-9-(4-(methoxycarb-
onyl)phenyl)-5a,5b,8,8,11a-pentamethylicosahydro-1H-cyclopenta[a]chrysene--
3a-carboxylic acid (0.154 g, 0.267 mmol) was added oxalyl chloride
(2M in dichloromethane) (5 mL, 10.00 mmol). The solution was
stirred at rt for 3 h. The mixture was concentrated under reduced
pressure and was dissolved in dichloromethane and concentrated two
additional times. The crude product was used in the next step with
no additional purification.
Preparation of methyl
4-((1S,3aS,5aR,5bR,7aS,9S,11aS,11bR,13aR,13bR)-1-isopropyl-5a,5b,8,8,11a--
pentamethyl-3a-(2-(pyridin-2-yl)ethylcarbamoyl)icosahydro-1H-cyclopenta[a]-
chrysen-9-yl)benzoate. Intermediate 14
##STR00144##
To a flask containing methyl
4-((1S,3aS,5aR,5bR,7aS,9S,11aS,11bR,13aR,13bR)-3a-(chlorocarbonyl)-1-isop-
ropyl-5a,5b,8,8,11a-pentamethylicosahydro-1H-cyclopenta[a]chrysen-9-yl)ben-
zoate (77 mg, 0.13 mmol) in DCE (2 mL) was added Hunig'sBase (0.068
mL, 0.390 mmol), DMAP (1 mg, 8.19 .mu.mol), and
2-(2-Aminoethyl)pyridine (0.031 mL, 0.260 mmol). The mixture was
stirred for 2.5 hours at rt. The reaction was diluted with 5 mL of
water and was extracted with dichloromethane (3.times.5 mL). The
combined organic layers were dried with Na.sub.2SO.sub.4. The
drying agent was removed by filtration and the filtrate was
concentrated under reduced pressure. The residue was purified by
Biotage flash chromatography using a 0-75% ethyl acetate in hexanes
gradient. The fractions containing the expected product were
combined and concentrated. The expected product, methyl
4-((1S,3aS,5aR,5bR,7aS,9S,11aS,11bR,13aR,13bR)-1-isopropyl-5a,5b,8,8,11a--
pentamethyl-3a-(2-(pyridin-2-yl)ethylcarbamoyl)icosahydro-1H-cyclopenta[a]-
chrysen-9-yl)benzoate (0.062 g, 0.091 mmol, 70.0% yield), was
isolated as a white foam. LCMS: m/e 679.7 (M-H).sup.-, 3.09 min
(method 3).
Example 54
Preparation of
4-((1S,3aS,5aR,5bR,7aS,9S,11aS,11bR,13aR,13bR)-1-isopropyl-5a,5b,8,8,11a--
pentamethyl-3a-(2-(pyridin-2-yl)ethylcarbamoyl)icosahydro-1H-cyclopenta[a]-
chrysen-9-yl)benzoic acid
##STR00145##
The title compound was prepared following the method described
above for the general procedure for the benzoic acid hydrolysis
using sodium hydroxide. The product was isolated as a light-yellow
(48 mg, 73%). LCMS: m/e 667.6 (M-H).sup.-, 2.32 min (method 3).
.sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 12.77 (br. s., 1H),
8.78 (br. s., 1H), 8.33 (br. s., 1H), 7.82 (d, J=7.93 Hz, 2H),
7.66-7.81 (m, 3H), 7.31 (d, J=7.93 Hz, 2H), 3.47-3.56 (m, 2H),
3.05-3.20 (m, 2H), 2.37-2.46 (m, 1H), 1.98-2.23 (m, 3H), 1.64-1.79
(m, 2H), 0.57-1.63 (m, 42H).
Preparation of methyl
4-((1S,3aS,5aR,5bR,7aS,9S,11aS,11bR,13aR,13bR)-3a-(2-(dimethylamino)ethyl-
carbamoyl)-1-isopropyl-5a,5b,8,8,11a-pentamethylicosahydro-1H-cyclopenta[a-
]chrysen-9-yl)benzoate. Intermediate 15
##STR00146##
To a flask containing methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(chlorocarbonyl)-5a,5b,8,8-
,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,1-
2,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoate
(77 mg, 0.13 mmol) in DCE (2 mL) was added Hunig's base (0.068 mL,
0.390 mmol), DMAP (1 mg, 8.19 mmol), and
N,N-dimethylethylenediamine (0.029 mL, 0.260 mmol). The mixture was
stirred for two hours at rt. The reaction was quenched with 5 mL of
water and was extracted with dichloromethane (3.times.5 mL). The
combined organic layers were dried with Na.sub.2SO.sub.4. The
drying agent was removed by filtration and the filtrate was
concentrated under reduced pressure and was purified by Biotage
flash chromatography using a 0-10% MeOH in dichloromethane
gradient. The fractions containing the expected product were
combined and concentrated under reduced pressure to give methyl
4-((1S,3aS,5aR,5bR,7aS,9S,11aS,11bR,13aR,13bR)-3a-(2-(dimethylamino)ethyl-
carbamoyl)-1-isopropyl-5a,5b,8,8,11a-pentamethylicosahydro-1H-cyclopenta[a-
]chrysen-9-yl)benzoate as a white foam (37 mg, 44% yield). LCMS:
m/e 647.7 (M+H).sup.+, 3.09 min (method 3).
Example 55
Preparation of
4-((1S,3aS,5aR,5bR,7aS,9S,11aS,11bR,13aR,13bR)-3a-(2-(dimethylamino)ethyl-
carbamoyl)-1-isopropyl-5a,5b,8,8,11a-pentamethylicosahydro-1H-cyclopenta[a-
]chrysen-9-yl)benzoic acid
##STR00147##
The title compound was prepared following the method described
above for the general procedure for the benzoic acid ester
hydrolysis using sodium hydroxide. The product was isolated as a
white film (3 mg, 8%). LCMS: m/e 631.7 (M-H).sup.-, 2.31 min
(method 3). .sup.1H NMR (500 MHz, CHLOROFORM-d) .delta. ppm 7.94
(d, J=7.94 Hz, 2H), 7.21 (d, J=7.93 Hz, 2H), 7.02 (br. s., 1H),
3.40-3.62 (m, 2H), 2.73-2.85 (m, 2H), 2.54 (s, 6H), 0.65-2.73 (m,
48H).
Example 56
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((S)-carboxy(phenyl)methyl-
carbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6-
,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-y-
l)benzoic acid
##STR00148##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
(S)-methyl 2-amino-2-phenylacetate as the reactant amine. The
product was isolated as a white solid (23 mg, 40%). LCMS: m/e
692.60 (M+H).sup.+, 2.06 min (method 1). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 7.78 (d, J=7.93 Hz, 2H), 7.59 (d, J=5.19
Hz, 1H), 7.29 (d, J=7.32 Hz, 2H), 7.20 (t, J=7.48 Hz, 2H),
7.15-7.04 (m, 3H), 5.19 (d, J=4.88 Hz, 1H), 4.65 (s, 1H), 4.63 (d,
J=5.19 Hz, 1H), 4.54 (s, 1H), 3.13-3.02 (m, 1H), 2.31 (d, J=12.82
Hz, 1H), 2.18-1.98 (m, 2H), 1.64 (s, 3H), 1.86-1.01 (m, 19H), 0.95
(s, 3H), 0.88 (s, 3H), 0.87 (s, 6H), 0.66 (s, 3H).
Example 57
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((S)-1-carboxyethylcarbamo-
yl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8-
,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzo-
ic acid
##STR00149##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
(S)-methyl 2-aminopropanoate as the reactant amine. The product was
isolated as a white solid (33 mg, 55%). LCMS: m/e 630.50
(M+H).sup.+, 2.01 min (method 1). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 7.82 (d, J=8.24 Hz, 2H), 7.45 (d, J=6.10
Hz, 1H), 7.14 (d, J=8.24 Hz, 2H), 5.22 (d, J=4.58 Hz, 1H), 4.67 (d,
J=1.83 Hz, 1H), 4.55 (s, 1H), 3.80-3.76 (m, 1H), 3.08-2.94 (m, 1H),
2.59-2.49 (m, 1H), 2.19-1.99 (m, 2H), 1.65 (s, 3H), 1.18 (d, J=7.02
Hz, 3H), 1.81-0.96 (m, 19H), 0.95 (s, 3H), 0.94 (s, 3H), 0.90 (s,
3H), 0.88 (s, 6H).
Example 58
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((S)-1-carboxy-2-phenyleth-
ylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b-
,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-
-yl)benzoic acid
##STR00150##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
(S)-methyl 2-amino-3-phenylpropanoate as the reactant amine. The
product was isolated as a white solid (28 mg, 46%). LCMS: m/e
706.60 (M+H).sup.+, 2.13 min (method 1). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 7.82 (d, J=8.24 Hz, 2H),7.28-7.08 (m,
8H), 5.22 (d, J=4.58 Hz, 1H), 4.64 (d, J=2.14 Hz, 1H), 4.52 (s,
1H), 4.21-4.08 (m, 2H), 3.09 (dd, J=13.12, 4.88 Hz, 1H), 2.98 (dd,
J=13.12, 7.02 Hz, 1H), 2.57-2.52 (m, 1H), 2.13-1.97 (m, 2H), 1.61
(s, 3H), 1.72-0.96 (m, 19H), 0.93 (s, 6H), 0.88 (s, 3H), 0.88 (s,
6H).
Example 59
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((S)-1-carboxy-3-methylbut-
ylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b-
,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-
-yl)benzoic acid
##STR00151##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
(S)-methyl 2-amino-4-methylpentanoate as the reactant amine. The
product was isolated as a white solid (24 mg, 40%). LCMS: m/e
672.58 (M+H).sup.+, 2.08 min (method 1). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 7.82 (d, J=7.93 Hz, 2H), 7.49 (d, J=7.32
Hz, 1H), 7.15 (d, J=8.24 Hz, 2H), 5.23 (d, J=4.58 Hz, 1H), 4.67 (d,
J=2.44 Hz, 1H), 4.55 (s, 1H), 4.19-4.04 (m, 1H), 3.03-2.96 (m, 1H),
2.63-2.53 (m, 1H), 2.23 (d, J=12.82 Hz, 1H), 2.06 (dd, J=17.40,
6.71 Hz, 1H), 1.65 (s, 3H), 1.86-0.96 (m, 22H), 0.95 (s, 3H), 0.93
(s, 3H), 0.90 (s, 3H), 0.88 (s, 6H), 0.86 (d, J=6.41 Hz, 3H), 0.84
(d, J=6.41 Hz, 3H).
Example 60
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(4-chlorobenzylcarbamoyl)--
5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,-
11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic
acid
##STR00152##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
(4-chlorophenyl)methanamine as the reactant amine. The product was
isolated as a white solid (44 mg, 71%). LCMS: m/e 682.53
(M+H).sup.+, 2.22 min (method 1). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 8.22 (t, J=6.26 Hz, 1H), 7.85 (d, J=8.24
Hz, 2H), 7.42-7.33 (m, 2H), 7.27 (d, J=8.55 Hz, 2H), 7.20 (d,
J=7.93 Hz, 2H), 5.24 (d, J=4.58 Hz, 1H), 4.67 (d, J=1.83 Hz, 1H),
4.55 (s, 1H), 4.32-4.23 (m, 1H), 4.21-4.13 (m, 1H), 3.03 (td,
J=10.99, 3.97 Hz, 1H), 2.56 (d, J=19.84 Hz, 1H), 2.24-2.15 (m, 1H),
2.07 (dd, J=17.85, 6.87 Hz, 1H), 1.64 (s, 3H), 1.88-0.97 (m, 19H),
0.95 (s, 3H), 0.94 (s, 3H), 0.89 (s, 6H), 0.83 (s, 3H).
Example 61
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((S)-1-carboxy-2-methylpro-
pylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5-
b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen--
9-yl)benzoic acid
##STR00153##
The title compound was prepared following the method described
above for the general procedure for C-28 amide formation and
hydrolysis using (S)-methyl 2-amino-3-methylbutanoate as the
reactant amine. The product was isolated as a white solid (30 mg,
50%). LCMS: m/e 658.56 (M+H).sup.+, 2.04 min (method 1). .sup.1H
NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 7.85 (d, J=8.24 Hz, 2H),
7.41 (d, J=8.24 Hz, 1H), 7.21 (d, J=8.24 Hz, 2H), 5.24 (d, J=4.58
Hz, 1H), 4.66 (d, J=2.14 Hz, 1H), 4.54 (s, 1H), 4.06 (t, J=7.17 Hz,
1H), 3.06-2.94 (m, 1H), 2.69-2.56 (m, 1H), 2.27 (br. s., 1H),
2.17-2.02 (m, 2H), 1.98-1.89 (m, 1H), 1.65 (s, 3H), 1.77-1.59 (m,
3H), 1.50 (t, J=11.14 Hz, 10H), 1.30-0.97 (m, 5H), 0.96 (s, 3H),
0.94 (s, 3H), 0.92-0.85 (m, 15H).
Example 62
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(carboxymethylcarbamoyl)-5-
a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,1-
1a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic
acid
##STR00154##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
methyl 2-aminoacetate as the reactant amine. The product was
isolated as a white solid (10 mg, 17%). LCMS: m/e 616.48
(M+H).sup.+, 2.01 min (method 1). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 7.78 (d, J=7.93 Hz, 2H), 7.17 (br. s.,
1H), 7.08 (d, J=7.32 Hz, 2H), 5.21 (d, J=4.58 Hz, 1H), 4.67 (s,
1H), 4.55 (s, 1H), 3.49-3.40 (m, 2H), 3.05 (t, J=10.38 Hz, 1H),
2.58-2.53 (m, 1H), 2.16-1.98 (m, 2H), 1.64 (s, 3H), 1.84-0.97 (m,
19H), 0.96 (s, 3H), 0.94 (s, 3H), 0.91 (s, 3H), 0.88 (d, J=2.75 Hz,
6H).
Example 63
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((S)-1-carboxy-3-(methylth-
io)propylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,-
5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]ch-
rysen-9-yl)benzoic acid
##STR00155##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
(S)-methyl 2-amino-4-(methylthio)butanoate as the reactant amine.
The product was isolated as a white solid (33 mg, 54%). LCMS: m/e
690.56 (M+H).sup.+, 2.04 min (method 1). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 7.82 (d, J=8.24 Hz, 2H), 7.33 (d, J=5.80
Hz, 1H), 7.15 (d, J=8.24 Hz, 2H), 5.22 (d, J=4.58 Hz, 1H), 4.67 (d,
J=1.83 Hz, 1H), 4.55 (s, 1H), 3.92 (d, J=5.49 Hz, 1H), 3.11-2.98
(m, 1H), 2.61-2.53 (m, 1H), 2.42 (t, J=7.78 Hz, 2H), 2.13-2.04 (m,
2H), 2.01 (s, 3H), 1.65 (s, 3H), 2.00-0.98 (m, 21H), 0.96 (s, 3H),
0.94 (s, 3H), 0.92 (s, 3H), 0.88 (s, 6H).
Example 64
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(3-amino-2-hydroxypropylca-
rbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7-
,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)-
benzoic acid
##STR00156##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
1,3-diaminopropan-2-ol as the reactant amine. The product was
isolated as a white solid (31 mg, 50%). LCMS: m/e 631.56
(M+H).sup.+, 2.11 min (method 1). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 7.72 (d, J=7.93 Hz, 2H), 7.60 (d, J=5.19
Hz, 1H), 6.95 (d, J=7.94 Hz, 2H), 5.18 (d, J=5.19 Hz, 1H), 4.67
(br. s., 1H), 4.55 (br. s., 1H), 3.44-3.38 (m, 1H), 3.21-2.88 (m,
4H), 2.69-2.58 (m, 1H), 2.45-2.35 (m, 1H), 2.14 (d, J=13.73 Hz,
1H), 2.05 (dd, J=16.48, 6.10 Hz, 1H), 1.64 (s, 3H), 1.85-0.98 (m,
19H), 0.95 (s, 6H), 0.92 (d, J=4.88 Hz, 3H), 0.88 (s, 3H), 0.87 (s,
3H).
Example 65
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((S)-1-carboxy-2-(dimethyl-
amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,-
4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]-
chrysen-9-yl)benzoic acid
##STR00157##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
(S)-2-amino-3-(dimethylamino)propanoic acid as the reactant amine.
The product was isolated as a white solid (15 mg, 24%). LCMS: m/e
673.60 (M+H).sup.+, 2.04 min (method 1). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 7.83 (d, J=8.24 Hz, 2H), 7.41-7.28 (m,
1H), 7.18 (d, J=8.24 Hz, 2H), 5.23 (d, J=4.88 Hz, 1H), 4.67 (s,
1H), 4.55 (s, 1H), 4.21-4.11 (m, 1H), 3.10-2.99 (m, 1H), 2.89-2.69
(m, 2H), 2.55-2.52 (m, 1H), 2.44 (s, 6H), 2.15-2.03 (m, 2H), 1.65
(s, 3H), 1.90-1.02 (m, 19H), 0.96 (s, 3H), 0.94 (s, 3H), 0.93 (s,
3H), 0.88 (s, 6H).
Example 66
Procedures for the Preparation of
5-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(dimethylamino)ethylcar-
bamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,-
7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)t-
hiophene-2-carboxylic acid
##STR00158##
Preparation of
(1R,3aS,5aR,5bR,7aR,11aR,11bR,13aR,13bR)--N-(2-(dimethylamino)ethyl)-5a,5-
b,8,8,11a-pentamethyl-9-oxo-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]c-
hrysene-3a-carboxamide. Intermediate 16
##STR00159##
To a mixture of N1,N1-dimethylethane-1,2-diamine (74.5 mg, 0.845
mmol), Hunig'sBase (0.369 mL, 2.114 mmol) and DMAP (5.16 mg, 0.042
mmol) in dichloromethane (2 mL) was added
(1R,3aS,5aR,5bR,7aR,11aR,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-9-oxo--
1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysene-3a-carbonyl
chloride (200 mg, 0.423 mmol). The reaction mixture was stirred for
16 h. LCMS indicated the formation of desired product. The reaction
mixture was concentrated under reduced pressure. The residue was
dissolved in methanol and the clear solution was purified by prep
HPLC to provide the title compound as a colorless oil (150 mg,
68%). LCMS: m/e 525.56 (M+H).sup.+, 2.27 min (method 1). .sup.1H
NMR (500 MHz, CHLOROFORM-d) .delta. ppm 6.89 (t, J=5.04 Hz, 1H),
4.72 (d, J=2.14 Hz, 1H), 4.58 (s, 1H), 3.59-3.34 (m, 2H), 3.12 (td,
J=11.06, 4.12 Hz, 1H), 2.67 (t, J=5.80 Hz, 2H), 2.53-2.43 (m, 2H),
2.41 (s, 6H), 2.40-2.32 (m, 1H), 2.07-2.03 (m, 1H), 1.97-1.84 (m,
2H), 1.78 (dd, J=11.60, 7.93 Hz, 1H), 1.71 (dd, J=13.12, 2.44 Hz,
1H), 1.67 (s, 3H), 1.62-1.22 (m, 14H), 1.21-1.11 (m, 1H), 1.06 (s,
3H), 1.01 (s, 3H), 1.04-0.97 (m, 1H), 0.97 (s, 6H), 0.91 (s,
3H).
Preparation of methyl
5-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(dimethylamino)ethylcar-
bamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,-
7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)t-
hiophene-2-carboxylate. Intermediate 17
##STR00160##
To
(1R,3aS,5aR,5bR,7aR,11aR,13aR,13bR)--N-(2-(dimethylamino)ethyl)-5a,5b,-
8,8,11a-pentamethyl-9-oxo-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chr-
ysene-3a-carboxamide (150 mg, 0.286 mmol) in THF (5 mL) at
-78.degree. C. was added KHMDS (1.143 mL, 0.572 mmol), the reaction
mixture was stirred for 15 minutes at -78.degree. C. then
1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide
(112 mg, 0.314 mmol) in THF (15 ml) and toluene (5 ml) was added
slowly through 20 minutes at -78.degree. C. The reaction mixture
was stirred for 2 hours at -78.degree. C. TLC indicated formation
of desired product. The reaction mixture was quenched with water,
extracted with ethyl acetate (3.times.5 mL), the extracts was
combined, dried over sodium sulfate, filtered and concentrated
under reduced pressure to provide the crude
(1R,3aS,5aR,5bR,7aR,11aR,13aR,13bR)-3a-(2-(dimethylamino)ethylcarbamoyl)--
5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,-
11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl
trifluoromethanesulfonate 100 mg as pale red oil.
A mixture of
(1R,3aS,5aR,5bR,7aR,11aR,13aR,13bR)-3a-(2-(dimethylamino)ethylcarbamoyl)--
5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,-
11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl
trifluoromethanesulfonate (100 mg, 0.152 mmol),
5-(methoxycarbonyl)thiophen-2-ylboronic acid (36 mg, 0.228 mmol),
tetrakis(triphenylphosphine)palladium(0) (5.2 mg, 0.0045 mmol) and
sodium carbonate (48 mg, 0.456 mmol) in water (1 mL) and DME (1 mL)
was heated up at 90.degree. C. for 2 hours. The reaction mixture
was quenched with distilled water, extracted with ethyl acetate
(3.times.5 mL), the extracts were combined, dried over sodium
sulfate, filtered and concentrated under reduced pressure to
provide the desired product as a brown oil (60 mg, 32%). LCMS: m/e
647.63 (M-H).sup.-, 2.67 min (method 1).
Preparation of
5-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(dimethylamino)ethylcar-
bamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,-
7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)t-
hiophene-2-carboxylic acid
##STR00161##
A mixture of methyl
5-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(dimethylamino)ethylcar-
bamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,-
7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)t-
hiophene-2-carboxylate (60 mg, 0.092 mmol) and sodium hydroxide
(0.028 mL, 0.277 mmol) in dioxane (2 mL) was heated up at
70.degree. C. for 3 hours. LCMS indicated the formation of desired
product. The reaction mixture was filtered and purified by prep
HPLC to give the title compound as a white solid (6.4 mg, 10%).
LCMS: m/e 635.35 (M+H).sup.+, 2.18 min (method 1). .sup.1H NMR (500
MHz, DMSO-d.sub.6) .delta. ppm 7.49 (t, J=5.65 Hz, 1H), 7.37 (br.
s., 1H), 6.86 (d, J=3.66 Hz, 1H), 5.72 (d, J=4.88 Hz, 1H), 4.67 (d,
J=2.44 Hz, 1H), 4.55 (s, 1H), 3.21 (td, J=13.20, 6.56 Hz, 1H),
3.08-2.98 (m, 2H), 2.61-2.53 (m, 1H), 2.26 (td, J=6.79, 2.29 Hz,
2H), 2.15 (s, 6H), 2.15-2.06 (m, 2H), 1.64 (s, 3H), 1.82-1.04 (m,
19H), 1.03 (s, 3H), 1.01 (s, 3H), 0.94 (s, 3H), 0.91 (s, 3H), 0.87
(s, 3H).
Preparation of
(1R,3aS,5aR,5bR,7aR,11aR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-9-oxo-1-(pr-
op-1-en-2-yl)-N-(2-(pyridin-2-yl)ethyl)icosahydro-1H-cyclopenta[a]chrysene-
-3a-carboxamide. Intermediate 18
##STR00162##
The title compound was prepared following the method described
above for
(1R,3aS,5aR,5bR,7aR,11aR,11bR,13aR,13bR)--N-(2-(dimethylamino)ethyl)-5a,5-
b,8,8,11a-pentamethyl-9-oxo-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]c-
hrysene-3a-carboxamide using N1,N1-diisopropylethane-1,2-diamine as
the reactant amine. The product was isolated as a white solid (150
mg, 64%). LCMS: m/e 559.25 (M+H).sup.+, 2.25 min (method 1).
.sup.1H NMR (500 MHz, CHLOROFORM-d) .delta. ppm 8.51 (d, J=3.97 Hz,
1H), 7.62 (td, J=7.63, 1.83 Hz, 1H), 7.22-7.10 (m, 2H), 6.71 (t,
J=5.34 Hz, 1H), 4.72 (d, J=2.14 Hz, 1H), 4.58 (s, 1H), 3.80-3.58
(m, 2H), 3.08 (td, J=11.14, 3.97 Hz, 1H), 3.03-2.92 (m, 2H),
2.58-2.29 (m, 4H), 1.96 (dt, J=13.35, 3.09 Hz, 1H), 1.92-1.82 (m,
2H), 1.70-1.65 (m, 2H), 1.66 (s, 3H), 1.56 (t, J=11.44 Hz, 1H),
1.50-1.14 (m, 13H), 1.05 (s, 3H), 1.00 (s, 3H), 1.04-0.95 (m, 1H),
0.93 (s, 3H), 0.88 (s, 3H), 0.86 (s, 3H).
Example 67
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(diisopropylamino)ethyl-
carbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6-
,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-y-
l)benzoic acid
##STR00163##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
N1,N1-diisopropylethane-1,2-diamine as the reactant amine. The
product was isolated as a white solid (19 mg, 31%). LCMS: m/e
685.39 (M+H).sup.+, 2.22 min (method 1). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 7.95 (d, J=8.24 Hz, 2H), 7.63 (br. s.,
1H), 7.16 (d, J=8.24 Hz, 2H), 5.28 (d, J=4.58 Hz, 1H), 4.74 (s,
1H), 4.58 (s, 1H), 3.65-3.43 (m, 2H), 3.43-3.32 (m, 2H), 3.21-3.08
(m, 1H), 3.01-2.78 (m, 2H), 2.48 (td, J=12.13, 3.51 Hz, 1H), 1.25
(t, J=5.95 Hz, 12H), 2.30-0.99 (m, 21H), 0.98 (s, 3H), 0.97 (s,
3H), 0.96 (s, 3H), 0.91 (s, 6H).
Example 68
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((S)-1-(dimethylamino)prop-
an-2-ylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,-
5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chry-
sen-9-yl)benzoic acid
##STR00164##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
(S)--N1,N1-dimethylpropane-1,2-diamine as the reactant amine. The
product was isolated as a white solid (39 mg, 76%). LCMS: m/e
643.58 (M+H).sup.+, 2.25 min (method 1). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 7.93 (d, J=7.94 Hz, 2H), 7.18 (d, J=8.24
Hz, 2H), 5.29 (d, J=5.19 Hz, 1H), 4.72 (d, J=10.07 Hz, 1H), 4.56
(br. s., 1H), 4.38-4.04 (m, 1H), 3.30-3.02 (m, 1H), 2.77-2.30 (m,
8H), 1.65 (s, 3H), 2.23-1.03 (m, 25H), 0.99 (d, J=3.97 Hz, 3H),
0.96 (s, 3H), 0.94 (d, J=3.97 Hz 3H), 0.92 (s, 6H).
Example 69
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-methoxyethylcarbamoyl)--
5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,-
11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic
acid
##STR00165##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
2-methoxyethanamine as the reactant amine. The product was isolated
as a white solid (31 mg, 50%). LCMS: m/e 616.47 (M+H).sup.+, 2.18
min (method 1). .sup.1H NMR (500 MHz, CHLOROFORM-d) .delta. ppm
7.98 (d, J=7.93 Hz, 2H), 7.22 (d, J=8.24 Hz, 2H), 5.98 (t, J=5.49
Hz, 1H), 5.29 (d, J=4.58 Hz, 1H), 4.75 (d, J=1.83 Hz, 1H), 4.59 (s,
1H), 3.57-3.37 (m, 4H), 3.36 (s, 3H), 3.14 (td, J=11.06, 4.12 Hz,
1H), 2.56-2.41 (m, 1H), 2.10 (dd, J=17.24, 6.56 Hz, 1H), 1.96 (d,
J=10.38 Hz, 1H), 1.68 (s, 3H), 1.82-1.01 (m, 19H), 1.00 (s, 6H),
0.97 (s, 3H), 0.92 (d, J=1.83 Hz, 6H).
Example 70
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(diethylamino)ethylcarb-
amoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7-
a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)be-
nzoic acid
##STR00166##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
N1,N1-diethylethane-1,2-diamine as the reactant amine. The product
was isolated as a white solid (30 mg, 49%). LCMS: m/e 657.51
(M+H).sup.+, 2.27 min (method 1). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 7.93 (d, J=8.24 Hz, 2H), 7.48 (br. s.,
1H), 7.15 (d, J=8.24 Hz, 2H), 5.29 (d, J=5.19 Hz, 1H), 4.73 (s,
1H), 4.58 (s, 1H), 3.69-3.48 (m, 2H), 3.19-3.08 (m, 1H), 3.02-2.89
(m, 6H), 2.52-2.40 (m, 1H), 1.67 (s, 3H), 1.28-1.22 (m, 6H),
2.18-0.99 (m, 21H), 0.97 (s, 3H), 0.95 (s, 6H), 0.91 (s, 6H).
Example 71
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2,3-dihydroxypropylcarbam-
oyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,-
8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benz-
oic acid
##STR00167##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
3-aminopropane-1,2-diol as the reactant amine. The product was
isolated as a white solid (33 mg, 55%). LCMS: m/e 632.44
(M+H).sup.+, 2.08 min (method 1). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 7.97 (d, J=7.94 Hz, 2H), 7.22 (d, J=8.24
Hz, 2H), 6.03 (t, J=5.95 Hz, 1H), 5.29 (d, J=5.49 Hz, 1H), 4.75 (s,
1H), 4.61 (s, 1H), 3.81-3.73 (m, 1H), 3.62-3.51 (m, 2H), 3.52-3.35
(m, 2H), 3.19-3.03 (m, 1H), 2.58-2.40 (m, 1H), 2.11 (dd, J=17.09,
6.71 Hz, 1H), 2.02-1.89 (m, 1H), 1.69 (s, 3H), 1.82-1.02 (m, 19H),
1.01 (s, 3H), 1.00 (s, 3H), 0.98 (s, 3H), 0.92 (s, 6H).
Example 72
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(ethyl(2-hydroxyethyl)a-
mino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4-
,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]c-
hrysen-9-yl)benzoic acid
##STR00168##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
2-((2-aminoethyl)(ethyl)amino)ethanol as the reactant amine. The
product was isolated as a white solid (37 mg, 72%). LCMS: m/e
673.56 (M+H).sup.+, 2.15 min (method 1). .sup.1H NMR (500 MHz,
Acetic Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d,
J=8.55 Hz, 2H), 5.37 (d, J=4.58 Hz, 1H), 4.78 (d, J=1.83 Hz, 1H),
4.65 (s, 1H), 4.06 (t, J=5.04 Hz, 2H), 3.88-3.64 (m, 2H), 3.55-3.35
(m, 6H), 3.14 (t, J=11.29 Hz, 1H), 2.62-2.47 (m, 1H), 2.29-2.14 (m,
2H), 1.39 (t, J=7.17 Hz, 3H), 2.13-1.09 (m, 19H), 1.08 (s, 3H),
1.06 (s, 3H), 1.06 (s, 3H), 1.01 (s, 3H), 0.99 (s, 3H).
Example 73
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((2-hydroxyethyl)(methy-
l)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3-
a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[-
a]chrysen-9-yl)benzoic acid
##STR00169##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
2-((2-aminoethyl)(methyl)amino)ethanol as the reactant amine. The
product was isolated as a white solid (30 mg, 56%). LCMS: m/e
659.48 (M+H).sup.+, 2.15 min (method 1). .sup.1H NMR (500 MHz,
Acetic Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d,
J=8.24 Hz, 2H), 5.37 (d, J=4.27 Hz, 1H), 4.78 (d, J=1.22 Hz, 1H),
4.65 (s, 1H), 4.05 (t, J=5.04 Hz, 2H), 3.89-3.68 (m, 2H), 3.60-3.38
(m, 4H), 3.22-3.10 (m, 1H), 3.04 (s, 3H), 2.54 (td, J=12.21, 3.36
Hz, 1H), 2.28-2.20 (m, 2H), 1.74 (s, 3H), 2.11-1.09 (m, 19H), 1.08
(s, 3H), 1.06 (s, 3H), 1.05 (s, 3H), 1.01 (s, 3H), 0.99 (s,
3H).
Example 74
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(2-hydroxyethylamino)et-
hylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5-
b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen--
9-yl)benzoic acid
##STR00170##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
2-(2-aminoethylamino)ethanol as the reactant amine. The product was
isolated as a white solid (32 mg, 56%). LCMS: m/e 645.54
(M+H).sup.+, 2.13 min (method 1). .sup.1H NMR (500 MHz, Acetic
Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.54 Hz, 2H), 7.30 (d, J=8.24
Hz, 2H), 5.37 (d, J=4.58 Hz, 1H), 4.78 (s, 1H), 4.65 (s, 1H),
4.10-3.92 (m, 2H), 3.84-3.60 (m, 2H), 3.46-3.28 (m, 4H), 3.24-2.95
(m, 1H), 2.56 (td, J=12.13, 3.20 Hz, 1H), 1.74 (s, 3H), 2.28-1.19
(m, 21H), 1.08 (s, 3H), 1.06 (s, 3H), 1.05 (s, 3H), 1.01 (s, 3H),
0.99 (s, 3H).
Example 75
Procedures for the Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(2-(N-methylacetamido)ethylcarbamoyl)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,-
6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9--
yl)benzoic acid
##STR00171##
Preparation of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(tert-butoxycarbonyl(me-
thyl)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,-
3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopen-
ta[a]chrysen-9-yl)benzoate. Intermediate 19
##STR00172##
To a mixture of tert-butyl 2-aminoethyl(methyl)carbamate (17.68 mg,
0.101 mmol), Hunig'sBase (0.053 mL, 0.304 mmol) and DMAP (1.240 mg,
10.15 .mu.mol) in DCM (1 mL) was added methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(chlorocarbonyl)-5a,5b,8,8-
,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,1-
2,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoate
(60 mg, 0.101 mmol) in DCM (1 mL). The reaction mixture was stirred
for 1 hour. LCMS indicated the formation of desired product. The
reaction mixture was quenched with distilled water, extracted with
DCM (3.times.3 mL). All the extracts were combined, dried over
sodium sulfate, filtered and concentrated under reduced pressure to
provide the desired product as white solid (65 mg, 88%). LCMS: m/e
729.61 (M+H).sup.+, 2.72 min (method 1).
Preparation of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(2-(methylamino)ethylcarbamoyl)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a-
,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)ben-
zoate. Intermediate 20
##STR00173##
A mixture of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(tert-butoxycarbonylmet-
hyl)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3-
,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopent-
a[a]chrysen-9-yl)benzoate (65 mg, 0.089 mmol) and 4N HCl (0.111 mL,
0.446 mmol) in DCM (1 mL) was stirred for 16 hours at room
temperature. LCMS indicated the formation of desired product. The
reaction mixture was concentrated under reduced pressure to provide
the desired product as white solid (45 mg, 80%). LCMS: m/e 629.52
(M+H).sup.+, 2.65 min (method 1).
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(2-(N-methylacetamido)ethylcarbamoyl)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,-
6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9--
yl)benzoic acid
##STR00174##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(2-(methylamino)ethylcarbamoyl)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a-
,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)ben-
zoate as the reactant amine and acetyl chloride as the reactant
acid chloride. The product was isolated as a white solid (35 mg,
75%). LCMS: m/e 657.53 (M+H).sup.+, 2.13 min (method 1). .sup.1H
NMR (500 MHz, Acetic Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.24 Hz,
2H), 7.30 (d, J=8.24 Hz, 2H), 5.37 (d, J=4.27 Hz, 1H), 4.78 (s,
1H), 4.64 (br. s., 1H), 3.72-3.41 (m, 4H), 3.20-3.15 (m, 1H), 3.14
(s, 3H), 2.68-2.48 (m, 1H), 2.18 (s, 3H), 1.73 (s, 3H), 2.26-1.17
(m, 21H), 1.07 (s, 3H), 1.06 (s, 3H), 1.06 (s, 3H), 1.01 (s, 3H),
0.99 (s, 3H).
Example 76
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(bis(2-hydroxyethyl)ami-
no)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5-
,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chr-
ysen-9-yl)benzoic acid
##STR00175##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
2,2'-(2-aminoethylazanediyl)diethanol as the reactant amine. The
product was isolated as a white solid (14 mg, 28%). LCMS: m/e
689.56 (M+H).sup.+, 2.11 min (method 1). .sup.1H NMR (500 MHz,
Acetic Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d,
J=8.24 Hz, 2H), 5.50-5.29 (m, 1H), 4.78 (s, 1H), 4.65 (s, 1H), 4.11
(t, J=4.58 Hz, 4H), 3.95-3.72 (m, 2H), 3.62 (d, J=4.58 Hz, 6H),
3.25-3.06 (m, 1H), 2.54 (td, J=12.59, 2.90 Hz, 1H), 1.74 (s, 3H),
2.34-1.21 (m, 21H), 1.08 (s, 3H), 1.06 (s, 3H), 1.06 (s, 3H), 1.01
(s, 3H), 0.99 (s, 3H).
Example 77
Procedures for the Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-(dimethylamino)ethyl)(-
2-hydroxyethyl)carbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3-
,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopent-
a[a]chrysen-9-yl)benzoic acid
##STR00176##
Preparation of 2-hydroxyethyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-(dimethylamino)ethyl)(-
2-hydroxyethyl)carbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3-
,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopent-
a[a]chrysen-9-yl)benzoate. Intermediate 21
##STR00177##
To a mixture of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(dimethylamino)ethylcar-
bamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,-
7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)b-
enzoate (30 mg, 0.047 mmol) in DMF (1 mL) was added 60% sodium
hydride (3.73 mg, 0.093 mmol) under nitrogen atmosphere. The
reaction mixture was stirred for 20 minutes at room temperature.
(2-bromoethoxy)(tert-butyl)dimethylsilane (13.39 mg, 0.056 mmol)
was added under nitrogen atmosphere at room temperature. The
reaction mixture was heated up at 78.degree. C. for 18 hours. The
reaction mixture was quenched with water, extracted with DCM
(3.times.4 mL), the extracts was combined, dried over sodium
sulfate, filtered and concentrated under reduced to provide the
desired intermediate as colourless oil. To this intermediate in DCM
(1 mL) was added TBAF (16.46 mg, 0.047 mmol). The reaction mixture
was stirred for 20 minutes. LCMS indicated the formation of desired
product. The reaction mixture was concentrated under reduced
pressure to provide the title compound as white solid (6 mg, 33%).
LCMS: m/e 717.64 (M+H).sup.+, 2.27 min (method 1).
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-(dimethylamino)ethyl)(-
2-hydroxyethyl)carbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3-
,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopent-
a[a]chrysen-9-yl)benzoic acid
##STR00178##
A mixture of 2-hydroxyethyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-(dimethylamino)ethyl)(-
2-hydroxyethyl)carbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3-
,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopent-
a[a]chrysen-9-yl)benzoate (6 mg, 8.37 .mu.mol) and sodium hydroxide
(0.042 mL, 0.042 mmol) in dioxane (1 mL) was heated up at
78.degree. C. for 3 hours. The solution was diluted with water and
filtered. The clear solution was purified by prep HPLC to provide
the title compound as a white solid (5 mg, 84%). LCMS: m/e 673.58
(M+H).sup.+, 2.08 min (method 1). .sup.1H NMR (500 MHz, Acetic
Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d, J=8.55
Hz, 2H), 5.43-5.31 (m, 1H), 4.78 (d, J=1.53 Hz, 1H), 4.66 (s, 1H),
4.26-4.13 (m, 2H), 3.90-3.78 (m, 2H), 3.75-3.63 (m, 4H), 3.30 (s,
6H), 3.20-3.07 (m, 1H), 2.60-2.45 (m, 1H), 1.74 (s, 3H), 2.26-1.22
(m, 21H), 1.08 (s, 3H), 1.07 (s, 3H), 1.05 (s, 3H), 1.01 (s, 3H),
0.99 (s, 3H).
Example 78
Procedures for the Preparation of
4-((1S,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(dimethylamino)ethylcar-
bamoyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2,3,3a,4,5,5a,5b,6,7,7a,8,11-
,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic
acid
##STR00179##
Preparation of methyl
4-((1S,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(dimethylamino)ethylcar-
bamoyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2,3,3a,4,5,5a,5b,6,7,7a,8,11-
,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoate-
. Intermediate 22
##STR00180##
A mixture of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(dimethylamino)ethylcar-
bamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,-
7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)b-
enzoate (27 mg, 0.042 mmol) and Pd/C (14.30 mg, 0.013 mmol) in
acetic acid (4 mL) and MeOH (4 mL) was reacted in Parr shaker for
18 hours under 40 psi. The reaction mixture was filtered through
celite to remove Pd/C. The filtrates were concentrated under
reduced pressure. The residue was dissolved in methanol and then
purified by prep HPLC to provide the title compound as a white
solid (6 mg, 22%). LCMS: m/e 645.62 (M+H).sup.+, 2.87 min (method
1). .sup.1H NMR (500 MHz, Acetic Acid-d.sub.4) .delta. ppm 7.98 (d,
J=8.24 Hz, 2H), 7.27 (d, J=8.24 Hz, 2H), 5.37 (d, J=4.88 Hz, 1H),
3.94 (s, 3H), 3.74 (t, J=5.95 Hz, 2H), 3.43-3.32 (m, 2H), 2.95 (s,
6H), 2.59-2.48 (m, 1H), 2.42-2.31 (m, 1H), 2.28-1.10 (m, 22H), 1.07
(d, J=3.97 Hz, 6H), 1.05 (s, 3H), 1.00 (s, 3H), 0.99 (s, 3H), 0.91
(d, J=6.71 Hz, 3H), 0.82 (d, J=6.71 Hz, 3H).
Preparation of
4-((1S,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(dimethylamino)ethylcar-
bamoyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2,3,3a,4,5,5a,5b,6,7,7a,8,11-
,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic
acid
##STR00181##
A mixture of methyl
4-((1S,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(dimethylamino)ethylcar-
bamoyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2,3,3a,4,5,5a,5b,6,7,7a,8,11-
,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoate
(6 mg, 9.30 mmol) and sodium hydroxide (0.037 mL, 0.037 mmol) in
dioxane (1 mL) was heated for 3 hours at 78.degree. C. The reaction
mixture was filtered and purified by prep HPLC to provide the title
compound as a white solid (2.2 mg, 36%). LCMS: m/e 631.59
(M+H).sup.+, 2.29 min (method 1). .sup.1H NMR (500 MHz, Acetic
Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d, J=8.24
Hz, 2H), 5.38 (d, J=4.58 Hz, 1H), 3.74 (t, J=6.10 Hz, 2H),
3.46-3.33 (m, 2H), 2.96 (s, 6H), 2.63-2.47 (m, 1H), 2.44-2.27 (m,
1H), 2.25-1.15 (m, 22H), 1.08 (s, 3H), 1.06 (s, 3H), 1.05 (s, 3H),
1.01 (s, 3H), 1.00 (s, 3H), 0.91 (d, J=6.71 Hz, 3H), 0.82 (d,
J=6.71 Hz, 3H).
Example 79
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-carboxy-2-hydroxyethylc-
arbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,-
7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl-
)benzoic acid
##STR00182##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
methyl 3-amino-2-hydroxypropanoate as the reactant amine. The
product was isolated as a white solid (22 mg, 40%). LCMS: m/e
646.34 (M+H).sup.+, 2.04 min (method 1). .sup.1H NMR (500 MHz,
Acetic Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d,
J=8.24 Hz, 2H), 5.37 (d, J=4.88 Hz, 1H), 4.78 (s, 1H), 4.64 (s,
1H), 4.55-4.45 (m, 1H), 3.81-3.68 (m, 2H), 3.22-3.06 (m, 1H),
2.71-2.53 (m, 1H), 2.26-2.13 (m, 2H), 1.74 (s, 3H), 2.03-1.18 (m,
19H), 1.07 (s, 3H), 1.07 (s, 3H), 1.06 (s, 3H), 1.01 (s, 3H), 0.99
(s, 3H).
Example 80
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((carboxymethyl)(methyl-
)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a-
,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,
13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic acid
##STR00183##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
ethyl 2-((2-aminoethyl)(methyl)amino)acetate as the reactant amine.
The product was isolated as a white solid (40 mg, 83%). LCMS: m/e
673.38 (M+H).sup.+, 2.08 min (method 1). .sup.1H NMR (500 MHz,
Acetic Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d,
J=8.55 Hz, 2H), 5.37 (d, J=4.88 Hz, 1H), 4.78 (s, 1H), 4.65 (s,
1H), 4.03 (s, 2H), 3.88-3.65 (m, 2H), 3.49 (t, J=5.80 Hz, 2H),
3.19-3.12 (m, 1H), 3.11 (s, 3H), 2.63-2.48 (m, 1H), 1.74 (s, 3H),
2.29-1.18 (m, 21H), 1.08 (s, 3H), 1.06 (s, 3H), 1.05 (s, 3H), 1.01
(s, 3H), 0.99 (s, 3H).
Example 81
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(carboxymethylamino)eth-
ylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b-
,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-
-yl)benzoic acid
##STR00184##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
methyl 2-(2-aminoethylamino)acetate as the reactant amine. The
product was isolated as a white solid (26 mg, 64%). LCMS: m/e
659.38 (M+H).sup.+, 2.08 min (method 1). .sup.1H NMR (500 MHz,
Acetic Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d,
J=8.24 Hz, 2H), 5.37 (d, J=4.58 Hz, 1H), 4.78 (s, 1H), 4.65 (s,
1H), 3.98 (d, J=2.75 Hz, 2H), 3.84-3.72 (m, 1H), 3.66 (ddd,
J=14.80, 5.49, 5.34 Hz, 1H), 3.40 (t, J=5.65 Hz, 2H), 3.13 (td,
J=10.99, 3.97 Hz, 1H), 2.70-2.47 (m, 1H), 2.25-2.13 (m, 2H), 1.75
(s, 3H), 2.02-1.17 (m, 19H), 1.09 (s, 3H), 1.07 (s, 3H), 1.06 (s,
3H), 1.01 (s, 3H), 0.99 (s, 3H).
Example 82
Preparation of sodium
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-1-(-
prop-1-en-2-yl)-3a-(2-sulfonatoethylcarbamoyl)-2,3,3a,4,5,5a,5b,6,7,7a,8,1-
1,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoat-
e
##STR00185##
To a solution of 2-aminoethanesulfonic acid (19.05 mg, 0.152 mmol)
and triethylamine (0.141 mL, 1.015 mmol) in water (1 mL) was added
methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(chlorocarbonyl)-5a,5b,8,8-
,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,1-
2,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoate(80492-081-
) (30 mg, 0.051 mmol) and triethylamine (0.141 mL, 1.015 mmol) in
dioxane (1 mL). The reaction mixture was stirred for 1 hour at room
temperature. LCMS indicated the formation of desired intermediate.
To the reaction mixture was then added 1N sodium hydroxide (0.099
mL, 0.099 mmol) and heated up at 78.degree. C. for 3 hours until
LCMS indicated the consumption of starting material. The reaction
mixture was filtered and the clear solution was purified by prep
HPLC to provide the title compound as a white solid (15 mg, 49%).
LCMS: m/e 666.32 (M+H).sup.+, 2.04 min (method 1). .sup.1H NMR (500
MHz, MeOD) .delta. ppm 7.90 (d, J=7.93 Hz, 2H), 7.69 (t, J=5.34 Hz,
1H), 7.18 (d, J=8.24 Hz, 2H), 5.30 (d, J=5.19 Hz, 1H), 4.75 (s,
1H), 4.61 (s, 1H), 3.79-3.55 (m, 2H), 3.19-3.08 (m, 1H), 3.05-2.91
(m, 2H), 2.59 (t, J=13.73 Hz, 1H), 2.22-2.09 (m, 2H), 1.72 (s, 3H),
1.96-1.15 (m, 19H), 1.06 (s, 6H), 1.05 (s, 3H), 0.98 (s, 3H), 0.96
(s, 3H).
Example 83
Procedures for the Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((carboxymethyl)(ethyl)-
amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,-
4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]-
chrysen-9-yl)benzoic acid
##STR00186##
Preparation of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(2-methoxy-2-oxoethylam-
ino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,-
5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]ch-
rysen-9-yl)benzoate. Intermediate 23
##STR00187##
To a solution of methyl 2-(2-aminoethylamino)acetate (33.5 mg,
0.254 mmol), Hunig'sBase (0.089 mL, 0.507 mmol) and DMAP (20.66 mg,
0.169 mmol) in DCM (1.5 mL) was added methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(chlorocarbonyl)-5a,5b,8,8-
,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,1-
2,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoate
(100 mg, 0.169 mmol) in DCM (1.5 mL). The reaction mixture was
stirred at 20.degree. C. for three hours. LCMS indicated the
formation of desired product. The reaction mixture was quenched
with distilled water, extracted with DCM (3.times.4 mL). All the
extracts were combined, dried over sodium sulfate, filtered and
concentrated under reduced pressure to provide the title compound
as a white solid (90 mg, 76%). LCMS: m/e 713.45 (M-H).sup.-, 2.75
min (method 1).
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((carboxymethyl)(ethyl)-
amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,-
4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]-
chrysen-9-yl)benzoic acid
##STR00188##
A mixture of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(2-methoxy-2-oxoethylam-
ino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,-
5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]ch-
rysen-9-yl)benzoate (50 mg, 0.071 mmol), iodoethane (0.047 mL,
0.571 mmol) and potassium carbonate (19.72 mg, 0.143 mmol) in
acetonitrile (2.0 mL) and dioxane (2.0 mL) was heated up for 8
hours. LCMS indicated the formation of desired product and
consumption of starting material. The reaction mixture was quenched
with distilled water, extracted with DCM (3.times.3 mL). All the
extracts were combined, dried over sodium sulfate, filtered and
concentrated under reduced pressure to provide the crude
intermediate methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(ethyl(2-methoxy-2-oxoe-
thyl)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,-
3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopen-
ta[a]chrysen-9-yl)benzoate. To this intermediate in dioxane (1 mL)
was added 1N sodium hydroxide (0.224 mL, 0.224 mmol). The reaction
mixture was heated up at 78.degree. C. for 3 hours until LCMS
indicated the consumption of starting material. The reaction
mixture was filtered and the clear solution was purified by prep
HPLC to provide the title compound as a white solid (29 mg, 59%).
LCMS: m/e 687.40 (M+H).sup.+, 2.11 min (method 1). .sup.1H NMR (500
MHz, Acetic Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.24 Hz, 2H), 7.30
(d, J=8.24 Hz, 2H), 5.37 (d, J=4.58 Hz, 1H), 4.78 (s, 1H), 4.65 (s,
1H), 4.02 (s, 2H), 3.85-3.63 (m, 2H), 3.58-3.37 (m, 4H), 3.22-3.01
(m, 1H), 2.69-2.43 (m, 1H), 1.73 (s, 3H), 2.30-1.20 (m, 24H), 1.08
(s, 3H), 1.07 (s., 3H), 1.06 (s., 3H), 1.01 (s, 3H), 0.99 (s,
3H).
Example 84
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-1-(-
prop-1-en-2-yl)-3a-(vinylcarbamoyl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,1-
2,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic
acid
##STR00189##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
2-chloroethanaminium chloride as the reactant amine. The product
was isolated as a white solid (9 mg, 58%). LCMS: m/e 584.30
(M+H).sup.+, 2.37 min (method 1). .sup.1H NMR (400 MHz,
CHLOROFORM-d) .delta. ppm 7.98 (br. s., 2H), 7.26-7.20 (m, 2H),
5.31 (d, J=4.52 Hz, 1H), 4.78 (br. s., 1H), 4.62 (br. s., 1H), 4.18
(t, J=10.67 Hz, 1H), 3.91 (t, J=9.16 Hz, 2H), 3.18-2.98 (m, 1H),
2.61-1.10 (m, 25H), 1.01 (s., 3H), 1.00 (s., 3H), 0.98 (s., 3H),
0.94 (s., 6H).
Example 85
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((3-(1,1-dioxido-4-thiomor-
pholinyl)propyl)carbamoyl)-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-2,3,3a,-
4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]-
chrysen-9-yl)benzoic acid
##STR00190##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
4-(3-aminopropyl)thiomorpholine 1,1-dioxide as the reactant amine.
The product was isolated as a white solid (27 mg, 65%). LCMS: m/e
733.44 (M+H).sup.+, 2.11 min (method 1). .sup.1H NMR (500 MHz,
Acetic Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d,
J=8.24 Hz, 2H), 5.37 (d, J=4.58 Hz, 1H), 4.78 (s, 1H), 4.65 (s,
1H), 3.85 (br. s., 4H), 3.60 (br. s., 4H), 3.49-3.33 (m, 2H),
3.33-3.25 (m, 2H), 3.15 (td, J=11.06, 4.73 Hz, 1H), 2.66-2.54 (m,
1H), 2.26-2.13 (m, 2H), 1.74 (s, 3H), 2.03-1.09 (m, 21H), 1.08 (s,
3H), 1.07 (s, 3H), 1.06 (s, 3H), 1.01 (s, 3H), 0.99 (s, 3H).
Example 86
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(3-(1H-imidazol-1-yl)propy-
lcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,-
6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9--
yl)benzoic acid
##STR00191##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
3-(1H-imidazol-1-yl)propan-1-amine as the reactant amine. The
product was isolated as a white solid (7 mg, 23%). LCMS: m/e 666.39
(M+H).sup.+, 2.15 min (method 1). .sup.1H NMR (500 MHz, Acetic
Acid-d.sub.4) .delta. ppm 9.05-8.94 (m, 1H), 8.03 (d, J=8.24 Hz,
2H), 7.59 (d, J=14.65 Hz, 2H), 7.30 (d, J=8.24 Hz, 2H), 5.37 (d,
J=4.88 Hz, 1H), 4.78 (s, 1H), 4.65 (s, 1H), 4.36 (t, J=6.87 Hz,
2H), 3.47-3.31 (m, 2H), 3.17 (td, J=11.06, 4.12 Hz, 1H), 2.69-2.54
(m, 1H), 2.30-2.13 (m, 4H), 1.75 (s, 3H), 2.03-1.07 (m, 19H), 1.08
(s, 3H), 1.06 (s, 3H), 1.05 (s, 3H), 1.00 (s, 3H), 0.99 (s,
3H).
Example 87
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(3-(2-oxopyrrolidin-1-yl)propylcarbamoyl)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a-
,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chryse-
n-9-yl)benzoic acid
##STR00192##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
1-(3-aminopropyl)pyrrolidin-2-one as the reactant amine. The
product was isolated as a white solid (17 mg, 47%). LCMS: m/e
683.42 (M+H).sup.+, 2.18 min (method 1). .sup.1H NMR (500 MHz,
Acetic Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d,
J=8.24 Hz, 2H), 5.37 (d, J=4.58 Hz, 1H), 4.78 (s, 1H), 4.64 (s,
1H), 3.62-3.42 (m, 3H), 3.42-3.29 (m, 2H), 3.27-3.13 (m, 2H),
2.66-2.58 (m, 1H), 2.56 (t, J=8.09 Hz, 2H), 2.26-2.15 (m, 2H), 1.74
(s, 3H), 2.15-1.09 (m, 23H), 1.09 (s, 3H), 1.06 (s, 3H), 1.06 (s,
3H), 1.01 (s, 3H), 0.99 (s, 3H).
Example 88
Procedures for the preparation of
2,2'-(2-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-5a,-
5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a-
,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)e-
thylazanediyl)diacetic acid
##STR00193##
Preparation of dimethyl
2,2'-(2-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-(methoxycarbonyl)p-
henyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7-
a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-car-
boxamido)ethylazanediyl)diacetate. Intermediate 24
##STR00194##
To a solution of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-aminoethylcarbamoyl)-5a-
,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11-
a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoate
(20 mg, 0.033 mmol) in acetonitrile (1 mL) and dioxane (1 mL) was
added methyl 2-bromoacetate (14.93 mg, 0.098 mmol) and potassium
carbonate (22.48 mg, 0.163 mmol). The reaction mixture was heated
up at 78.degree. C. for 3 hours. LCMS indicated the formation of
desired product and consumption of starting material. The reaction
mixture was quenched with distilled water, extracted with DCM
(3.times.3 mL). All the extracts were combined, dried over sodium
sulfate, filtered and concentrated under reduced pressure to
provide the desired product (17 mg, 69%) as white solid. LCMS: m/e
759.7 (M+H).sup.+, 2.88 min (method 1).
Preparation of
2,2'-(2-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-5a,-
5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a-
,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)e-
thylazanediyl)diacetic acid
##STR00195##
A mixture of dimethyl
2,2'-(2-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-(methoxycarbonyl)p-
henyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7-
a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-car-
boxamido)ethylazanediyl)diacetate (17 mg, 0.022 mmol) and 1 N
sodium hydroxide (0.112 mL, 0.112 mmol) in dioxane (0.5 mL) was
heated up at 78.degree. C. for 3 hours. LCMS indicated the
formation of desired product. The reaction mixture was filtered and
the clear solution was purified by prep HPLC to provide the title
compound (10 mg, 59%) as white solid. LCMS: m/e 717.35 (M+H).sup.+,
1.97 min (method 1). .sup.1H NMR (500 MHz, Acetic Acid-d.sub.4)
.delta. ppm 8.03 (d, J=7.93 Hz, 2H), 7.30 (d, J=8.24 Hz, 2H), 5.37
(d, J=4.88 Hz, 1H), 4.78 (s, 1H), 4.64 (s, 1H), 4.35-4.14 (m, 4H),
3.94-3.81 (m, 1H), 3.71-3.61 (m, 1H), 3.60-3.49 (m, 2H), 3.18-3.06
(m, 1H), 2.53 (td, J=12.13, 3.51 Hz, 1H), 2.24-2.13 (m, 2H), 1.75
(s, 3H), 2.10-1.09 (m, 19H), 1.08 (s, 3H), 1.06 (s, 3H), 1.05 (s,
3H), 1.01 (s, 3H), 0.99 (s, 3H).
Example 89
Procedures for Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((2-carboxyethyl)(ethyl-
)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a-
,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a-
]chrysen-9-yl)benzoic acid
##STR00196##
Preparation of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(3-methoxy-3-oxopropyla-
mino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4-
,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]c-
hrysen-9-yl)benzoate. Intermediate 25
##STR00197##
To a solution of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-aminoethylcarbamoyl)-5a-
,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11-
a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoate
(60 mg, 0.098 mmol) in methanol (1 mL) was added methyl acrylate
(25.2 mg, 0.293 mmol), the reaction mixture was stirred at
20.degree. C. for 3 hours. LCMS indicated the formation of desired
product. The reaction mixture was quenched with distilled water,
extracted with DCM (3.times.3 mL). All the extracts were combined,
dried over sodium sulfate, filtered and concentrated under reduced
pressure to provide the desired product as white solid (60 mg,
88%). LCMS: m/e 701.46 (M+H).sup.+, 2.58 min (method 1).
Preparation of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(ethyl(3-methoxy-3-oxop-
ropyl)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2-
,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclope-
nta[a]chrysen-9-yl)benzoate. Intermediate 26
##STR00198##
A mixture of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(3-methoxy-3-oxopropyla-
mino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4-
,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]c-
hrysen-9-yl)benzoate (20 mg, 0.029 mmol), iodoethane (0.019 mL,
0.228 mmol) and potassium carbonate (7.89 mg, 0.057 mmol) in
acetonitrile (2 mL) and dioxane (2 mL) was refluxed for 8 hours.
LCMS indicated the formation of desired product and consumption of
starting material. The reaction mixture was quenched with distilled
water, extracted with DCM (3.times.3 mL). All the extracts were
combined, dried over sodium sulfate, filtered and concentrated
under reduced pressure to provide the title compound as white solid
(16 mg, 77%). LCMS: m/e 729.45 (M+H).sup.+, 2.76 min (method
1).
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((2-carboxyethyl)(ethyl-
)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a-
,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a-
]chrysen-9-yl)benzoic acid
##STR00199##
The title compound was prepared following the method described
above for
2,2'-(2-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-5a,-
5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a-
,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)e-
thylazanediyl)diacetic acid (example 88). The product was isolated
as a white solid (8.7 mg, 54%). LCMS: m/e 701.41 (M+H).sup.+, 2.06
min (method 1). .sup.1H NMR (500 MHz, Acetic Acid-d.sub.4) .delta.
ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d, J=8.55 Hz, 2H), 5.37 (d,
J=4.58 Hz, 1H), 4.78 (d, J=1.22 Hz, 1H), 4.65 (s, 1H), 3.90-3.69
(m, 2H), 3.53 (t, J=7.02 Hz, 2H), 3.49-3.31 (m, 4H), 3.13 (td,
J=10.76, 4.43 Hz, 1H), 2.96 (t, J=6.87 Hz, 2H), 2.64-2.48 (m, 1H),
2.24-2.14 (m, 2H), 1.75 (s, 3H), 1.40 (t, J=7.17 Hz, 3H), 2.05-1.09
(m, 19H), 1.08 (s, 3H), 1.06 (s, 3H), 1.06 (s, 3H), 1.01 (s, 3H),
0.99 (s, 3H).
Example 90
Procedures for Preparation of
3,3'-(2-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-5a,-
5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a-
,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)e-
thylazanediyl)dipropanoic acid
##STR00200##
Preparation of dimethyl
3,3'-(2-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-(methoxycarbonyl)p-
henyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7-
a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-car-
boxamido)ethylazanediyl)dipropanoate. Intermediate 27
##STR00201##
A mixture of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-aminoethylcarbamoyl)-5a-
,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11-
a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoate
(20 mg, 0.033 mmol) and methyl acrylate (8.40 mg, 0.098 mmol) in
methanol (1 mL) was stirred at 20.degree. C. for 3 hours. LCMS
indicated the mono-substitution. Methyl acrylate (8.40 mg, 0.098
mmol) was added to the reaction mixture again. The reaction mixture
was stirred for 16 hours. The reaction mixture was quenched with
distilled water, extracted with DCM (3.times.3 mL). All the
extracts were combined, dried over sodium sulfate, filtered and
concentrated under reduced pressure to provide the title compound
as a white solid (25 mg, 98%). LCMS: m/e 787.48 (M+H).sup.+, 2.67
min (method 1).
Preparation of
3,3'-(2-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-5a,-
5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a-
,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)e-
thylazanediyl)dipropanoic acid
##STR00202##
The title compound was prepared following the method described
above for
2,2'-(2-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-5a,-
5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a-
,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)e-
thylazanediyl)diacetic acid (example 88). The product was isolated
as a white solid (16 mg, 64%). LCMS: m/e 745.39 (M+H).sup.+, 1.97
min (method 1). .sup.1H NMR (500 MHz, Acetic Acid-d.sub.4) .delta.
ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d, J=8.24 Hz, 2H), 5.37 (d,
J=4.58 Hz, 1H), 4.78 (s, 1H), 4.65 (s, 1H), 3.89-3.75 (m, 2H), 3.59
(t, J=6.56 Hz, 4H), 3.54-3.41 (m, 2H), 3.19-3.07 (m, 1H), 3.00 (t,
J=6.56 Hz, 4H), 2.62-2.49 (m, 1H), 2.24-2.14 (m, 2H), 1.74 (s, 3H),
2.03-1.09 (m, 19H), 1.08 (s, 3H), 1.06 (s, 3H), 1.06 (s, 3H), 1.01
(s, 3H), 0.99 (s, 3H).
Example 91
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(2-carboxyethylamino)et-
hylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5-
b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen--
9-yl)benzoic acid
##STR00203##
The title compound was prepared following the method described
above for
2,2'-(2-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-5a,-
5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a-
,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)e-
thylazanediyl)diacetic acid (example 88). The product was isolated
as a white solid (5.5 mg, 54%). LCMS: m/e 673.38 (M+H).sup.+, 2.08
min (method 1). .sup.1H NMR (500 MHz, Acetic Acid-d.sub.4) .delta.
ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d, J=8.24 Hz, 2H), 5.37 (d,
J=4.58 Hz, 1H), 4.78 (s, 1H), 4.65 (s, 1H), 3.83-3.59 (m, 2H), 3.44
(t, J=6.41 Hz, 2H), 3.37 (t, J=5.80 Hz, 2H), 3.14 (td, J=10.83,
4.27 Hz, 1H), 2.93 (t, J=6.41 Hz, 2H), 2.56 (td, J=12.51, 2.75 Hz,
1H), 2.26-2.14 (m, 2H), 1.74 (s, 3H), 2.06-1.09 (m, 19H), 1.08 (s,
3H), 1.06 (s, 3H), 1.05 (s, 3H), 1.01 (s, 3H), 0.99 (s, 3H).
Example 92
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-1-(-
prop-1-en-2-yl)-3a-(2-(2-sulfoethylamino)ethylcarbamoyl)-2,3,3a,4,5,5a,5b,-
6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9--
yl)benzoic acid
##STR00204##
The title compound was prepared following the method described
above for
2,2'-(2-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-5a,-
5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a-
,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)e-
thylazanediyl)diacetic acid (example 88). using
2-bromoethanesulfonic acid as alkylating reagent. The product was
isolated as a white solid (3 mg, 39%). LCMS: m/e 709.37
(M+H).sup.+, 2.04 min (method 1). .sup.1H NMR (500 MHz, Acetic
Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.54 Hz, 2H), 7.30 (d, J=8.24
Hz, 2H), 5.37 (d, J=6.10 Hz, 1H), 4.79 (s, 1H), 4.66 (s, 1H),
3.93-3.75 (m, 2H), 3.74-3.62 (m, 2H), 3.50-3.44 (m, 2H), 3.42 (t,
J=5.80 Hz, 2H), 3.20-3.06 (m, 1H), 2.66-2.47 (m, 1H), 1.75 (s, 3H),
2.31-1.10 (m, 21H), 1.09 (s, 3H), 1.06 (s, 3H), 1.06 (s, 3H), 1.01
(s, 3H), 0.99 (s, 3H).
Example 93
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((2-carboxyethyl)(propy-
l)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3-
a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[-
a]chrysen-9-yl)benzoic acid
##STR00205##
The title compound was prepared following the method described
above for the preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((2-carboxyethyl)(ethyl-
)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a-
,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a-
]chrysen-9-yl)benzoic acid (example 89). using 1-iodopropane as
alkylating reagent. The product was isolated as a white solid (10
mg, 49%). LCMS: m/e 715.50 (M+H).sup.+, 2.08 min (method 1).
.sup.1H NMR (500 MHz, Acetic Acid-d.sub.4) .delta. ppm 8.03 (d,
J=7.93 Hz, 2H), 7.30 (d, J=8.24 Hz, 2H), 5.37 (d, J=4.58 Hz, 1H),
4.78 (s, 1H), 4.65 (s, 1H), 3.88-3.72 (m, 2H), 3.55 (t, J=7.02 Hz,
2H), 3.44 (q, J=6.51 Hz, 2H), 3.32-3.21 (m, 2H), 3.13 (td, J=11.22,
3.51 Hz, 1H), 2.97 (t, J=6.71 Hz, 2H), 2.55 (td, J=12.13, 3.81 Hz,
1H), 2.25-2.13 (m, 2H), 1.75 (s, 3H), 2.04-1.10 (m, 21H), 1.08 (s,
3H), 1.07 (s, 3H), 1.06 (s, 3H), 1.03 (t, J=5 Hz, 2H), 1.01 (s,
3H), 0.99 (s, 3H).
Example 94
Procedures for the preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((carboxymethyl)(propyl-
)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a-
,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a-
]chrysen-9-yl)benzoic acid
##STR00206##
Preparation of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((2-methoxy-2-oxoethyl)-
(propyl)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-
-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclo-
penta[a]chrysen-9-yl)benzoate. Intermediate 28
##STR00207##
A mixture of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(2-methoxy-2-oxoethylam-
ino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,-
5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]ch-
rysen-9-yl)benzoate (28 mg, 0.041 mmol), 1-iodopropane (55.4 mg,
0.326 mmol) and potassium carbonate (11.27 mg, 0.082 mmol) in
acetonitrile (2 mL) and dioxane (2.000 mL) was heated up for 8
hours. LCMS indicated the formation of desired product and
consumption of starting material. The reaction mixture was quenched
with distilled water, extracted with DCM (3.times.3 mL). All the
extracts were combined, dried over sodium sulfate, filtered and
concentrated under reduced pressure to provide the desired product
as a white solid (20 mg, 67%). LCMS: m/e 729.47 (M+H).sup.+, 2.96
min (method 1).
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((carboxymethyl)(propyl-
)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a-
,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a-
]chrysen-9-yl)benzoic acid
##STR00208##
The title compound was prepared following the method described
above for
2,2'-(2-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-5a,-
5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a-
,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)e-
thylazanediyl)diacetic acid (example 88). The product was isolated
as a white solid (14 mg, 68%). LCMS: m/e 701.50 (M+H).sup.+, 2.08
min (method 1). .sup.1H NMR (500 MHz, Acetic Acid-d.sub.4) .delta.
ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d, J=8.24 Hz, 2H), 5.37 (d,
J=5.49 Hz, 1H), 4.78 (s, 1H), 4.65 (s, 1H), 4.04 (s, 2H), 3.86-3.64
(m, 2H), 3.58-3.46 (m, 2H), 3.34 (dd, J=10.68, 6.71 Hz, 2H),
3.22-3.04 (m, 1H), 2.67-2.45 (m, 1H), 2.26-2.13 (m, 2H), 1.75 (s,
3H), 2.03-1.11 (m, 21H), 1.08 (s, 3H), 1.07 (s, 3H), 1.06 (s, 3H),
1.04 (t, J=5 Hz, 3H), 1.01 (s, 3H), 0.99 (s, 3H).
Example 95
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((carboxymethyl)(isopro-
pyl)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3-
,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopent-
a[a]chrysen-9-yl)benzoic acid
##STR00209##
The title compound was prepared following the method described
above for the preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((carboxymethyl)(propyl-
)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a-
,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a-
]chrysen-9-yl)benzoic acid (example 94) using 2-iodopropane as
alkylating reagent. The product was isolated as a white solid (16
mg, 65%). LCMS: m/e 701.63 (M+H).sup.+, 2.06 min (method 1). 1H NMR
(500 MHz, Acetic Acid-d.sub.4) .delta. ppm 8.03 (d, J=7.93 Hz, 2H),
7.30 (d, J=7.93 Hz, 2H), 5.37 (d, J=4.88 Hz, 1H), 4.78 (s, 1H),
4.65 (s, 1H), 4.06-3.85 (m, 3H), 3.82-3.62 (m, 2H), 3.56-3.33 (m,
2H), 3.13 (td, J=10.91, 4.12 Hz, 1H), 2.66-2.48 (m, 1H), 2.25-2.13
(m, 2H), 1.74 (s, 3H), 1.41 (d, J=6.41 Hz, 6H), 2.04-1.10 (m, 19H),
1.08 (s, 3H), 1.06 (s, 3H), 1.06 (s, 3H), 1.01 (s, 3H), 0.99 (s,
3H).
Example 96
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((2-carboxyethyl)(isopr-
opyl)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,-
3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopen-
ta[a]chrysen-9-yl)benzoic acid
##STR00210##
The title compound was prepared following the method described
above for the preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((2-carboxyethyl)(ethyl-
)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a-
,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a-
]chrysen-9-yl)benzoic acid (example 89) using 2-iodopropane as
alkylating reagent. The product was isolated as a white solid (12
mg, 66%). LCMS: m/e 715.62 (M+H).sup.+, 2.08 min (method 1).
.sup.1H NMR (500 MHz, Acetic Acid-d.sub.4) .delta. ppm 8.03 (d,
J=7.93 Hz, 2H), 7.30 (d, J=8.24 Hz, 2H), 5.37 (d, J=4.88 Hz, 1H),
4.78 (s, 1H), 4.65 (s, 1H), 4.00-3.85 (m, 1H), 3.85-3.65 (m, 2H),
3.55-3.32 (m, 4H), 3.23-3.08 (m, 1H), 3.01-2.87 (m, 2H), 2.64-2.47
(m, 1H), 2.27-2.14 (m, 2H), 1.75 (s, 3H), 1.41 (d, J=4.88 Hz, 6H),
2.04-1.10 (m, 19H), 1.08 (s, 3H), 1.06 (s, 3H), 1.06 (s, 3H), 1.01
(s, 3H), 0.99 (s, 3H).
Example 97
Procedures for the preparation of
2-((1S,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-1-isoprop-
yl-5a,5b,8,8,11a-pentamethyl-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13-
a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)-N,N-dimethyle-
thanamine oxide
##STR00211##
Preparation of
(1S,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy-1-isopropyl-5a,5b,8-
,8,11a-pentamethylicosahydro-1H-cyclopenta[a]chrysene-3a-carboxylic
acid. Intermediate 29
##STR00212##
A mixture of
(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy-5a,5b,8,8,11a-penta-
methyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysene-3a-carboxylic
acid (4 g, 8.76 mmol) and 10% Pd/C (1.398 g, 1.314 mmol) in ethyl
acetate (80 mL) and MeOH (30 mL) was connected to Parr Shaker and
shaked for 18 h under 45 psi at room temperature. LCMS indicated
the formation of desired product. The reaction mixture was filtered
through celite and the filtrates were concentrated under reduced
pressure to give the title compound as white solid (3 g, 75%).
LCMS: m/e 457.27 (M-H).sup.-, 2.40 min (method 1).
Preparation of (1S,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-benzyl
9-hydroxy-1-isopropyl-5a,5b,8,8,11a-pentamethylicosahydro-1H-cyclopenta[a-
]chrysene-3a-carboxylate. Intermediate 30
##STR00213##
To a solution of
(1S,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy-1-isopropyl-5a,5b,8-
,8,11a-pentamethylicosahydro-1H-cyclopenta[a]chrysene-3a-carboxylic
acid (3 g, 6.54 mmol) and potassium carbonate (1.808 g, 13.08 mmol)
in DMF (60 mL) was added (bromomethyl)benzene (0.816 mL, 6.87
mmol). The reaction mixture was heated up to 60.degree. C. for 3 h.
LCMS indicated the starting material was consumed. The reaction
mixture was quenched with 60 ml water, a white precipitate was
observed. The white solid was collected through filtration and
washed with distilled water. The solid was dried in the air to
provide the title compound as white solid (3.3 g, 92%). .sup.1H NMR
(500 MHz, CHLOROFORM-d) .delta. ppm 7.42-7.28 (m, 5H), 5.27-5.01
(m, 2H), 3.18 (dt, J=11.22, 5.53 Hz, 1H), 2.40-2.09 (m, 3H),
1.91-1.73 (m, 2H), 1.72-0.78 (m, 21H), 0.95 (s, 3H), 0.91 (s, 3H),
0.84 (d, J=7.02 Hz, 3H), 0.80 (s, 3H), 0.75 (s, 3H), 0.73 (s, 3H),
0.73 (d, J=6.71 Hz, 3H).
Preparation of (1S,3aS,5aR,5bR,7aR,11aR,11bR,13aR,13bR)-benzyl
1-isopropyl-5a,5b,8,8,11a-pentamethyl-9-oxoicosahydro-1H-cyclopenta[a]chr-
ysene-3a-carboxylate. Intermediate 31
##STR00214##
To a solution of (1S,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-benzyl
9-hydroxy-1-isopropyl-5a,5b,8,8,11a-pentamethylicosahydro-1H-cyclopenta[a-
]chrysene-3a-carboxylate (3.3 g, 6.01 mmol) in DCM (50 mL) was
added PCC (3.89 g, 18.04 mmol). The reaction mixture was stirred
for 4 hours. TLC indicated sm was consumed and desired product was
formed. The reaction mixture was concentrated under reduced
pressure. The residue was purified by biotage with 0-10% ethyl
acetate/hexane to provide the title compound as white solid (3.05,
93%). LCMS: m/e 547.25 (M+H).sup.+, 2.77 min (method 1). 1H NMR
(500 MHz, CHLOROFORM-d) .delta. ppm 7.41-7.28 (m, 5H), 5.10 (q,
J=12.41 Hz, 2H), 2.57-2.34 (m, 2H), 2.31-2.16 (m, 3H), 1.98-1.86
(m, 1H), 1.85-1.73 (m, 2H), 1.73-1.61 (m, 1H), 1.54-1.07 (m, 17H),
1.06 (s, 3H), 1.01 (s, 3H), 0.92 (s, 3H), 0.90 (s, 3H), 0.84 (d,
J=7.02 Hz, 3H), 0.76 (s, 3H), 0.73 (d, 3H).
Preparation of (1S,3aS,5aR,5bR,7aR,11aR,13aR,13bR)-benzyl
1-isopropyl-5a,5b,8,8,11a-pentamethyl-9-(trifluoromethylsulfonyloxy)-2,3,-
3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta-
[a]chrysene-3a-carboxylate. Intermediate 32
##STR00215##
To (1S,3aS,5aR,5bR,7aR,11aR,13aR,13bR)-benzyl
1-isopropyl-5a,5b,8,8,11a-pentamethyl-9-oxoicosahydro-1H-cyclopenta[a]chr-
ysene-3a-carboxylate (3.05 g, 5.58 mmol) in THF (100 mL) at
-78.degree. C. was added KHMDS (22.31 mL, 11.16 mmol), the reaction
mixture was stirred for 15 minutes at -78.degree. C. then
1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide
(2.192 g, 6.14 mmol) in THF (15 mL) and toluene (5 mL) was added
slowly through 20 minutes at -78.degree. C. The reaction mixture
was stirred for 2 hours at that temperature. TLC indicated the
formation of desired product. The reaction mixture was quenched
with water (100 mL), extracted with ethyl acetate (3.times.50 mL).
The extracts were dried over sodium sulfate, filtered and
concentrated under reduced pressure. The residue was purified by
biotage with 0-6% ethyl acetate/hexanes to provide the title
compound as a white solid (3.5 g, 92%). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 7.42-7.28 (m, 5H), 5.55 (dd, J=6.71, 2.14
Hz, 1H), 5.19-5.03 (m, 2H), 2.32-2.11 (m, 4H), 1.87-1.62 (m, 4H),
1.11 (s, 3H), 1.53-1.06 (m, 16H), 1.00 (s, 3H), 0.92 (s, 3H), 0.88
(s, 3H), 0.84 (d, J=6.71 Hz, 3H), 0.75 (s, 3H), 0.74 (d, J=6.71 Hz,
3H).
Preparation of (1S,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-benzyl
1-isopropyl-9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-2,3,3-
a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[-
a]chrysene-3a-carboxylate. Intermediate 33
##STR00216##
A mixture of (1S,3aS,5aR,5bR,7aR,11aR,11bR,13aR,13bR)-benzyl
1-isopropyl-5a,5b,8,8,11a-pentamethyl-9-(trifluoromethylsulfonyloxy)-2,3,-
3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta-
[a]chrysene-3a-carboxylate (3.5 g, 5.16 mmol),
4-(methoxycarbonyl)phenylboronic acid (1.206 g, 6.70 mmol),
Pd(Ph.sub.3P).sub.4 (0.179 g, 0.155 mmol) and sodium carbonate
(1.639 g, 15.47 mmol) in dioxane (20 mL) and water (20 mL) was
heated up at 90.degree. C. for 2 h. TLC indicated starting material
was consumed and a new spot was present. The reaction mixture was
purified by biotage with 0-10% ethyl acetate/hexanes to provide the
title compound as white solid (3.05 g, 89%). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 7.92 (d, J=8.24 Hz, 2H), 7.48-7.28 (m,
5H), 7.19 (d, J=7.93 Hz, 2H), 5.28 (dd, J=6.26, 1.68 Hz, 1H),
5.19-5.00 (m, 2H), 3.90 (s, 3H), 2.38-2.20 (m, 3H), 2.11 (dd,
J=17.09, 6.41 Hz, 1H), 1.89-1.75 (m, 2H), 1.72-1.61 (m, 2H),
1.53-1.07 (m, 16H), 0.95 (s, 6H), 0.92 (s, 3H), 0.90 (s, 3H), 0.85
(d, J=6.71 Hz, 3H), 0.80 (s, 3H), 0.75 (d, 3H).
Preparation of
(1S,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-1-isopropyl-9-(4-(methoxycarbony-
l)phenyl)-5a,5b,8,8,11a-pentamethyl-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,1-
2,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxylic
acid. Intermediate 34
##STR00217##
A mixture of (1S,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-benzyl
1-isopropyl-9-(4-(methoxycarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-2,3,3-
a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[-
a]chrysene-3a-carboxylate (220 mg, 0.331 mmol),
tert-butyldimethylsilane (77 mg, 0.662 mmol), TEA (0.074 mL, 0.529
mmol) and palladium (II) acetate (18.57 mg, 0.083 mmol) in DCM (2
mL) was heated up at 60.degree. C. for 3 h, TLC indicated the
starting material was consumed. The reaction mixture was filtered a
pad of celite. The filtrates were concentrated under reduced
pressure to provide the intermediate. To this intermediate in
dioxane (2 mL) was added TBAF (346 mg, 0.993 mmol), the reaction
mixture was stirred for 2 h at room temperature. LCMS indicated the
formation of desired product. The reaction mixture was quenched
with distilled water (5 mL), extracted with DCM (3.times.8 mL). All
the extracts were combined, dried over sodium sulfate, filtered and
concentrated under reduced pressure to provide the desired product
as a pale yellow solid (150 mg, 79%). LCMS: m/e 575.35 (M+H).sup.+,
2.84 min (method 1).
Preparation of methyl
4-((1S,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(dimethylamino)ethylcar-
bamoyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2,3,3a,4,5,5a,5b,6,7,7a,8,11-
,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoate-
. Intermediate 35
##STR00218##
A mixture of
(1S,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-1-isopropyl-9-(4-(methoxycarbony-
l)phenyl)-5a,5b,8,8,11a-pentamethyl-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,1-
2,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxylic
acid (150 mg, 0.261 mmol) and oxalyl dichloride (0.783 mL, 1.566
mmol) in DCM (4 mL) was stirred for 2 h at room temperature. LCMS
indicated the formation of desired product. The reaction mixture
was concentrated under reduced pressure to provide the intermediate
acid chloride as a yellow solid. To a mixture of
N1N1-dimethylethane-1,2-diamine (46.0 mg, 0.522 mmol) and
Hunig'sBase (0.228 mL, 1.305 mmol) in DCM (4 mL) was added the acid
chloride in DCM (4 mL), the reaction mixture was stirred for 2 h at
20.degree. C. LCMS indicated the formation of desired product. The
reaction mixture was quenched with distilled water (3 mL),
extracted with DCM (3.times.3 mL). All the extracts were combined,
dried over sodium sulfate, filtered and concentrated under reduced
pressure to provide the title compound as a pale yellow solid (140
mg, 83%). LCMS: m/e 645.51 (M+H).sup.+, 3.00 min (method 1).
Preparation of
2-((1S,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-1-isoprop-
yl-5a,5b,8,8,11a-pentamethyl-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13-
a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)-N,N-dimethyle-
thanamine oxide. Intermediate 36
##STR00219##
To a mixture of methyl
4-((1S,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(dimethylamino)ethylcar-
bamoyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2,3,3a,4,5,5a,5b,6,7,7a,8,11-
,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoate
(20 mg, 0.031 mmol) in DCM (2 mL) was added 3-chlorobenzoperoxoic
acid (13.90 mg, 0.062 mmol) at -78.degree. C. The reaction mixture
was stirred for 3 hours. LCMS indicated the formation of desired
product and consumption of the starting material. The reaction
mixture was quenched with distilled water, extracted with DCM
(3.times.2 mL). All the extracts were combined, dried over sodium
sulfate, filtered and concentrated under reduced pressure to
provide the title compound as an yellow oil (10 mg, 49%). LCMS: m/e
661.49 (M+H).sup.+, 2.79 min (method 1).
Preparation of
2-((1S,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-1-isoprop-
yl-5a,5b,8,8,11a-pentamethyl-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13-
a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)-N,N-dimethyle-
thanamine oxide
##STR00220##
The title compound was prepared following the method described
above for
2,2'-(2-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-5a,-
5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a-
,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)e-
thylazanediyl)diacetic acid (example 88). The product was isolated
as a white solid (7 mg, 68%). LCMS: m/e 647.45 (M+H).sup.+, 2.22
min (method 1). .sup.1H NMR (500 MHz, Acetic Acid-d.sub.4) .delta.
ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d, J=8.24 Hz, 2H), 5.38 (d,
J=4.58 Hz, 1H), 4.08-3.83 (m, 4H), 3.59 (s, 6H), 2.61-2.47 (m, 1H),
2.41-2.30 (m, 1H), 2.27-2.16 (m, 2H), 1.90-1.67 (m, 4H), 1.67-1.38
(m, 12H), 1.36-1.17 (m, 4H), 1.08 (s, 3H), 1.07 (s, 3H), 1.05 (s,
3H), 1.01 (s, 3H), 1.00 (s, 3H), 0.91 (d, J=6.71 Hz, 3H), 0.82 (d,
J=6.71 Hz, 3H).
Example 98
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(3-aminopropylcarbamoyl)-5-
a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,1-
1a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic
acid
##STR00221##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
propane-1,3-diamine as the reactant amine. The product was isolated
as a white solid (1.2 mg, 15%). LCMS: m/e 615.42 (M+H).sup.+, 2.15
min (method 1). .sup.1H NMR (500 MHz, Acetic Acid-d.sub.4) .delta.
ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d, J=8.55 Hz, 2H), 5.37 (d,
J=4.58 Hz, 1H), 4.79 (d, J=1.83 Hz, 1H), 4.65 (s, 1H), 3.58-3.33
(m, 2H), 3.25-3.03 (m, 3H), 2.72-2.50 (m, 1H), 2.25-2.13 (m, 2H),
1.75 (s, 3H), 2.04-1.09 (m, 21H), 1.08 (s, 3H), 1.07 (s, 3H), 1.06
(s, 3H), 1.01 (s, 3H), 0.99 (s, 3H).
Example 99
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(3-((2-carboxyethyl)(ethyl-
)amino)propylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3-
a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[-
a]chrysen-9-yl)benzoic acid
##STR00222##
The title compound was prepared following the method described
above for the preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((2-carboxyethyl)(ethyl-
)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a-
,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a-
]chrysen-9-yl)benzoic acid (example 89) using methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(3-(3-methoxy-3-oxopropyla-
mino)propylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,-
4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]-
chrysen-9-yl)benzoate as amine and iodoethane as alkylating
reagent. The product was isolated as a white solid (3 mg, 30%).
LCMS: m/e 715.49 (M+H).sup.+, 2.11 min (method 1). .sup.1H NMR (500
MHz, Acetic Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.24 Hz, 2H), 7.30
(d, J=8.24 Hz, 2H), 5.37 (d, J=5.19 Hz, 1H), 4.78 (s, 1H), 4.65 (s,
1H), 3.50 (t, J=7.17 Hz, 2H), 3.46-3.40 (m, 2H), 3.39-3.31 (m, 2H),
3.27 (t, J=7.63 Hz, 2H), 3.21-3.08 (m, 1H), 2.97 (t, J=7.02 Hz,
2H), 2.67-2.54 (m, 1H), 2.25-2.17 (m, 2H), 1.74 (s, 3H), 1.39 (t,
J=7.17 Hz, 3H), 2.05-1.10 (m, 21H), 1.08 (s, 3H), 1.06 (s, 6H),
1.01 (s, 3H), 0.99 (s, 3H).
Example 100
Preparation of
3,3'-(3-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-5a,-
5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a-
,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)p-
ropylazanediyl)dipropanoic acid
##STR00223##
The title compound was prepared following the method described
above for
3,3'-(2-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-5a,-
5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a-
,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)e-
thylazanediyl)dipropanoic acid (example 90) using methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(3-(3-methoxy-3-oxopropyla-
mino)propylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,-
4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]-
chrysen-9-yl)benzoate as amine. The product was isolated as a white
solid (4 mg, 40%). LCMS: m/e 759.62 (M+H).sup.+, 2.01 min (method
1). .sup.1H NMR (500 MHz, Acetic Acid-d.sub.4) .delta. ppm 8.03 (d,
J=8.24 Hz, 2H), 7.30 (d, J=8.24 Hz, 2H), 5.31-5.43 (m, 1H), 4.78
(d, J=1.53 Hz, 1H), 4.65 (s, 1H), 3.55 (t, J=6.71 Hz, 4H),
3.48-3.39 (m, 2H), 3.34 (t, J=7.93 Hz, 2H), 3.15 (td, J=10.83, 4.58
Hz, 1H), 3.00 (t, J=6.71 Hz, 4H), 2.59 (td, J=11.90, 3.66 Hz, 1H),
1.74 (s, 3H), 2.23-1.09 (m, 23H), 1.08 (s, 3H), 1.06 (s, 6H), 1.01
(s, 3H), 0.99 (s, 3H).
Example 101
Procedure for the preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(3-((3-carboxypropyl)(ethy-
l)amino)propylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,-
3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta-
[a]chrysen-9-yl)benzoic acid
##STR00224##
Preparation of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(3-(4-methoxy-4-oxobutylam-
ino)propylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4-
,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]c-
hrysen-9-yl)benzoate. Intermediate 37
##STR00225##
A mixture of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(3-aminopropylcarbamoyl)-5-
a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,1-
1a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoate
(30 mg, 0.048 mmol), methyl 4-bromobutanoate (25.9 mg, 0.143 mmol)
and potassium carbonate (19.78 mg, 0.143 mmol) in dioxane (1 mL)
and Acetonitrile (1 mL) was heated up at 78.degree. C. for 3 hours.
LCMS indicated the formation of desired product, the reaction
mixture was filtered and the clear solution was purified by prep
HPLC to give the title compound as a white solid (10 mg, 29%).
LCMS: m/e 729.48 (M+H).sup.+, 2.62 min (method 1).
Preparation of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(3-(ethyl(4-methoxy-4-oxob-
utyl)amino)propylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2-
,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclope-
nta[a]chrysen-9-yl)benzoate. Intermediate 38
##STR00226##
A mixture of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(3-(4-methoxy-4-oxobutylam-
ino)propylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4-
,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]c-
hrysen-9-yl)benzoate (10 mg, 0.014 mmol) and potassium carbonate
(5.69 mg, 0.041 mmol) in dioxane (1 mL) and acetonitrile (1.000 mL)
was heated up at 78.degree. C. for 3 hours, LCMS indicated the
formation of desired product. The reaction mixture was quenched
with distilled water (2 mL), extracted with DCM (3.times.2 mL). All
the extracts were combined, dried over sodium sulfate, filtered and
concentrated under reduced pressure to provide the title compound
as a colorless oil (10 mg, 96%). LCMS: m/e 757.50 (M+H).sup.+, 2.73
min (method 1).
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(3-((3-carboxypropyl)(ethy-
l)amino)propylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,-
3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta-
[a]chrysen-9-yl)benzoic acid
##STR00227##
The title compound was prepared following the method described
above for
2,2'-(2-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-5a,-
5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a-
,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)e-
thylazanediyl)diacetic acid (example 88). The product was isolated
as a white solid (3 mg, 30%). LCMS: m/e 730.31 (M+H).sup.+, 2.08
min (method 1). .sup.1H NMR (500 MHz, Acetic Acid-d.sub.4) .delta.
ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d, J=7.93 Hz, 2H), 5.37 (d,
J=4.88 Hz, 1H), 4.78 (s, 1H), 4.65 (s, 1H), 3.56-3.37 (m, 4H),
3.36-3.31 (m, 1H), 3.29-3.21 (m, 2H), 3.20-3.07 (m, 2H), 2.74-2.48
(m, 3H), 1.74 (s, 3H), 2.33-1.10 (m, 28H), 1.09 (s, 3H), 1.06 (s,
6H), 1.01 (s, 3H), 0.99 (s, 3H).
Example 102
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(3-((carboxymethyl)(ethyl)-
amino)propylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a-
,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a-
]chrysen-9-yl)benzoic acid
##STR00228##
The title compound was prepared following the method described
above for the preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((carboxymethyl)(propyl-
)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a-
,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a-
]chrysen-9-yl)benzoic acid (example 94) using methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(3-(2-methoxy-2-oxoethylam-
ino)propylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4-
,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]c-
hrysen-9-yl)benzoate as starting material. The product was isolated
as a white solid (11 mg, 39%). LCMS: m/e 701.04 (M+H).sup.+, 2.04
min (method 1). .sup.1H NMR (500 MHz, Acetic Acid-d.sub.4) .delta.
ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d, J=8.24 Hz, 2H), 5.37 (d,
J=4.88 Hz, 1H), 4.78 (br. s., 1H), 4.65 (br. s., 1H), 4.05-3.92 (m,
2H), 3.45 (s, 2H), 3.42-3.35 (m, 2H), 3.35-3.21 (m, 2H), 3.16 (td,
J=10.99, 3.97 Hz, 1H), 2.67-2.55 (m, 1H), 2.25-2.13 (m, 2H), 1.74
(s, 3H), 1.39 (t, J=7.32 Hz, 3H), 2.05-1.13 (m, 22H), 1.08 (s, 3H),
1.07 (s, 3H), 1.06 (s, 3H), 1.01 (s, 3H), 0.99 (s, 3H).
Example 103
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((3-carboxypropyl)(ethy-
l)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3-
a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[-
a]chrysen-9-yl)benzoic acid
##STR00229##
The title compound was prepared following the method described
above for
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((3-carboxypropyl)(ethy-
l)amino)propylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,-
3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta-
[a]chrysen-9-yl)benzoic acid (example 101) using methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-aminoethylcarbamoyl)-5a-
,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11-
a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoate
as amine. The product was isolated as a white solid (3 mg, 25%).
LCMS: m/e 715.45 (M+H).sup.+, 2.06 min (method 1). .sup.1H NMR (500
MHz, Acetic Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.24 Hz, 2H), 7.30
(d, J=8.24 Hz, 2H), 5.37 (d, J=4.88 Hz, 1H), 4.78 (s, 1H), 4.65 (s,
1H), 3.88-3.68 (m, 2H), 3.49-3.34 (m, 4H), 3.34-3.27 (m, 2H),
3.19-3.06 (m, 1H), 2.67-2.49 (m, 3H), 2.23-2.15 (m, 2H), 1.74 (s,
3H), 1.38 (t, J=7.17 Hz, 3H), 2.04-1.09 (m, 21H), 1.08 (s, 3H),
1.06 (s, 3H), 1.05 (s, 3H), 1.01 (s, 3H), 0.99 (s, 3H).
Example 104
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(dimethylamino)ethylcar-
bamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,-
7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)--
2-fluorobenzoic acid
##STR00230##
The title compound was prepared following the general procedures
described above for the Suzuki coupling using
3-fluoro-4-(methoxycarbonyl)phenylboronic acid as boronic acid, the
C-28 amide formation and hydrolysis using
N1,N1-dimethylethane-1,2-diamine as the reactant amine. The product
was isolated as a white solid (30 mg, 71%). LCMS: m/e 647.54
(M+H).sup.+, 2.26 min (method 1). .sup.1H NMR (500 MHz, Acetic
Acid-d.sub.4) .delta. ppm 7.96 (t, J=7.93 Hz, 1H), 7.08 (d, J=8.24
Hz, 1H), 7.02 (d, J=11.90 Hz, 1H), 5.42 (d, J=4.88 Hz, 1H), 4.78
(d, J=1.53 Hz, 1H), 4.65 (s, 1H), 3.75 (t, J=5.95 Hz, 2H),
3.44-3.33 (m, 2H), 3.14 (td, J=10.91, 4.12 Hz, 1H), 2.95 (s, 6H),
2.54 (td, J=12.28, 2.90 Hz, 1H), 2.25-2.15 (m, 2H), 1.73 (s, 3H),
2.01-1.09 (m, 19H), 1.08 (s, 3H), 1.04 (s, 6H), 1.02 (s, 3H), 1.00
(s, 3H).
Example 105
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((3-(1,1-dioxido-4-thiomor-
pholinyl)propyl)carbamoyl)-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-2,3,3a,-
4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]-
chrysen-9-yl)-2-fluorobenzoic acid
##STR00231##
The title compound was prepared following the general procedures
described above for the Suzuki coupling using
3-fluoro-4-(methoxycarbonyl)phenylboronic acid as boronic acid, the
C-28 amide formation and hydrolysis using
4-(3-aminopropyl)thiomorpholine 1,1-dioxide as the reactant amine.
The product was isolated as a white solid (15 mg, 36%). LCMS: m/e
751.46 (M+H).sup.+, 2.27 min (method 1). .sup.1H NMR (500 MHz,
Acetic Acid-d.sub.4) .delta. ppm 7.96 (t, J=7.93 Hz, 1H), 7.08 (dd,
J=8.09, 1.37 Hz, 1H), 7.03 (d, J=11.60 Hz, 1H), 5.42 (d, J=4.58 Hz,
1H), 4.78 (d, J=1.53 Hz, 1H), 4.65 (s, 1H), 3.85 (br. s., 4H), 3.59
(br. s., 4H), 3.50-3.32 (m, 2H), 3.32-3.24 (m, 2H), 3.15 (td,
J=10.99, 3.97 Hz, 1H), 2.60 (td, J=12.21, 3.05 Hz, 1H), 2.25-2.12
(m, 2H), 1.74 (s, 3H), 2.05-1.10 (m, 21H), 1.08 (s, 3H), 1.06 (s,
3H), 1.05 (s, 3H), 1.02 (s, 3H), 1.00 (s, 3H).
Example 106
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-(1,1-dioxido-4-thiomor-
pholinyl)ethyl)carbamoyl)-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-2,3,3a,4-
,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]c-
hrysen-9-yl)benzoic acid
##STR00232##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
N-(2-aminoethyl)thiomorpholine 1,1-dioxide as the reactant amine.
The product was isolated as a white solid (39 mg, 69%). LCMS: m/e
720.18 (M+H).sup.+, 2.15 min (method 1). .sup.1H NMR (500 MHz,
Acetic Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d,
J=8.24 Hz, 2H), 5.37 (d, J=4.58 Hz, 1H), 4.78 (s, 1H), 4.65 (s,
1H), 3.83 (br. s., 4H), 3.81-3.67 (m, 2H), 3.56 (br. s., 4H),
3.46-3.31 (m, 2H), 3.14 (td, J=10.91, 4.12 Hz, 1H), 2.60-2.48 (m,
1H), 2.26-2.11 (m, 2H), 1.74 (s, 3H), 2.03-1.09 (m, 19H), 1.08 (s,
3H), 1.06 (s, 3H), 1.04 (s, 3H), 1.01 (s, 3H), 0.99 (s, 3H).
Example 107
Procedures for the preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(benzyl(carboxymethyl)a-
mino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4-
,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]c-
hrysen-9-yl)benzoic acid
##STR00233##
Preparation of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(benzyl(2-methoxy-2-oxo-
ethyl)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2-
,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclope-
nta[a]chrysen-9-yl)benzoate. Intermediate 39
##STR00234##
A mixture of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(benzylamino)ethylcarba-
moyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a-
,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)ben-
zoate (50 mg, 0.071 mmol), methyl 2-bromoacetate (32.5 mg, 0.213
mmol) and potassium carbonate (29.4 mg, 0.213 mmol) in dioxane (1
mL) and acetonitrile (1 mL) was heated up at 78.degree. C. for 3
hours. LCMS indicated the formation of desired product. The
reaction mixture was quenched with distilled water, extracted with
DCM (3.times.4 mL). All the extracts were combined, dried over
sodium sulfate, filtered and concentrated under reduced pressure to
provide the title compound as a white solid (45 mg, 82%). LCMS: m/e
777.48 (M+H).sup.+, 3.12 min (method 1).
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(benzyl(carboxymethyl)a-
mino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4-
,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]c-
hrysen-9-yl)benzoic acid
##STR00235##
The title compound was prepared following the method described
above for
2,2'-(2-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-5a,-
5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a-
,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)e-
thylazanediyl)diacetic acid (example 88). The product was isolated
as a white solid (23 mg, 50%). LCMS: m/e 749.44 (M+H).sup.+, 2.13
min (method 1). .sup.1H NMR (500 MHz, Acetic Acid-d.sub.4) .delta.
ppm 8.03 (d, J=8.24 Hz, 2H), 7.69-7.61 (m, 2H), 7.56-7.47 (m, 3H),
7.30 (d, J=8.24 Hz, 2H), 5.37 (d, J=4.58 Hz, 1H), 4.79 (d, J=1.53
Hz, 1H), 4.66 (s, 1H), 4.64-4.54 (m, 2H), 4.03 (s, 2H), 3.90-3.79
(m, 1H), 3.71 (ddd, J=14.42, 6.03, 5.80 Hz, 1H), 3.59-3.40 (m, 2H),
3.11 (td, J=10.91, 4.12 Hz, 1H), 2.61-2.47 (m, 1H), 2.25-2.12 (m,
2H), 1.74 (s, 3H), 2.03-1.08 (m, 19H), 1.07 (s, 3H), 1.07 (s, 3H),
1.01 (s, 3H), 1.01 (s, 3H), 0.99 (s, 3H).
Example 108
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(2-(3-oxopiperazin-1-yl)ethylcarbamoyl)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5-
b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen--
9-yl)benzoic acid
##STR00236##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
4-(2-aminoethyl)piperazin-2-one as the reactant amine. The product
was isolated as a white solid (18 mg, 44%). LCMS: m/e 684.54
(M+H).sup.+, 2.13 min (method 1). .sup.1H NMR (500 MHz, Acetic
Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d, J=8.24
Hz, 2H), 5.37 (d, J=4.88 Hz, 1H), 4.78 (d, J=1.53 Hz, 1H), 4.65 (s,
1H), 4.06 (s, 2H), 3.87-3.76 (m, 2H), 3.73 (d, J=5.19 Hz, 2H), 3.62
(d, J=4.88 Hz, 2H), 3.46 (d, J=5.19 Hz, 2H), 3.14 (td, J=10.91,
4.12 Hz, 1H), 2.69-2.41 (m, 1H), 2.28-2.12 (m, 2H), 1.74 (s, 3H),
2.03-1.10 (m, 19H), 1.08 (s, 3H), 1.06 (s, 3H), 1.05 (s, 3H), 1.01
(s, 3H), 0.99 (s, 3H).
Example 109
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((3-(1,1-dioxido-4-thiomor-
pholinyl)propyl)carbamoyl)-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-2,3,3a,-
4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]-
chrysen-9-yl)-3-fluorobenzoic acid
##STR00237##
The title compound was prepared following the general procedures
described above for the Suzuki coupling using
2-fluoro-4-(methoxycarbonyl)phenylboronic acid as boronic acid, the
C-28 amide formation and hydrolysis using
4-(3-aminopropyl)thiomorpholine 1,1-dioxide as the reactant amine.
The product was isolated as a white solid (12 mg, 33%). LCMS: m/e
751.39 (M+H).sup.+, 2.08 min (method 1). .sup.1H NMR (500 MHz,
Acetic Acid-d.sub.4) .delta. ppm 7.85 (dd, J=7.93, 1.22 Hz, 1H),
7.77 (dd, J=9.61, 1.37 Hz, 1H), 7.28 (t, J=7.63 Hz, 1H), 5.43 (d,
J=4.88 Hz, 1H), 4.78 (s, 1H), 4.65 (s, 1H), 3.85 (br. s., 4H), 3.59
(br. s., 4H), 3.50-3.40 (m, 1H), 3.40-3.32 (m, 1H), 3.29 (ddd,
J=12.21, 3.51, 3.20 Hz, 2H), 3.15 (td, J=10.91, 4.12 Hz, 1H),
2.69-2.54 (m, 1H), 2.25-2.13 (m, 2H), 1.74 (s, 3H), 2.04-1.10 (m,
21H), 1.08 (s, 6H), 1.06 (s, 3H), 1.00 (s, 3H), 0.96 (s, 3H).
Example 110
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(2-(phenylamino)ethylcarbamoyl)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a-
,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)ben-
zoic acid
##STR00238##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
N1-phenylethane-1,2-diamine as the reactant amine. The product was
isolated as a white solid (1.1 mg, 11%). LCMS: m/e 677.5
(M+H).sup.+, 2.43 min (method 1). .sup.1H NMR (500 MHz, Acetic
Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.24 Hz, 2H), 7.45 (t, J=7.93
Hz, 2H), 7.34 (d, J=7.63 Hz, 2H), 7.32-7.24 (m, 3H), 5.36 (d,
J=4.88 Hz, 1H), 4.78 (s, 1H), 4.64 (s, 1H), 3.75-3.65 (m, 2H), 3.57
(t, J=5.49 Hz, 2H), 3.23-3.10 (m, 1H), 2.56 (td, J=11.90, 3.66 Hz,
1H), 2.24-2.13 (m, 2H), 1.74 (s, 3H), 2.09-1.09 (m, 19H), 1.07 (s,
3H), 1.05 (s, 3H), 1.00 (s, 3H), 1.00 (s, 3H), 0.98 (s, 3H).
Example 111
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((carboxymethyl)(phenyl-
)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a-
,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a-
]chrysen-9-yl)benzoic acid
##STR00239##
The title compound was prepared following the method described
above for the preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(benzyl(carboxymethyl)a-
mino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4-
,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]c-
hrysen-9-yl)benzoic acid (example 89) using
N1-phenylethane-1,2-diamine as amine. The product was isolated as a
white solid (0.9 mg, 9%). LCMS: m/e 735.5 (M+H).sup.+, 1.80 min
(method 1). .sup.1H NMR (500 MHz, Acetic Acid-d.sub.4) .delta. ppm
8.03 (d, J=8.24 Hz, 2H), 7.30 (d, J=8.24 Hz, 2H), 7.26-7.19 (m,
2H), 6.86-6.70 (m, 3H), 5.37 (d, J=4.58 Hz, 1H), 4.77 (s, 1H), 4.63
(s, 1H), 4.22 (s, 2H), 3.82-3.43 (m, 4H), 3.21-3.07 (m, 1H),
2.69-2.53 (m, 1H), 2.23-2.13 (m, 2H), 1.73 (s, 3H), 2.05-1.07 (m,
19H), 1.06 (s, 3H), 1.04 (s, 3H), 1.02 (s, 3H), 1.01 (s, 3H), 0.99
(s, 3H).
Example 112
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((3-(1,1-dioxido-4-thiomor-
pholinyl)propyl)carbamoyl)-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-2,3,3a,-
4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]-
chrysen-9-yl)phthalic acid
##STR00240##
The title compound was prepared following the general procedures
described above for the Suzuki coupling using
3,4-bis(methoxycarbonyl)phenylboronic acid as boronic acid, the
C-28 amide formation and hydrolysis using
4-(3-aminopropyl)thiomorpholine 1,1-dioxide as the reactant amine.
The product was isolated as a white solid (13 mg, 52%). LCMS: m/e
777.43 (M+H).sup.+, 2.34 min (method 1). .sup.1H NMR (500 MHz,
Acetic Acid-d.sub.4) .delta. ppm 7.83 (d, J=7.93 Hz, 1H), 7.61 (d,
J=1.83 Hz, 1H), 7.44 (dd, J=7.78, 1.68 Hz, 1H), 5.48-5.35 (m, 1H),
4.78 (s, 1H), 4.65 (s, 1H), 3.87 (br. s., 4H), 3.62 (br. s., 4H),
3.52-3.43 (m, 2H), 3.31 (d, J=3.97 Hz, 2H), 3.15 (td, J=10.68, 4.88
Hz, 1H), 2.70-2.49 (m, 1H), 2.23-2.13 (m, 2H), 1.74 (s, 3H),
2.03-1.10 (m, 21H), 1.08 (s, 3H), 1.06 (s, 3H), 1.06 (s, 3H), 1.02
(s, 3H), 1.00 (s, 3H).
Example 113
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(dimethylamino)ethylcar-
bamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,-
7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)p-
hthalic acid
##STR00241##
The title compound was prepared following the general procedures
described above for the Suzuki coupling using
3,4-bis(methoxycarbonyl)phenylboronic acid as boronic acid,
followed by the C-28 amide formation and hydrolysis using
N1,N1-dimethylethane-1,2-diamine as the reactant amine. The product
was isolated as a white solid (2.6 mg, 8%). LCMS: m/e 673.37
(M+H).sup.+, 2.39 min (method 1). .sup.1H NMR (500 MHz, Acetic
Acid-d.sub.4) .delta. ppm 7.84 (d, J=7.93 Hz, 1H), 7.61 (d, J=1.22
Hz, 1H), 7.49-7.39 (m, 1H), 5.42 (d, J=4.88 Hz, 1H), 4.78 (s, 1H),
4.65 (s, 1H), 3.75 (t, J=5.80 Hz, 2H), 3.49-3.33 (m, 2H), 3.22-3.07
(m, 1H), 2.96 (s, 6H), 2.64-2.45 (m, 1H), 2.29-2.13 (m, 2H), 1.73
(s, 3H), 2.03-1.10 (m, 19H), 1.08 (s, 3H), 1.06 (s, 3H), 1.05 (s,
3H), 1.02 (s, 3H), 1.00 (s, 3H).
Example 114
Preparation of
4-(2-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-5a,5b,-
8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11-
b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)ethy-
lamino)benzoic acid
##STR00242##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
ethyl 4-(2-aminoethylamino)benzoate as the reactant amine. The
product was isolated as a white solid (3.6 mg, 45%). LCMS: m/e
721.42 (M+H).sup.+, 2.37 min (method 1). .sup.1H NMR (500 MHz,
Acetic Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.24 Hz, 2H), 7.90 (d,
J=8.85 Hz, 2H), 7.29 (d, J=8.24 Hz, 2H), 6.68 (d, J=8.85 Hz, 2H),
5.35 (d, J=4.58 Hz, 1H), 4.78 (d, J=1.53 Hz, 1H), 4.64 (s, 1H),
3.71 (dt, J=13.73, 6.10 Hz, 1H), 3.57-3.46 (m, 1H), 3.44-3.35 (m,
2H), 3.16 (td, J=10.91, 4.12 Hz, 1H), 2.63-2.50 (m, 1H), 2.24-2.13
(m, 2H), 1.72 (s, 3H), 2.05-1.05 (m, 19H), 1.04 (s, 3H), 1.02 (s,
3H), 0.99 (s, 3H), 0.97 (s, 3H), 0.90 (s, 3H).
Example 115
Procedures for the preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((2-(3-carboxypropanoyl-
oxy)ethyl)(methyl)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop--
1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydr-
o-1H-cyclopenta[a]chrysen-9-yl)benzoic acid
##STR00243##
Preparation of
2-((2-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-(tert-butoxycarbonyl-
)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7-
,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-c-
arboxamido)ethyl)(methyl)amino)ethyl tert-butyl succinate.
Intermediate 40
##STR00244##
A mixture of tert-butyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((2-hydroxyethyl)(methy-
l)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3-
a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[-
a]chrysen-9-yl)benzoate (40 mg, 0.056 mmol), tert-butyl methyl
succinate (21.06 mg, 0.112 mmol), Hunig'sBase (0.049 mL, 0.280
mmol) and EDC (21.45 mg, 0.112 mmol) in dichloromethane (1 mL) was
stirred at 20.degree. C. for 12 hours. LCMS indicated the formation
of desired product. The reaction mixture was quenched with
distilled water, extracted with DCM (3.times.4 mL). All the
extracts were combined, dried over sodium sulfate, filtered and
concentrated under reduced pressure to provide the crude including
the title compound as a white solid (40 mg, 82%). LCMS: m/e 871.43
(M+H).sup.+, 3.93 min (method 1).
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-((2-(3-carboxypropanoyl-
oxy)ethyl)(methyl)amino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop--
1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydr-
o-1H-cyclopenta[a]chrysen-9-yl)benzoic acid
##STR00245##
To a solution of
2-((2-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-(tert-butoxycarbonyl-
)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7-
,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-c-
arboxamido)ethyl)(methyl)amino)ethyl tert-butyl succinate (40 mg,
0.046 mmol) in dioxane (1 mL) was added 4N HCl (0.115 mL, 0.459
mmol). The reaction mixture was stirred at 20.degree. C. for 3
hours. LCMS indicated the formation of desired product. The
reaction mixture was neutralized with 1N NaOH and then filtered.
The clear solution was purified by prep HPLC to provide the desired
product as colourless oil (7.2 mg, 20%). LCMS: m/e 759.34
(M+H).sup.+, 2.37 min (method 1). .sup.1H NMR (400 MHz, Acetic
Acid-d.sub.4) .delta. ppm 7.99 (d, J=8.28 Hz, 2H), 7.26 (d, J=8.53
Hz, 2H), 5.33 (d, J=4.77 Hz, 1H), 4.74 (s, 1H), 4.61 (s, 1H),
4.56-4.44 (m, 2H), 3.90-3.65 (m, 2H), 3.62-3.52 (m, 2H), 3.50-3.38
(m, 2H), 3.19-3.05 (m, 1H), 3.01 (s, 3H), 2.72 (s, 4H), 2.58-2.42
(m, 1H), 2.26-2.11 (m, 2H), 1.69 (s, 3H), 1.96-1.07 (m, 19H), 1.04
(s, 3H), 1.02 (s, 3H), 1.02 (s, 3H), 0.97 (s, 3H), 0.95 (s,
3H).
Example 116
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-(1,1-dioxido-4-thiomor-
pholinyl)ethyl)carbamoyl)-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-2,3,3a,4-
,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]c-
hrysen-9-yl)-2-fluorobenzoic acid
##STR00246##
The title compound was prepared following the general procedures
described above for the Suzuki coupling using
3-fluoro-4-(methoxycarbonyl)phenylboronic acid as boronic acid, the
C-28 amide formation and hydrolysis using
N-(2-aminoethyl)thiomorpholine 1,1-dioxide as the reactant amine.
The product was isolated as a white solid (23 mg, 56%). LCMS: m/e
737.36 (M+H).sup.+, 2.37 min (method 1). .sup.1H NMR (500 MHz,
Acetic Acid-d.sub.4) .delta. ppm 7.96 (t, J=7.93 Hz, 1H), 7.08 (dd,
J=8.09, 1.37 Hz, 1H), 7.02 (d, J=11.90 Hz, 1H), 5.42 (d, J=4.58 Hz,
1H), 4.78 (d, J=1.53 Hz, 1H), 4.65 (s, 1H), 3.83 (br. s., 4H),
3.80-3.67 (m, 2H), 3.57 (br. s., 4H), 3.43-3.34 (m, 2H), 3.14 (td,
J=10.76, 4.43 Hz, 1H), 2.62-2.46 (m, 1H), 2.26-2.12 (m, 2H), 1.74
(s, 3H), 2.02-1.09 (m, 19H), 1.08 (s, 3H), 1.05 (s, 3H), 1.04 (s,
3H), 1.02 (s, 3H), 1.00 (s, 3H).
Example 117
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(4,4-difluoropiperidin--
1-yl)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4-
,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]c-
hrysen-9-yl)-2-fluorobenzoic acid
##STR00247##
The title compound was prepared following the general procedures
described above for the Suzuki coupling using
3-fluoro-4-(methoxycarbonyl)phenylboronic acid as boronic acid,
followed by the C-28 amide formation and hydrolysis using
2-(4,4-difluoropiperidin-1-yl)ethanamine as the reactant amine. The
product was isolated as a white solid (10 mg, 24%). LCMS: m/e
723.39 (M+H).sup.+, 2.46 min (method 1). .sup.1H NMR (500 MHz,
Acetic Acid-d.sub.4) .delta. ppm 7.96 (t, J=7.78 Hz, 1H), 7.08 (dd,
J=8.09, 1.37 Hz, 1H), 7.02 (d, J=11.60 Hz, 1H), 5.50-5.32 (m, 1H),
4.77 (d, J=1.83 Hz, 1H), 4.65 (s, 1H), 3.90-3.69 (m, 2H), 3.55 (br.
s., 4H), 3.47-3.36 (m, 2H), 3.13 (td, J=10.91, 4.12 Hz, 1H),
2.59-2.48 (m, 1H), 2.42 (br. s., 4H), 2.25-2.13 (m, 2H), 1.73 (s,
3H), 2.05-1.08 (m, 19H), 1.07 (s, 3H), 1.05 (s, 3H), 1.04 (s, 3H),
1.02 (s, 3H), 1.00 (s, 3H).
Example 118
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(4,4-difluoropiperidin--
1-yl)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4-
,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]c-
hrysen-9-yl)benzoic acid
##STR00248##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
2-(4,4-difluoropiperidin-1-yl)ethanamine as the reactant amine. The
product was isolated as a white solid (40 mg, 78%). LCMS: m/e
705.42 (M+H).sup.+, 2.53 min (method 1). .sup.1H NMR (500 MHz,
Acetic Acid-d.sub.4) .delta. ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d,
J=8.24 Hz, 2H), 5.43-5.30 (m, 1H), 4.77 (d, J=1.83 Hz, 1H), 4.65
(s, 1H), 3.78 (dt, J=16.17, 6.26 Hz, 2H), 3.55 (br. s., 4H),
3.47-3.35 (m, 2H), 3.13 (td, J=10.76, 4.12 Hz, 1H), 2.61-2.48 (m,
1H), 2.42 (br. s., 4H), 2.26-2.12 (m, 2H), 1.74 (s, 3H), 2.00-1.09
(m, 19H), 1.08 (s, 3H), 1.06 (s, 3H), 1.04 (s, 3H), 1.00 (s, 3H),
0.99 (s, 3H).
Example 119
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(4,4-difluoropiperidin--
1-yl)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4-
,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]c-
hrysen-9-yl)-3-fluorobenzoic acid
##STR00249##
The title compound was prepared following the general procedures
described above for the Suzuki coupling using
2-fluoro-4-(methoxycarbonyl)phenylboronic acid as boronic acid, the
C-28 amide formation using 2-(4,4-difluoropiperidin-1-yl)ethanamine
as the reactant amine and hydrolysis. The product was isolated as a
white solid (21 mg, 51%). LCMS: m/e 723.43 (M+H).sup.+, 2.48 min
(method 1). .sup.1H NMR (500 MHz, Acetic Acid-d.sub.4) .delta. ppm
7.85 (dd, J=7.93, 1.53 Hz, 1H), 7.77 (dd, J=9.77, 1.53 Hz, 1H),
7.28 (t, J=7.48 Hz, 1H), 5.43 (d, J=4.58 Hz, 1H), 4.78 (d, J=1.53
Hz, 1H), 4.65 (s, 1H), 3.91-3.68 (m, 2H), 3.54 (br. s., 4H),
3.48-3.35 (m, 2H), 3.14 (td, J=10.91, 4.12 Hz, 1H), 2.53 (td,
J=12.21, 3.05 Hz, 1H), 2.48-2.35 (m, 4H), 2.24-2.12 (m, 2H), 1.74
(s, 3H), 2.01-1.10 (m, 19H), 1.08 (s, 6H), 1.04 (s, 3H), 1.00 (s,
3H), 0.96 (s, 3H).
Example 120
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-(1,1-dioxido-4-thiomor-
pholinyl)ethyl)carbamoyl)-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-2,3,3a,4-
,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]c-
hrysen-9-yl)-3-fluorobenzoic acid
##STR00250##
The title compound was prepared following the general procedures
described above for the Suzuki coupling using
2-fluoro-4-(methoxycarbonyl)phenylboronic acid as boronic acid, the
C-28 amide formation using N-(2-aminoethyl)thiomorpholine
1,1-dioxide as the reactant amine and hydrolysis. The product was
isolated as a white solid (22 mg, 47%). LCMS: m/e 737.34
(M+H).sup.+, 2.37 min (method 1). .sup.1H NMR (500 MHz, Acetic
Acid-d.sub.4) .delta. ppm 7.85 (dd, J=7.78, 1.37 Hz, 1H), 7.80-7.73
(m, 1H), 7.28 (t, J=7.48 Hz, 1H), 5.43 (d, J=4.58 Hz, 1H), 4.78 (s,
1H), 4.65 (s, 1H), 3.83 (br. s., 4H), 3.80-3.66 (m, 2H), 3.56 (br.
s., 4H), 3.47-3.33 (m, 2H), 3.14 (td, J=10.83, 4.27 Hz, 1H),
2.63-2.48 (m, 1H), 2.30-2.13 (m, 2H), 1.74 (s, 3H), 2.03-1.11 (m,
19H), 1.08 (s, 6H), 1.04 (s, 3H), 1.00 (s, 3H), 0.96 (s, 3H).
Example 121
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-(1,1-dioxido-4-thiomor-
pholinyl)ethyl)carbamoyl)-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-2,3,3a,4-
,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]c-
hrysen-9-yl)-2,6-difluorobenzoic acid
##STR00251##
The title compound was prepared following the general procedures
described above for the Suzuki coupling using
3,5-difluoro-4-(methoxycarbonyl)phenylboronic acid as boronic acid,
the C-28 amide formation using N-(2-aminoethyl)thiomorpholine
1,1-dioxide as the reactant amine and hydrolysis. The product was
isolated as a white solid (22 mg, 53%). LCMS: m/e 755.40
(M+H).sup.+, 2.32 min (method 1). .sup.1H NMR (500 MHz, Acetic
Acid-d.sub.4) .delta. ppm 6.87 (d, J=9.16 Hz, 2H), 5.57-5.35 (m,
1H), 4.77 (s, 1H), 4.65 (s, 1H), 3.84 (br. s., 4H), 3.80-3.65 (m,
2H), 3.57 (br. s., 4H), 3.46-3.33 (m, 2H), 3.22-3.04 (m, 1H), 2.54
(td, J=12.36, 3.36 Hz, 1H), 2.25-2.11 (m, 2H), 1.73 (s, 3H),
2.00-1.10 (m, 19H), 1.07 (s, 3H), 1.04 (s, 3H), 1.03 (s, 3H), 1.03
(s, 3H), 1.00 (s, 3H).
Example 122
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-(dimethylamino)ethylcar-
bamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,-
7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)--
2,6-difluorobenzoic acid
##STR00252##
The title compound was prepared following the general procedures
described above for the Suzuki coupling using
3,5-difluoro-4-(methoxycarbonyl)phenylboronic acid as boronic acid,
the C-28 amide formation using N1,N1-dimethylethane-1,2-diamine as
the reactant amine and hydrolysis. The product was isolated as a
white solid (6 mg, 17%). LCMS: m/e 665.42 (M+H).sup.+, 2.39 min
(method 1). .sup.1H NMR (500 MHz, Acetic Acid-d.sub.4) .delta. ppm
6.87 (d, J=9.46 Hz, 2H), 5.45 (d, J=4.58 Hz, 1H), 4.78 (d, J=1.83
Hz, 1H), 4.64 (s, 1H), 3.82-3.69 (m, 2H), 3.50-3.34 (m, 2H),
3.22-3.08 (m, 1H), 2.96 (s, 6H), 2.54 (td, J=12.21, 3.36 Hz, 1H),
2.26-2.15 (m, 2H), 1.73 (s, 3H), 2.02-1.09 (m, 19H), 1.07 (s, 3H),
1.04 (s, 3H), 1.03 (s, 3H), 1.03 (s, 3H), 1.00 (s, 3H).
Example 123
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((3-(1,1-dioxido-4-thiomor-
pholinyl)propyl)carbamoyl)-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-2,3,3a,-
4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]-
chrysen-9-yl)-2,6-difluorobenzoic acid
##STR00253##
The title compound was prepared following the general procedures
described above for the Suzuki coupling using
3,5-difluoro-4-(methoxycarbonyl)phenylboronic acid as boronic acid,
the C-28 amide formation using 4-(3-aminopropyl)thiomorpholine
1,1-dioxide as the reactant amine and hydrolysis. The product was
isolated as a white solid (13 mg, 31%). LCMS: m/e 769.46
(M+H).sup.+, 2.34 min (method 1). .sup.1H NMR (500 MHz, Acetic
Acid-d.sub.4) .delta. ppm 6.87 (d, J=9.46 Hz, 2H), 5.45 (d, J=4.58
Hz, 1H), 4.78 (d, J=1.83 Hz, 1H), 4.65 (s, 1H), 3.85 (br. s., 4H),
3.57 (br. s., 4H), 3.50-3.33 (m, 2H), 3.29 (dd, J=9.00, 4.12 Hz,
2H), 3.15 (td, J=10.99, 4.27 Hz, 1H), 2.60 (td, J=12.28, 3.20 Hz,
1H), 2.29-2.12 (m, 2H), 1.74 (s, 3H), 2.04-1.09 (m, 21H), 1.07 (s,
3H), 1.05 (s, 3H), 1.04 (s, 3H), 1.03 (s, 3H), 1.00 (s, 3H).
Example 124
Preparation of
4-((1S,3aS,5aR,5bR,7aS,9S,11aS,11bR,13aR,13bR)-3a-(2-carboxyethylcarbamoy-
l)-1-isopropyl-5a,5b,8,8,11a-pentamethylicosahydro-1H-cyclopenta[a]chrysen-
-9-yl)benzoic acid
##STR00254##
Preparation of 2-(trimethylsilyl)ethyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(3-oxo-3-(2-(trimethylsilyl)ethoxy)propylcarbamoyl)-1-(prop-1-en-2-yl)-2,3-
,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopent-
a[a]chrysen-9-yl)benzoate. Intermediate 41
##STR00255##
A mixture of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-carboxyethylcarbamoyl)--
5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,-
11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic
acid (35 mg, 0.056 mmol) and (Z)-2-(trimethylsilyl)ethyl
N,N'-diisopropylcarbamimidate (27.2 mg, 0.111 mmol) was refluxed in
THF (1 mL) for 4 h. Then the mixture was placed at room temperature
for 16 h. TLC showed no starting material and a new less polar
product Rf=0.4 in 10% AcOEt/Hex. The solvent was removed in vacuo.
The residue was dissolved in methylene chloride and purified in
silica gel (0-10% AcOEt/Hex) to afford 2-(trimethylsilyl)ethyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(3-oxo-3-(2-(trimethylsilyl)ethoxy)propylcarbamoyl)-1-(prop-1-en-2-yl)-2,3-
,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopent-
a[a]chrysen-9-yl)benzoate (43 mg, 0.049 mmol, 89% yield) as a white
solid. .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 7.93 (d,
J=8.28 Hz, 2H), 7.20 (d, J=8.03 Hz, 2H), 6.24 (t, J=6.02 Hz, 1H),
5.30 (d, J=4.77 Hz, 1H), 4.76 (d, J=1.51 Hz, 1H), 4.61 (s, 1H),
4.49-4.37 (m, 2H), 4.28-4.17 (m, 2H), 3.65-3.52 (m, 1H), 3.52-3.39
(m, 1H), 3.15 (td, J=10.85, 3.64 Hz, 1H), 2.63-2.43 (m, 3H), 2.11
(dd, J=17.19, 6.40 Hz, 1H), 2.02-1.90 (m, 2H), 1.80-1.04 (m, 22H),
1.70 (s, 3H), 1.01 (s, 3H), 1.00 (s, 3H), 0.98 (s, 3H), 0.93 (s,
6H), 0.10 (s, 9H), 0.06 (s, 9H).
Preparation of 2-(trimethylsilyl)ethyl
4-((1S,3aS,5aR,5bR,7aS,9S,11aS,11bR,13aR,13bR)-1-isopropyl-5a,5b,8,8,11a--
pentamethyl-3a-(3-oxo-3-(2-(trimethylsilyl)ethoxy)propylcarbamoyl)icosahyd-
ro-1H-cyclopenta[a]chrysen-9-yl)benzoate. Intermediate 42
##STR00256##
2-(trimethylsilyl)ethyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a--
(3-oxo-3-(2-(trimethylsilyl)ethoxy)propylcarbamoyl)-1-(prop-1-en-2-yl)-2,3-
,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopent-
a[a]chrysen-9-yl)benzoate (15 mg, 0.018 mmol) was dissolved in a
mixture of ethyl acetate and methanol (2 ml, 1:1) and treated with
palladium (10% in carbon, 1 mg, 9.40 mmol) and a balloon with
hydrogen. The mixture was stirred at rt for 3 h. The solvent was
removed in vacuo and the residue was dissolved in methylene
chloride and filtered through a fine pad of celite. The solvent was
removed in vacuo and the crude was purified in silica gel to afford
2-(trimethylsilyl)ethyl
4-((1S,3aS,5aR,5bR,7aS,11aS,11bR,13aR,13bR)-1-isopropyl-5a,5b,8,8,11a-pen-
tamethyl-3a-(3-oxo-3-(2-(trimethylsilyl)ethoxy)propylcarbamoyl)icosahydro--
1H-cyclopenta[a]chrysen-9-yl) (12 mg, 80%) as a clear oil. .sup.1H
NMR (400 MHz, CHLOROFORM-d) .delta. ppm 7.92 (d, J=8.28 Hz, 2H),
7.23 (d, J=8.53 Hz, 2H), 6.22 (t, J=6.15 Hz, 1H), 4.50-4.36 (m,
2H), 4.24-4.16 (m, 2H), 3.51 (td, J=11.48, 6.40 Hz, 2H), 2.59-2.49
(m, 2H), 2.40 (dd, J=12.92, 2.89 Hz, 2H), 2.35-2.24 (m, 1H),
2.18-2.04 (m, 1H), 2.03-1.95 (m, 1H), 1.89-0.91 (m, 26H), 0.99 (s,
3H), 0.96 (s, 6H), 0.88 (d, J=7.03 Hz, 3H), 0.77 (d, J=7.03 Hz,
3H), 0.76 (s, 3H), 0.70 (s, 3H), 0.09 (s, 9H), 0.06 (s, 9H).
Preparation of
4-((1S,3aS,5aR,5bR,7aS,9S,11aS,11bR,13aR,13bR)-3a-(2-carboxyethylcarbamoy-
l)-1-isopropyl-5a,5b,8,8,11a-pentamethylicosahydro-1H-cyclopenta[a]chrysen-
-9-yl)benzoic acid
##STR00257##
2-(trimethylsilyl)ethyl
4-((1S,3aS,5aR,5bR,7aS,11aS,11bR,13aR,13bR)-1-isopropyl-5a,5b,8,8,11a-pen-
tamethyl-3a-(3-oxo-3-(2-(trimethylsilyl)ethoxy)propylcarbamoyl)icosahydro--
1H-cyclopenta[a]chrysen-9-yl)benzoate (14 mg, 0.017 mmol) was
dissolved in THF (Volume: 0.5 mL) and treated with TBAF (0.5 mL,
0.500 mmol). The mixture was stirred at rt for 1 h. The solvent was
removed in vacuo and the residue was dissolved in DMF and purified
using reverse phase prep HPLC to afford
4-((1S,3aS,5aR,5bR,7aS,11aS,11bR,13aR,13bR)-3a-(2-carboxyethylcarbamoyl)--
1-isopropyl-5a,5b,8,8,11a-pentamethylicosahydro-1H-cyclopenta[a]chrysen-9--
yl)benzoic acid (6 mg, 8.99 mmol, 53.6% yield) as a white solid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 7.82 (d, J=8.28 Hz,
2H), 7.56 (t, J=5.52 Hz, 1H), 7.29 (d, J=8.28 Hz, 2H), 3.37-3.11
(m, 2H), 2.65-2.56 (m, 1H), 2.47-2.39 (m, 1H), 2.39-2.31 (m, 2H),
2.28-2.18 (m, 1H), 2.18-2.08 (m, 2H), 1.84-0.97 (m, 22H), 0.94 (s,
6H), 0.91 (s, 3H), 0.83 (d, J=6.78 Hz, 3H), 0.74 (d, J=6.78 Hz,
3H), 0.72 (s, 3H), 0.67 (s, 3H).
Example 125
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(2-aminoethylcarbamoyl)-5a-
,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11-
a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic
acid
##STR00258##
The title compound was prepared following the general procedures
described above for the C-28 amide formation and hydrolysis using
ethane-1,2-diamine as the reactant amine. The product was isolated
as a white solid (40 mg, 63%). LCMS: m/e 601.41 (M+H).sup.+, 2.18
min (method 1). .sup.1H NMR (500 MHz, Acetic Acid-d.sub.4) .delta.
ppm 8.03 (d, J=8.24 Hz, 2H), 7.30 (d, J=8.24 Hz, 2H), 5.47-5.29 (m,
1H), 4.78 (s, 1H), 4.65 (s, 1H), 3.80-3.54 (m, 2H), 3.27 (td,
J=5.87, 2.29 Hz, 2H), 3.21-3.10 (m, 1H), 2.70-2.51 (m, 1H),
2.27-2.15 (m, 2H), 1.74 (s, 3H), 2.12-1.09 (m, 19H), 1.08 (s, 3H),
1.07 (s, 3H), 1.05 (s, 3H), 1.01 (s, 3H), 0.99 (s, 3H).
Example 126
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(furan-3-ylmethylcarbamoyl-
)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,1-
1,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic
acid
##STR00259##
The title compound was prepared following the method described
above for the general procedure for C-28 amide formation and
hydrolysis using furan-3-ylmethanamine as the reactant amine. The
product was isolated as a tan solid (38 mg, 67%). LCMS: m/e 636.5
(M-H).sup.-, 2.52 min (method 4). .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 7.98 (d, J=8.24 Hz, 2H), 7.37-7.39 (m,
2H), 7.22 (d, J=8.24 Hz, 2H), 6.36 (s, 1H), 5.76 (t, J=5.65 Hz,
1H), 5.29 (d, J=4.58 Hz, 1H), 4.75 (d, J=1.83 Hz, 1H), 4.60 (s,
1H), 4.35 (dd, J=14.95, 5.80 Hz, 1H), 4.20 (dd, J=14.80, 5.34 Hz,
1H), 3.17 (td, J=11.06, 4.43 Hz, 1H), 2.49-2.56 (m, 1H), 1.69 (s,
3H), 0.99 (s, 3H), 0.97 (s, 3H), 0.96 (s, 3H), 0.95-2.14 (m, 21H),
0.93 (s, 3H), 0.92 (s, 3H).
Example 127
Preparation of
1-(3-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-5a,5b,-
8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11-
b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)prop-
anoyl)pyrrolidine-2-carboxylic acid
##STR00260##
To a solution of
3-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-(methoxycarbonyl)phenyl)-
-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11-
,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxami-
do)propanoic acid (intermediate 8) (0.06 g, 0.093 mmol) in DCE (2
mL) was added DIEA (0.049 mL, 0.280 mmol),
O-Benzotriazol-1-yl-N,N,N',N'-tetra-methyluronium tetrafluoroborate
(0.045 g, 0.140 mmol), and methyl pyrrolidine-2-carboxylate (0.014
g, 0.112 mmol). The mixture was stirred at rt for 15.5 h, then was
diluted with 7 mL of water and was extracted with dichloromethane
(3.times.7 mL). The combined organic layers were dried with
Na.sub.2SO.sub.4. The drying agent was removed by filtration and
the filtrate was concentrated under reduced pressure. The residue
was purified by Biotage flash chromatography using a 0-75% EtOAc in
hexanes gradient. The fractions containing the expected product
were combined and concentrated under reduced pressure to give
methyl
1-(3-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-(methoxycarbonyl)phen-
yl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8-
,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carbox-
amido)propanoyl)pyrrolidine-2-carboxylate (63 mg, 0.083 mmol, 90%
yield) as a white foam. LCMS: m/e 753.5 (M-H).sup.-, 3.09 min
(method 4).
To a solution of methyl
1-(3-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-(methoxycarbonyl)phen-
yl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8-
,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carbox-
amido)propanoyl)pyrrolidine-2-carboxylate (63 mg, 0.083 mmol) in
Dioxane (2 mL) was added NaOH (1N) (0.417 mL, 0.417 mmol). The
mixture was heated to 85.degree. C. for 15 h, then cooled to rt and
was diluted with 5 mL of 1N HCl and was extracted with
dichloromethane (4.times.5 mL). The combined organic layers were
dried with Na.sub.2SO.sub.4, the drying agent was removed by
filtration, and the filtrate was concentrated under reduced
pressure. The residue was purified by Biotage flash chromatography
using a 0-10% MeOH in DCM gradient with 0.1% HOAc then by prep
HPLC. The fractions containing the expected product were combined
and concentrated under reduced pressure to give
1-(3-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-5a,5b,-
8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11-
b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxamido)prop-
anoyl)pyrrolidine-2-carboxylic acid (27.3 mg, 0.038 mmol, 45.0%
yield) as a white solid. LCMS: m/e 726.4 (M-H).sup.-, 2.36 min
(method 4). .sup.1H NMR (500 MHz, Acetic) .delta. ppm 8.03 (d,
J=8.24 Hz, 2H), 7.30 (d, J=8.24 Hz, 2H), 5.37 (d, J=4.58 Hz, 1H),
4.78 (s, 1H), 4.64 (s, 1H), 4.57 (dd, J=8.70, 3.51 Hz, 1H),
3.52-3.75 (m, 4H), 3.09-3.20 (m, J=18.43, 11.08, 11.08, 4.27 Hz,
1H), 2.68-2.82 (m, 2H), 2.58 (td, J=12.36, 3.05 Hz, 1H), 1.73 (s,
3H), 1.07 (s, 6H), 1.05 (s, 3H), 1.03-2.53 (m, 25H), 1.01 (s, 3H),
0.99 (s, 3H).
Example 128
Preparation of
1-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-carboxyphenyl)-5a,5b,8,8-
,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,1-
2,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carbonyl)pyrrolidin-
e-2-carboxylic acid
##STR00261##
The title compound was prepared following the method described
above for the general procedure for C-28 amide formation and
hydrolysis using methylpyrrolidine-2-carboxylate as the reactant
amine. The product was isolated as a white solid (19 mg, 23%).
LCMS: m/e 654.4 (M-H).sup.-, 2.47 min (method 4).
Preparation of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(isopentylcarbamoyl)-5a,5b-
,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,1-
1b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoate.
Intermediate 43
##STR00262##
To a solution of
(1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-(methoxycarbonyl)phenyl)-5a-
,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11-
a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxylic
acid (358.0 mg, 0.625 mmol) in THF (10 mL) was added
N,N-diisopropylamine (0.327 mL, 1.875 mmol), isoamylamine (0.110
mL, 0.937 mmol) and HATU (356 mg, 0.937 mmol). The reaction mixture
was stirred at 25.degree. C. After 16 h, the reaction mixture was
diluted with EtOAc (50 mL), washed with 1N HCl (5 mL), 5%
NaHCO.sub.3, brine, dried over MgSO.sub.4, filtered and
concentrated to a foam product. The residue was absorpted on to 4 g
of silica gel, loaded on to a silica gel column (40 g cartridge)
and eluted with 0% B to 50% B for 240 mL then 50% B (solvent:
A=hexanes, B=5:1 hex:EtOAc) to afford the title compound as a white
solid (229 mg, 0.342 mmol, 54.8% yield). LCMS: m/e 642.6
(M-H).sup.+, 3.24 min (method 5); .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 7.9 (2H, m, J=8.2 Hz), 7.2 (2H, m, J=8.5
Hz), 5.6 (1H, t, J=5.6 Hz), 5.3 (1H, dd, J=6.3, 2.0 Hz), 4.8 (1H,
d, J=2.1 Hz), 4.6-4.6 (1H, m), 3.9 (3H, s), 3.3-3.4 (1H, m),
3.2-3.3 (2H, m), 2.5-2.6 (1H, m), 2.1 (1H, dd, J=17.1, 6.4 Hz),
2.0-2.1 (1H, m), 1.9-2.0 (1H, m), 1.8 (2H, dd, J=11.7, 7.5 Hz), 1.7
(3H, s), 1.6-1.7 (2H, m), 1.6 (1H, s), 1.6 (1H, dd, J=13.3, 2.6
Hz), 1.4-1.5 (11H, m), 1.2-1.3 (2H, m), 1.1 (1H, dd, J=12.5, 4.6
Hz), 1.0 (6H, s), 1.0 (3H, s), 1.0 (3H, s), 0.9 (3H, s), 0.9 (6H,
d, J=2.4 Hz); .sup.13C NMR(CHLOROFORM-d) .delta. ppm 14.4, 15.6,
16.2, 19.3, 19.5, 20.7, 21.1, 22.2, 22.3, 25.5, 25.7, 29.2, 30.6,
33.4, 33.6, 36.0, 37.2, 37.7, 38.2, 38.5, 40.3, 41.5, 42.2, 46.5,
49.3, 49.9, 51.7, 52.6, 55.4, 65.6, 109.0, 123.9, 127.6, 128.2,
129.8, 145.9, 148.5, 150.8, 167.0, 175.6.
Example 129
Preparation of
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(isopentylcarbamoyl)-5a,5b-
,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,1-
1b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic
acid
##STR00263##
To a solution of methyl
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(isopentylcarbamoyl)-5a,5b-
,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,1-
1b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoate
(0.204 g, 0.318 mmol) in THF (5 mL) was added a solution of lithium
hydroxide monohydrate (0.040 g, 0.953 mmol) in H.sub.2O (1.000 mL).
The resulting white slurry was stirred at rt overnight. After 15 h,
TLC showed significant starting material left thus reaction was
heated to 75.degree. C. for 3 h. Reaction was treated with 1N HCl
(1 mL) and concentrated to dryness. Material was absorpted onto
silica gel, loaded onto a silica gel column (12 g cartridge) and
was eluted with 0% B to 100% B for 180 mL and held 100% B for 600
mL (Solvents: A=100% DCM, B=90:10 DCM:MeOH). Obtained
4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(isopentylcarbamoyl)-5a,5b-
,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,1-
1b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic
acid (182 mg, 0.281 mmol, 88% yield) as white solid. LCMS: m/e
628.6 (M-H).sup.+, 2.45 min (method 5); .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. ppm 8.0 (2H, d, J=8.2 Hz), 7.3 (2H, d, J=8.5
Hz), 5.6 (1H, t, J=5.6 Hz), 5.3 (1H, dd, J=6.1, 1.8 Hz), 4.8 (1H,
d, J=2.1 Hz), 4.6-4.6 (1H, m), 3.3-3.4 (1H, m), 3.2-3.3 (2H, m),
2.5-2.6 (1H, m), 2.1 (1H, dd, J=17.4, 6.4 Hz), 1.9-2.1 (2H, m),
1.7-1.8 (2H, m), 1.7 (3H, s), 1.6-1.7 (3H, m), 1.3-1.6 (11H, m),
1.2-1.3 (2H, m), 1.0 (6H, s), 1.0 (3H, s), 1.0 (6H, s), 0.9-1.0
(6H, m) .sup.13C NMR(CHLOROFORM-d) .delta. ppm 14.4, 15.6, 16.2,
19.3, 19.5, 20.8, 21.1, 22.2, 22.3, 25.5, 25.7, 29.2, 30.7, 33.4,
33.6, 36.0, 37.2, 37.7, 38.2, 38.5, 40.4, 41.5, 42.2, 46.5, 49.3,
49.9, 52.6, 55.4, 77.3, 109.0, 124.0, 126.7, 128.9, 129.9, 145.9,
149.4, 150.8, 171.1, 175.7.
Example 130
Preparation of
(4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-(1,1-dioxidothiomorph-
olino)ethyl)carbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a-
,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a-
]chrysen-9-yl)phenyl)boronic acid, TFA
##STR00264##
Step 1: To a solution of
(1R,3aS,5aR,5bR,7aR,11aR,11bR,13aR,13bR)-benzyl
5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-9-(((trifluoromethyl)sulfony-
l)oxy)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-
-cyclopenta[a]chrysene-3a-carboxylate (3.0 g, 4.43 mmol) in THF
(100 mL) was added 1,4-benzenediboronic acid (1.469 g, 8.86 mmol)
and tetrakis(triphenylphosphine)palladium(0) (0.259 g, 0.222 mmol).
The resulting yellow mixture was purged with N.sub.2. Then, a
solution of sodium carbonate (2.82 g, 26.6 mmol) in H.sub.2O (25.00
mL) was added and the reaction mixture was heated to reflux at
90.degree. C. After 6 h, the reaction mixture was cooled to rt,
diluted with EtOAc (50 mL) and washed with H.sub.2O (50 mL). The
aqueous layer was extracted with EtOAc (2.times.50 mL). The
combined organic layer was filtered through celite pad, washed with
brine, dried over MgSO.sub.4, filtered and concentrated to afford a
light brown solid. The crude material was absorbed onto silica gel
(20 g), loaded onto a silica gel column and eluted with 3:1
hexanes:EtOAc to give
(4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((benzyloxy)carbonyl)-5a,-
5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a-
,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)phenyl)boron-
ic acid (983 mg, 34.2%) as a white solid. .sup.1H NMR (500 MHz,
CHLOROFORM-d) .delta. 8.18-8.14 (m, 2H), 7.43-7.38 (m, 4H),
7.38-7.35 (m, 1H), 7.31-7.29 (m, 1H), 5.37-5.34 (m, 1H), 5.17 (t,
J=1.0 Hz, 2H), 4.77 (d, J=1.5 Hz, 1H), 4.64 (s, 1H), 3.08 (td,
J=10.8, 4.7 Hz, 1H), 2.35-2.30 (m, 1H), 2.30-2.25 (m, 1H), 2.15
(dd, J=17.1, 6.1 Hz, 1H), 1.98-1.89 (m, 2H), 1.73 (s, 3H), 1.69 (d,
J=3.7 Hz, 1H), 1.67-1.64 (m, 1H), 1.56-1.37 (m, 10H), 1.37-1.23 (m,
3H), 1.19 (d, J=13.1 Hz, 1H), 1.07 (dd, J=13.1, 4.3 Hz, 1H), 1.02
(s, 6H), 0.99 (br. s., 3H), 0.99 (br. s., 3H), 0.96-0.93 (m, 1H),
0.87 (s, 3H). .sup.13C NMR (126 MHz, CHLOROFORM-d) .delta. 175.8,
150.6, 148.41-148.39 (m, 1C), 148.3, 146.8, 136.5, 134.6, 129.7,
128.5, 128.2, 128.1, 123.7, 109.6, 65.7, 56.6, 52.9, 49.6, 49.4,
46.9, 42.4, 41.8, 40.5, 38.4, 37.5, 37.0, 36.3, 33.6, 32.1, 30.6,
29.6, 29.5, 25.7, 21.3, 21.1, 19.8, 19.4, 16.5, 15.6, 14.7.
Step 2: A -78.degree. C. solution of
(4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((benzyloxy)carbonyl)-5a,-
5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a-
,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)phenyl)boron-
ic acid (0.200 g, 0.308 mmol) in DCM (3 mL) was purged with
N.sub.2(g). Boron tribromide (1M solution in DCM) (1.079 mL, 1.079
mmol) was added dropwise. The resulting yellow reaction mixture was
stirred at -78.degree. C. for 1 h. The cold bath was removed and
H.sub.2O (5 mL) was added to quench the reaction. The resulting
white paste was filtered and washed with H.sub.2O. The crude
material was dissolved in THF and DCM loaded onto a silica gel
column and eluted with 1:1 hexanes:EtOAc to give 93 mg crude
material which was further purified by reverse phase HPLC to give
(1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-boronophenyl)-5a,5b,8,-
8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,-
12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxylic
acid (45.2 mg, 24.15%) as a white solid. .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. 12.09 (br. s., 1H), 7.97 (br. s., 2H), 7.68
(d, J=7.9 Hz, 2H), 7.04 (d, J=7.9 Hz, 2H), 5.18 (d, J=4.6 Hz, 1H),
4.70 (s, 1H), 4.57 (s, 1H), 3.02-2.90 (m, 1H), 2.33-2.23 (m, 1H),
2.12 (d, J=6.4 Hz, 1H), 2.05 (dd, J=17.2, 6.3 Hz, 1H), 1.80 (d,
J=7.3 Hz, 2H), 1.69-1.66 (m, 1H), 1.65 (s, 3H), 1.56 (t, J=11.3 Hz,
1H), 1.50 (br. s., 1H), 1.45-1.36 (m, 8H), 1.33-1.28 (m, 1H), 1.23
(br. s., 1H), 1.21-1.12 (m, 3H), 1.02-0.98 (m, 1H), 0.97 (s, 3H),
0.93 (s, 6H), 0.87 (s, 3H), 0.86 (s, 3H).
Step 3: To a solution of
(1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-boronophenyl)-5a,5b,8,8,11a-
-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13-
,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxylic acid
(104 mg, 0.186 mmol) in THF (3 mL) was added
N,N-diisopropylethylamine (0.162 mL, 0.931 mmol),
4-(2-aminoethyl)thiomorpholine 1,1-dioxide (46.5 mg, 0.261 mmol)
and
2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium
hexafluorophosphate(V) (106 mg, 0.279 mmol). The resulting creamy
mixture was stirred at rt. After two weeks, reaction was
concentrated and purified by reverse phase HPLC to give
(4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-(1,1-dioxidothiomorph-
olino)ethyl)carbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a-
,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a-
]chrysen-9-yl)phenyl)boronic acid, TFA (33 mg, 19.15%). .sup.1H NMR
(500 MHz, DMSO-d.sub.6) .delta. 7.74 (br. s., 1H), 7.68 (d, J=7.9
Hz, 2H), 7.04 (d, J=7.9 Hz, 2H), 5.18 (d, J=4.9 Hz, 1H), 4.66 (s,
1H), 4.55 (br. s., 1H), 3.62-3.57 (m, 1H), 3.39-3.23 (m, 9H), 3.02
(td, J=10.5, 4.4 Hz, 1H), 2.88 (br. s., 2H), 2.65-2.57 (m, 1H),
2.13-2.01 (m, 2H), 1.76 (dt, J=6.8, 3.2 Hz, 3H), 1.67 (br. s., 1H),
1.64 (s, 3H), 1.52-1.43 (m, 3H), 1.42-1.33 (m, 6H), 1.33-1.15 (m,
5H), 1.09 (d, J=12.8 Hz, 1H), 1.04 (s, 1H), 0.95 (s, 3H), 0.94 (s,
3H), 0.92 (s, 3H), 0.87 (br. s., 3H), 0.86 (br. s., 3H).
Preparation of Compounds of Formula III.
As previously set forth, compounds of formula III can be prepared
as described for compounds of formulas I and II, using ursolic
acid, oleanolic acid and moronic acid as starting material instead
of betulinic acid to give the corresponding E-ring modified final
products. The following scheme is a more specific version of the
scheme 7 for preparation of compounds of formula III set forth
above.
##STR00265##
Preparation of Intermediates A1, and B1
(1S,2R,4aS,6aS,6bR,8aR,10S,12aR,12bR,14bS)-benzyl
10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10-
,11,12,12a,12b,13,14b-icosahydropicene-4-a-carboxylate.
Intermediate A1
##STR00266##
Using ursolic acid as the starting material, the title compound was
prepared in accordance to the procedure described for the
preparation of intermediate 1, (white solid, 98%). .sup.1H NMR (400
MHz, CHLOROFORM-d) .delta. ppm 0.79 (s, 3H), 0.86 (d, J=6.53 Hz,
3H), 0.90 (s, 3H), 0.93-0.96 (m, 3H), 0.99 (s, 3H), 1.08 (s, 3H),
1.23-1.42 (m, 7H), 1.42-1.53 (m, 4H), 1.59-1.92 (m, 10H), 1.96-2.08
(m, 1H), 2.23-2.31 (m, 1H), 3.22 (dt, J=11.04, 5.52 Hz, 1H),
4.96-5.14 (m, 2H), 5.25 (t, J=3.64 Hz, 1H), 7.35 (s, 5H).
(4aS,6aS,6bR,8aR,10S,12aR,12bR,14bS)-benzyl
10-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10-
,11,12,12a,12b,13,14b-icosahydropicene-4-a-carboxylate.
Intermediate B1
##STR00267##
The title compound was obtained following the procedure described
above for intermediate 1 using oleanoic acid as the starting
material, (white solid, 94%). .sup.1H NMR (400 MHz, CHLOROFORM-d)
.delta. ppm 0.62 (s, 3H), 0.70-0.74 (m, 1H), 0.78 (s, 3H), 0.89 (s,
3H), 0.91 (s, 3H), 0.93 (s, 3H), 0.99 (s, 3H), 1.02-1.08 (m, 1H),
1.13 (s, 3H), 1.16-1.30 (m, 4H), 1.30-1.37 (m, 2H), 1.37-1.48 (m,
2H), 1.51-1.53 (m, 1H), 1.60-1.63 (m, 2H), 1.64-1.66 (m, 1H),
1.67-1.71 (m, 1H), 1.71-1.77 (m, 1H), 1.86 (dd, J=8.78, 3.51 Hz,
2H), 1.92-2.05 (m, 1H), 2.86-2.97 (m, 1H), 3.16-3.28 (m, 1H),
5.01-5.16 (m, 2H), 5.30 (t, J=3.51 Hz, 1H), 7.35 (s, 5H).
Preparation of Intermediates A2, and B2. Swern Oxidation
(1S,2R,4aS,6aS,6bR,8aR,12aR,12bR,14bS)-benzyl
1,2,6a,6b,9,9,12a-heptamethyl-10-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,-
12,12a,12b,13,14b-icosahydropicene-4-a-carboxylate. Intermediate
A2
##STR00268##
To a solution of oxalyl chloride (2.57 mL, 5.14 mmol) in methylene
chloride (5 mL) at -78.degree. C. under nitrogen was added dropwise
a solution of DMSO (0.46 mL 6.4 mmol) in methylene chloride (5 mL).
The mixture was allowed to warm to -50.degree. C. To this was added
a solution of the (1S,2R,4aS,6aS,6bR,8aR,10S,12aR,12bR,14bS)-benzyl
10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10-
,11,12,12a,12b,13,14b-icosahydropicene-4-a-carboxylate
(intermediate A1) (2.34 gm, 4.28 mmol) in methylene chloride (15
mL) forming a white milky suspension. The mixture was stirred for
an additional 15 minutes at -50.degree. C. after the addition, it
was then treated with triethylamine (1.79 mL, 12.84 mmol) and the
reaction mixture was slowly warmed to RT. It was diluted with
methylene chloride (100 mL), washed with water (2.times.100 mL),
followed by brine (50 mL). The organic phase was separated out,
dried over anhydrous sodium sulfate, and concentrated in vacuo to a
syrup. This crude material was partitioned over a silica gel
column, eluted with 9:1, hexanes:ethyl acetate solvent to give the
title compound as a pale solid (2.22 g, 95%). .sup.1H NMR (400 MHz,
CHLOROFORM-d) .delta. ppm 0.69 (s, 3H), 0.87 (d, J=6.53 Hz, 3H),
0.93-0.97 (m, 3H), 1.03 (s, 3H), 1.05 (s, 3H), 1.09 (s, 6H),
1.26-1.40 (m, 4H), 1.40-1.54 (m, 5H), 1.59 (d, J=9.03 Hz, 2H), 1.70
(br. s., 2H), 1.93 (dd, J=9.54, 3.26 Hz, 4H), 1.97-2.08 (m, 2H),
2.29 (d, J=11.04 Hz, 1H), 2.38 (ddd, J=15.94, 6.90, 3.76 Hz, 1H),
2.49-2.61 (m, 1H), 4.97-5.03 (m, 1H), 5.10-5.15 (m, 1H), 5.27 (t,
J=3.51 Hz, 1H), 7.31-7.39 (m, 5H).
(4aS,6aS,6bR,8aR,12aR,12bR,14bS)-benzyl
2,2,6a,6b,9,9,12a-heptamethyl-10-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,-
12,12a,12b,13,14b-icosahydropicene-4-a-carboxylate. Intermediate
B2
##STR00269##
The title compound was obtained via Swern oxidation as described
above using intermediate A1 as starting material, (pale solid,
94%). .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 0.66 (s, 3H),
0.91 (s, 3H), 0.93 (s, 3H), 1.03 (s, 3H), 1.05 (s, 3H), 1.09 (s,
3H), 1.14 (s, 3H), 1.17-1.24 (m, 2H), 1.25-1.50 (m, 8H), 1.57-1.78
(m, 6H), 1.84-1.94 (m, 3H), 1.95-2.05 (m, 1H), 2.37 (ddd, J=15.81,
6.78, 3.76 Hz, 1H), 2.50-2.60 (m, 1H), 2.93 (dd, J=13.93, 3.89 Hz,
1H), 5.04-5.09 (m, 1H), 5.09-5.14 (m, 1H), 5.32 (t, J=3.64 Hz, 1H),
7.35-7.37 (m, 5H).
Preparation of Intermediates A3 and B3
(1S,2R,4aS,6aS,6bR,8aR,12aR,12bR,14bS)-benzyl
1,2,6a,6b,9,9,12a-heptamethyl-10-(trifluoromethylsulfonyloxy)-1,2,3,4,4a,-
5,6,6a,6b,7,8,8a,9,12,12a,
12b,13,14b-octadecahydropicene-4-a-carboxylate. Intermediate A3
##STR00270##
The title compound was prepared using the procedure described
previously for the preparation of intermediate 3, using ketone
intermediate A2 as starting material (45%). .sup.1H NMR (400 MHz,
CHLOROFORM-d) .delta. ppm 0.67 (s, 3H), 0.87 (d, J=6.53 Hz, 3H),
0.93-0.97 (m, 3H), 0.99 (s, 3H), 1.04 (s, 3H), 1.08 (s, 3H), 1.14
(s, 3H), 1.17-1.21 (m, 1H), 1.21-1.47 (m, 5H), 1.50 (dd, J=13.05,
3.26 Hz, 2H), 1.56 (s, 3H), 1.58-1.78 (m, 3H), 1.78-1.97 (m, 3H),
1.97-2.07 (m, 2H), 2.15 (dd, J=17.07, 6.78 Hz, 1H), 2.30 (d,
J=11.54 Hz, 1H), 4.97-5.02 (m, 1H), 5.10-5.15 (m, 1H), 5.27 (t,
J=3.51 Hz, 1H), 5.59 (dd, J=6.78, 2.01 Hz, 1H), 7.35 (s, 5H);
.sup.19F NMR (376.46 MHz, CHLOROFORM-d) .delta. ppm -74.83.
(4aS,6aS,6bR,8aR,12aR,12bR,14bS)-benzyl
2,2,6a,6b,9,9,12a-heptamethyl-10-(trifluoromethylsulfonyloxy)-1,2,3,4,4a,-
5,6,6a,6b,7,8,8a,9,12,12a,12b,13,14b-octadecahydropicene-4-a-carboxylate.
Intermediate B3
##STR00271##
The title compound was prepared using the procedure described
previously for the preparation of intermediate 3, using ketone
intermediate B2 as starting material (29%). .sup.1H NMR (400 MHz,
CHLOROFORM-d) .delta. ppm 0.65 (s, 3H), 0.91 (s, 3H), 0.94 (s, 3H),
0.97 (s, 3H), 1.04 (s, 3H), 1.05-1.12 (m, 1H), 1.14 (s, 6H),
1.16-1.28 (m, 3H), 1.28-1.42 (m, 2H), 1.42-1.54 (m, 2H), 1.57-1.65
(m, 2H), 1.68 (d, J=14.56 Hz, 2H), 1.73 (d, J=4.52 Hz, 1H),
1.78-1.84 (m, 2H), 1.86 (dd, J=5.90, 4.14 Hz, 1H), 1.90-1.97 (m,
1H), 1.98-2.04 (m, 1H), 2.12 (dd, J=17.07, 6.78 Hz, 1H), 2.93 (dd,
J=13.93, 4.14 Hz, 1H), 5.03-5.14 (m, 3H), 5.33 (t, J=3.51 Hz, 1H),
5.58 (dd, J=6.78, 2.01 Hz, 1H), 7.34-7.38 (m, 5H); .sup.19F NMR
(376.46 MHz, CHLOROFORM-d) .delta. ppm -74.84.
Preparation of intermediates A4 and B4
(1S,2R,4aS,6aS,6bR,8aR,12aS,12bR,14bS)-benzyl
10-(4-(methoxycarbonyl)phenyl)-1,2,6a,6b,9,9,12a-heptamethyl-1,2,3,4,4a,5-
,6,6a,6b,7,8,8a,9,12,12a,12b,13,14b-octadecahydropicene-4-a-carboxylate.
Intermediate A4
##STR00272##
The title compound was prepared via from triflate intermediate A3
using the Suzuki coupling procedure described previously for the
preparation of intermediate 4, (68%). .sup.1H NMR (400 MHz,
CHLOROFORM-d) .delta. ppm 0.73 (s, 3H), 0.88 (d, J=6.53 Hz, 3H),
0.93-0.97 (m, 9H), 1.06 (s, 3H), 1.12 (s, 3H), 1.14-1.19 (m, 1H),
1.25 (d, J=12.30 Hz, 2H), 1.31-1.45 (m, 4H), 1.45-1.54 (m, 2H),
1.57-1.62 (m, 1H), 1.65 (dd, J=13.05, 4.02 Hz, 1H), 1.68-1.79 (m,
3H), 1.80-1.87 (m, 1H), 1.91-1.98 (m, 2H), 2.02 (dd, J=12.92, 4.64
Hz, 1H), 2.10 (dd, J=17.07, 6.27 Hz, 1H), 2.31 (d, J=11.04 Hz, 1H),
3.92 (s, 3H), 4.98-5.03 (m, 1H), 5.11-5.15 (m, 1H), 5.29-5.34 (m,
2H), 7.21 (d, J=8.53 Hz, 2H), 7.31-7.39 (m, 5H), 7.94 (d, J=8.28
Hz, 2H).
(4aS,6aS,6bR,8aR,12aS,12bR,14bS)-benzyl
10-(4-(methoxycarbonyl)phenyl)-2,2,6a,6b,9,9,12a-heptamethyl-1,2,3,4,4a,5-
,6,6a,6b,7,8,8a,9,12,12a,12b,13,14b-octadecahydropicene-4-a-carboxylate.
Intermediate B4
##STR00273##
The title compound was prepared via from triflate intermediate B3
using the Suzuki coupling procedure described previously for the
preparation of intermediate 4, (65%). .sup.1H NMR (400 MHz,
CHLOROFORM-d) .delta. ppm 0.70 (s, 3H), 0.92 (s, 3H), 0.95 (s, 9H),
1.04 (s, 3H), 1.08-1.15 (m, 1H), 1.17 (s, 3H), 1.19-1.25 (m, 2H),
1.27 (br. s., 2H), 1.30-1.38 (m, 2H), 1.40 (dd, J=8.03, 3.51 Hz,
1H), 1.43-1.54 (m, 2H), 1.58-1.68 (m, 3H), 1.68-1.78 (m, 3H), 1.90
(dd, J=6.15, 3.89 Hz, 1H), 1.92-2.03 (m, 2H), 2.07 (dd, J=17.07,
6.27 Hz, 1H), 2.95 (dd, J=13.80, 4.02 Hz, 1H), 3.92 (s, 3H),
5.04-5.15 (m, 2H), 5.31 (dd, J=6.15, 1.88 Hz, 1H), 5.36 (t, J=3.39
Hz, 1H), 7.21 (d, J=8.53 Hz, 2H), 7.33-7.38 (m, 5H), 7.94 (d,
J=8.28 Hz, 2H).
Preparation of Intermediates A5 and B5
(1S,2R,4aS,6aS,6bR,8aR,12aS,12bR,14bS)-tert-butyldimethylsilyl
10-(4-(methoxycarbonyl)phenyl)-1,2,6a,6b,9,9,12a-heptamethyl-1,2,3,4,4a,5-
,6,6a,6b,7,8,8a,9,12,12a,12b,13,14b-octadecahydropicene-4-a-carboxylate.
Intermediate A5
##STR00274##
Palladium catalyzed hydrosilylation of the benzyl esters
intermediate A4 as described in the preparation of intermediate 5
afforded the title compound (57%). .sup.1H NMR (400 MHz,
CHLOROFORM-d) .delta. ppm 0.24 (s, 3H), 0.25 (s, 3H), 0.87-0.90 (m,
6H), 0.93-0.98 (m, 18H), 1.09 (s, 3H), 1.12 (s, 3H), 1.16-1.51 (m,
6H), 1.52-1.59 (m, 7H), 1.59-1.88 (m, 4H), 1.88-2.07 (m, 3H), 2.11
(dd, J=17.07, 6.27 Hz, 1H), 2.22 (d, J=10.29 Hz, 1H), 3.92 (s, 3H),
5.30-5.34 (m, 2H), 7.22 (d, J=8.28 Hz, 2H), 7.94 (d, J=8.28 Hz,
2H);
(4aS,6aS,6bR,8aR,12aS,12bR,14bS)-tert-butyldimethylsilyl
10-(4-(methoxycarbonyl)phenyl)-2,2,6a,6b,9,9,12a-heptamethyl-1,2,3,4,4a,5-
,6,6a,6b,7,8,8a,9,12,12a,12b,13,14b-octadecahydropicene-4-a-carboxylate.
Intermediate 17 B5
##STR00275##
Palladium catalyzed hydrosilylation of the benzyl esters
intermediate B4 as described in the preparation of intermediate 5
afforded the title compound (54%). .sup.1H NMR (400 MHz,
CHLOROFORM-d) .delta. ppm 0.25 (s, 3H), 0.26 (s, 3H), 0.87 (s, 3H),
0.92 (s, 3H), 0.93-0.97 (m, 18H), 1.07 (s, 3H), 1.12-1.17 (m, 2H),
1.18 (s, 4H), 1.21-1.30 (m, 3H), 1.30-1.53 (m, 5H), 1.62-1.80 (m,
5H), 1.82-1.95 (m, 1H), 1.95-2.03 (m, 2H), 2.07 (dd, J=17.07, 6.27
Hz, 1H), 2.88 (dd, J=13.93, 4.64 Hz, 1H), 3.92 (s, 3H), 5.31 (dd,
J=6.27, 1.76 Hz, 1H), 5.35 (t, J=3.51 Hz, 1H), 7.22 (d, J=8.53 Hz,
2H), 7.94 (d, J=8.28 Hz, 2H).
Preparation of Intermediates A6 and B6
(1S,2R,4aS,6aS,6bR,8aR,12aS,12bR,14bS)-10-(4-(methoxycarbonyl)phenyl)-1,2,-
6a,6b,9,9,12a-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,12,12a,12b,13,14b--
octadecahydropicene-4-a-carboxylic acid. Intermediate A6
##STR00276##
The title compound was prepared following the procedure describe
for the preparation of intermediate 6 using intermediate A5 as
starting material, (98%). .sup.1H NMR (400 MHz, CHLOROFORM-d)
.delta. ppm 0.87 (s, 3H), 0.89 (d, J=6.53 Hz, 3H), 0.93 (s, 3H),
0.94 (s, 3H), 0.96 (s, 3H), 0.98 (s, 3H), 1.03 (t, J=7.28 Hz, 2H),
1.08-1.11 (m, 3H), 1.13 (s, 3H), 1.19 (s, 2H), 1.22-1.82 (m, 10H),
1.84-2.06 (m, 2H), 2.06-2.15 (m, 1H), 2.23 (d, J=11.04 Hz, 1H),
3.32-3.51 (m, 1H), 3.92 (s, 3H), 5.32 (dd, J=5.90, 1.63 Hz, 2H),
7.20 (d, J=8.28 Hz, 2H), 7.94 (d, J=8.28 Hz, 2H).
(4aS,6aS,6bR,8aR,12aS,12bR,14bS)-10-(4-(methoxycarbonyl)phenyl)-2,2,6a,6b,-
9,9,12a-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,12,12a,12b,13,14b-octade-
cahydropicene-4-a-carboxylic acid. Intermediate B6
##STR00277##
The title compound was prepared following the procedure describe
for the preparation of intermediate 6 using intermediate B5 as
starting material, (95%). .sup.1H NMR (400 MHz, CHLOROFORM-d)
.delta. ppm 0.85 (s, 3H), 0.91-0.97 (m, 12H), 1.03 (t, J=7.28 Hz,
2H), 1.08 (s, 3H), 1.12-1.16 (m, 1H), 1.18 (s, 3H), 1.21 (d, J=4.52
Hz, 2H), 1.26 (br. s., 2
H), 1.28 (br. s., 1H), 1.32-1.43 (m, 2H), 1.43-1.53 (m, 2H),
1.53-1.61 (m, 2H), 1.63 (d, J=4.27 Hz, 1H), 1.71 (d, J=6.02 Hz,
1H), 1.74-1.82 (m, 2H), 1.82-1.96 (m, 2H), 2.01 (dd, J=7.91, 3.64
Hz, 1H), 2.03-2.13 (m, 1H), 2.87 (dd, J=13.68, 3.89 Hz, 1H),
3.33-3.46 (m, 1H), 3.92 (s, 3H), 5.31 (dd, J=6.15, 1.63 Hz, 1H),
5.36 (t, J=3.39 Hz, 1H), 7.20 (d, J=8.28 Hz, 2H), 7.94 (d, J=8.53
Hz, 2H).
Preparation of Examples A1-2 and B1-2
Examples A1-2 and B1-2 were prepared accordingly to the previously
described general procedure for C-28 amide formation using either
intermediates A6 and B6 as starting materials; followed by the
general procedure for hydrolysis of the benzoic acid using
NaOH.
##STR00278##
Example A1
Preparation of
4-((4aR,6aR,6bS,8aS,11R,12S,12aS,14aR,14bS)-8a-(2-(dimethylamino)ethylcar-
bamoyl)-4,4,6a,6b,11,12,14b-heptamethyl-1,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12-
,12a,14,14a,14b-octadecahydropicen-3-yl)benzoic acid
##STR00279##
The title compound was prepared as described above using
intermediate A6 as starting material and
N1,N1-dimethylethane-1,2-diamine as the reactant amine. .sup.1H NMR
(400 MHz, Methanol-d.sub.4) .delta. ppm 0.90 (s, 3H), 0.94 (d,
J=6.53 Hz, 3H), 0.96-1.01 (m, 10H), 1.13 (s, 3H), 1.18 (s, 3H),
1.32 (dd, J=11.42, 1.88 Hz, 1H), 1.35-1.47 (m, 2H), 1.47-1.66 (m,
6H), 1.66-1.75 (m, 3H), 1.75-1.89 (m, 2H), 1.94-2.09 (m, 2H),
2.09-2.25 (m, 3H), 2.94 (s, 6H), 3.17-3.24 (m, 2H), 3.39-3.50 (m,
1H), 3.50-3.65 (m, 1H), 5.33 (dd, J=6.27, 1.76 Hz, 1H), 5.40 (t,
J=3.39 Hz, 1H), 7.24 (d, J=8.53 Hz, 2H), 7.72 (t, J=5.65 Hz, 1H),
7.93 (d, J=8.53 Hz, 2H).
Example B1
Preparation of
4-((4aR,6aR,6bS,8aS,12aS,14aR,14bS)-8a-(2-(dimethylamino)ethylcarbamoyl)--
4,4,6a,6b,11,11,14b-heptamethyl-1,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,-
14a,14b-octadecahydropicen-3-yl)benzoic acid
##STR00280##
The title compound was prepared as described above using
intermediate B6 as starting material and
N1,N1-dimethylethane-1,2-diamine as the reactant amine .sup.1H NMR
(400 MHz, Methanol-d.sub.4) .delta. ppm 0.88 (s, 3H), 0.94 (s, 3H),
0.97 (br. s., 3H), 0.98 (s, 6H), 1.12 (s, 4H), 1.23 (s, 4H), 1.33
(d, J=11.04 Hz, 1H), 1.36-1.49 (m, 2H), 1.49-1.58 (m, 2H),
1.58-1.67 (m, 4H), 1.68 (d, J=4.02 Hz, 1H), 1.70-1.78 (m, 2H),
1.78-1.90 (m, 2H), 1.90-2.27 (m, 4H), 2.84 (dd, J=13.30, 3.51 Hz,
1H), 2.95 (s, 6H), 3.22 (t, J=6.27 Hz, 2H), 3.39-3.66 (m, 2H), 5.33
(dd, J=6.15, 1.63 Hz, 1H), 5.41 (t, J=3.39 Hz, 1H), 7.24 (d, J=8.28
Hz, 2H), 7.81 (t, J=5.40 Hz, 1H), 7.93 (d, J=8.28 Hz, 2H).
Example A2
Preparation of
4-((4aR,6aR,6bS,8aS,11R,12S,12aS,14aR,14bS)-8a-((3-(1,1-dioxido-4-thiomor-
pholinyl)propyl)carbamoyl)-4,4,6a,6b,11,12,14b-heptamethyl-1,4,4a,5,6,6a,6-
b,7,8,8a,9,10,11,12,12a,14,14a,14b-octadecahydro-3-picenyl)benzoic
acid
##STR00281##
The title compound was prepared as described above using
intermediate A6 as starting material and
4-(3-aminopropyl)thiomorpholine 1,1-dioxide as the reactant amine
.sup.1H NMR (400 MHz, Methanol-d.sub.4) .delta. ppm 0.87-0.90 (m,
3H), 0.95 (d, J=5.02 Hz, 3H), 0.97-1.01 (m, 6H), 1.11-1.15 (m, 3H),
1.19 (s, 3H), 1.23 (s, 3H), 1.27-1.47 (m, 4H), 1.47-1.86 (m, 10H),
1.86-1.97 (m, 3H), 1.97-2.24 (m, 5H), 2.76-2.91 (m, 1H), 3.00-3.16
(m, 2H), 3.16-3.26 (m, 1H), 3.48 (d, J=5.02 Hz, 4H), 3.64 (d,
J=2.01 Hz, 4H), 5.33 (d, J=4.27 Hz, 1H), 5.37-5.50 (m, 1H), 7.24
(d, J=8.03 Hz, 2H), 7.93 (d, J=8.28 Hz, 2H).
Example B2
Preparation of
4-((4aR,6aR,6bS,8aS,12aS,14aR,14bS)-8a-((3-(1,1-dioxido-4-thiomorpholinyl-
)propyl)carbamoyl)-4,4,6a,6b,11,11,14b-heptamethyl-1,4,4a,5,6,6a,6b,7,8,8a-
,9,10,11,12,12a,14,14a,14b-octadecahydro-3-picenyl)benzoic acid
##STR00282##
The title compound was prepared as described above using
intermediate B6 as starting material and
4-(3-aminopropyl)thiomorpholine 1,1-dioxide as the reactant amine
.sup.1H NMR (400 MHz, Methanol-d.sub.4) .delta. ppm 0.88 (s, 3H),
0.94 (s, 3H), 0.98 (s, 9H), 1.12 (s, 3H), 1.15-1.22 (m, 2H), 1.23
(s, 4H), 1.32 (d, J=11.04 Hz, 1H), 1.36-1.36 (m, 1H), 1.36-1.52 (m,
3H), 1.52-1.70 (m, 7H), 1.70-1.86 (m, 3H), 1.86-2.20 (m, 7H), 2.84
(dd, J=12.92, 3.14 Hz, 1H), 3.05-3.17 (m, 2H), 3.17-3.28 (m, 1H),
3.48 (d, J=4.27 Hz, 4H), 3.64 (br. s., 4H), 5.33 (dd, J=6.15, 1.63
Hz, 1H), 5.43 (t, J=3.39 Hz, 1H), 7.24 (d, J=8.28 Hz, 2H), 7.93 (d,
J=8.28 Hz, 2H).
Biology Data for the Examples
".mu.M" means micromolar;
"mL" means milliliter;
".mu.l" jar means microliter;
"mg" means milligram;
".mu.g" means microgram;
The materials and experimental procedures used to obtain the
results reported in Tables 1-2 are described below.
HIV Cell Culture Assay--
MT-2 cells and 293T cells were obtained from the NIH AIDS Research
and Reference Reagent Program. MT-2 cells were propagated in RPMI
1640 media supplemented with 10% heat inactivated fetal bovine
serum, 100 .mu.g/ml penicillin G and up to 100 units/ml
streptomycin. The 293T cells were propagated in DMEM media
supplemented with 10% heat inactivated fetal bovine serum (FBS),
100 units/ml penicillin G and 100 .mu.g/ml streptomycin. The
proviral DNA clone of NL.sub.4-3 was obtained from the NIH AIDS
Research and Reference Reagent Program. A recombinant NL.sub.4-3
virus, in which a section of the nef gene from NL4-3 was replaced
with the Renilla luciferase gene, was used as a reference virus. In
addition, residue Gag P373 was converted to P373S. Briefly, the
recombinant virus was prepared by transfection of the altered
proviral clone of NL.sub.4-3. Transfections were performed in 293T
cells using LipofectAMINE PLUS from Invitrogen (Carlsbad, Calif.),
according to manufacturer's instruction. The virus was titered in
MT-2 cells using luciferase enzyme activity as a marker. Luciferase
was quantitated using the Dual Luciferase kit from Promega
(Madison, Wis.), with modifications to the manufacturer's protocol.
The diluted Passive Lysis solution was pre-mixed with the
re-suspended Luciferase Assay Reagent and the re-suspended Stop
& Glo Substrate (2:1:1 ratio). Fifty (50) .mu.L of the mixture
was added to each aspirated well on assay plates and luciferase
activity was measured immediately on a Wallac TriLux
(Perkin-Elmer). Antiviral activities of inhibitors toward the
recombinant virus were quantified by measuring luciferase activity
in cells infected for 4-5 days with NLRluc recombinants in the
presence serial dilutions of the inhibitor. The EC.sub.50s data for
the compounds is shown in Table 2. Table 1 is the key for the data
in Table 2.
Results
TABLE-US-00002 TABLE 1 Biological Data Key for EC.sub.50s Compounds
with EC.sub.50 > 0.1 .mu.M Compounds with EC.sub.50 < 0.1
.mu.M Group "B" Group "A"
TABLE-US-00003 TABLE 2 Compound Structure Group Example 1
##STR00283## A Example 2 ##STR00284## A Example 3 ##STR00285## A
Example 4 ##STR00286## A Example 5 ##STR00287## A Example 6
##STR00288## A Example 7 ##STR00289## A Example 8 ##STR00290## A
Example 9 ##STR00291## A Example 10 ##STR00292## A Example 11
##STR00293## 61 nM Example 12 ##STR00294## A Example 13
##STR00295## A Example 14 ##STR00296## 0.11 .mu.M Example 15
##STR00297## A Example 16 ##STR00298## A Example 17 ##STR00299## A
Example 18 ##STR00300## B Example 19 ##STR00301## 0.37 .mu.M
Example 20 ##STR00302## B Example 21 ##STR00303## B Example 22
##STR00304## A Example 23 ##STR00305## A Example 24 ##STR00306## 48
nM Example 25 ##STR00307## A Example 26 ##STR00308## A Example 27
##STR00309## A Example 28 ##STR00310## A Example 29 ##STR00311## A
Example 30 ##STR00312## A Example 31 ##STR00313## A Example 32
##STR00314## A Example 33 ##STR00315## A Example 34 ##STR00316## A
Example 35 ##STR00317## A Example 36 ##STR00318## A Example 37
##STR00319## A Example 38 ##STR00320## A Example 39 ##STR00321## A
Example 40 ##STR00322## A Example 41 ##STR00323## A Example 42
##STR00324## 0.12 .mu.M Example 43 ##STR00325## A Example 44
##STR00326## A Example 45 ##STR00327## A Example 46 ##STR00328## A
Example 47 ##STR00329## 8.7 nM Example 48 ##STR00330## A Example 49
##STR00331## A Example 50 ##STR00332## A Example 51 ##STR00333## A
Example 52 ##STR00334## A Example 53 ##STR00335## A Example 54
##STR00336## A Example 55 ##STR00337## A Example 56 ##STR00338## A
Example 57 ##STR00339## 0.70 .mu.M Example 58 ##STR00340## A
Example 59 ##STR00341## A Example 60 ##STR00342## 48 nM Example 61
##STR00343## A Example 62 ##STR00344## B Example 63 ##STR00345## B
Example 64 ##STR00346## A Example 65 ##STR00347## A Example 66
##STR00348## A Example 67 ##STR00349## 3.8 nM Example 68
##STR00350## A Example 69 ##STR00351## A Example 70 ##STR00352## A
Example 71 ##STR00353## A Example 72 ##STR00354## A Example 73
##STR00355## A Example 74 ##STR00356## A Example 75 ##STR00357## A
Example 76 ##STR00358## A Example 77 ##STR00359## B Example 78
##STR00360## A Example 79 ##STR00361## A Example 80 ##STR00362## A
Example 81 ##STR00363## A Example 82 ##STR00364## 1.23 .mu.M
Example 83 ##STR00365## A Example 84 ##STR00366## A Example 85
##STR00367## A Example 86 ##STR00368## A Example 87 ##STR00369## A
Example 88 ##STR00370## B Example 89 ##STR00371## A Example 90
##STR00372## B Example 91 ##STR00373## A Example 92 ##STR00374## A
Example 93 ##STR00375## A Example 94 ##STR00376## A Example 95
##STR00377## A Example 96 ##STR00378## A Example 97 ##STR00379##
2.6 nM Example 98 ##STR00380## A Example 99 ##STR00381## A Example
100 ##STR00382## B Example 101 ##STR00383## A Example 102
##STR00384## 10.5 nM Example 103 ##STR00385## A Example 104
##STR00386## A Example 105 ##STR00387## A Example 106 ##STR00388##
A Example 107 ##STR00389## A Example 108 ##STR00390## A Example 109
##STR00391## A Example 110 ##STR00392## A Example 111 ##STR00393##
A Example 112 ##STR00394## A Example 113 ##STR00395## B Example 114
##STR00396## 17.6 nM Example 115 ##STR00397## A Example 116
##STR00398## A Example 117 ##STR00399## A Example 118 ##STR00400##
A Example 119 ##STR00401## A Example 120 ##STR00402## A Example 121
##STR00403## A Example 122 ##STR00404## A Example 123 ##STR00405##
A
Example 124 ##STR00406## A Example 125 ##STR00407## A Example 126
##STR00408## A Example 127 ##STR00409## A Example 128 ##STR00410##
A Example 129 ##STR00411## A Example 130 ##STR00412## 13.4 nM
Example A1 ##STR00413## A Example B1 ##STR00414## A Example A2
##STR00415## A Example B2 ##STR00416## A
The foregoing description is merely illustrative and should not be
understood to limit the scope or underlying principles of the
invention in any way. Indeed, various modifications of the
invention, in addition to those shown and described herein, will
become apparent to those skilled in the art from the following
examples and the foregoing description. Such modifications are also
intended to fall within the scope of the appended claims.
* * * * *